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ABSTRACT 
Adenoviruses are the most commonly used in the development of oncolytic 
therapy. Oncolytic adenoviruses are genetically modified to selectivity replicate in and 
kill tumor cells. The p53 molecule is a tumor suppressor protein that responds to viral 
infection through the activation of apoptosis, which is inhibited by adenovirus E1B55kDa 
protein leading to progressive viral lytic cycle. The non-specificity of replication has 
limited the use of wild type adenovirus in cancer therapy. This issue was resolved by 
using an E1b deleted Ad that can only replicate in cells with a deficiency in the p53 
protein, a common feature of most cancer cells.  
Although demonstrating a moderate success rate, E1b55kDa deleted Ad has not 
been approved as a standard therapy for all cancer types. Several studies have revealed 
that E1b deleted Ad replication was independent of p53 status in the cell, as the virus 
replicated better in some p53 deficient cancers more than others. However, this 
mechanism has not been investigated deeply. Therefore, the objective of this study is to 
understand the relationship between p53 status, levels and functional activity, and 
oncolytic Ad5dlE1b55kDa replication efficiency.  
Firstly, five transient p53 expression vectors that contain different regulatory 
elements were engineered and then evaluated in H1299, HEK293 and HeLa cell lines. 
Data indicated that vector that contains the MARs and HPRE regulatory elements 
achieved the highest stability of p53 expression. Secondly, we used these vectors to 
examine the effect of various p53 expression levels on the replication efficiency of 
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oncolytic Ad5dlE1b55kDa. We found that the level of p53 in the cell had an insignificant 
effect on the oncolytic viruses’ replication. However, the functional activity of p53 had a 
significant effect on its replication, as Ad5dlE1b55kDa was shown to have selective 
activity in H1299 cells (p53-null). In contrast, a decrease in viral replication was found in 
HeLa cells (p53-positive).  
Finally, the effect of p53’s functional activity on the replication efficiency of 
oncolytic Ad5dlE1b55kDa was examined. Viral growth was evaluated in H1299 cells 
expressing number of p53 mutants. P53-R175H mutant successfully rescued viral growth 
by allowing the virus to exert its mechanism of selectivity. The mechanism entailed 
deregulating the expression of specific genes, cell cycle and apoptosis, in the p53 
pathway to promote its production leading to efficient oncolytic effect. These results 
confirmed that oncolytic Ad5dlE1b55kDa sensitivity is mutation-type specific. 
Therefore, before it is applied clinically as cancer therapy for p53 deficient tumors, the 
type of p53 mutation must be determined for efficient antitumor effect.  
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Introduction and Literature Review 
Cancer 
 Cancer is a rapid uncontrolled growth of cells in an organism. The abnormal cells    
progress together to develop a tumor as well as spread to other tissues. If spreading 
occurs and is not controlled, it can lead to metastasis, a major cause of death (reviewed in 
Chaffer and Weinberg, 2011). According to Statistics Canada 2014, the overall cancer 
incidence rate has been continually increasing in females whereas mostly stable in males 
per year over the past 30 years. Cancer accounts for nearly 30% of all deaths, making it 
the leading cause of death in Canada. Two in five Canadians are expected to develop 
cancer during their lifetime (Statistics Canada, 2014). 
 There are hundreds of types of cancer named for the organ where it started. The 
most common types are prostate, breast and lung cancer (American National Cancer 
Institute, 2014). Cancer develops through an accumulation of genetic mutations in genes 
that regulate cellular growth and division. This is caused by several factors, including 
external (chemicals and radiation) and internal (inherited and somatic mutations). 
Although some of the factors are alike, each type of cancer behaves differently (reviewed 
by Fearon and Vogelstein, 1990). 
 Steady progress has been made to improve cancer therapy since the war on cancer 
was launched in the 1970s. However, most metastatic tumors remain incurable (reviewed 
in Choi and Yun, 2013). The main reason for this is that cancer is born of the body’s own 
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cells, making it difficult for treatments to differentiate between healthy and malignant 
tissues.  
Cancer Therapy 
Traditional Therapy 
Before 1950, surgery and surgical treatment have been routinely performed to 
treat several cancers for many years such as colorectal carcinoma, as it results in 25-40% 
5-year survival rate (Wagner, et al., 1984; Perlmutter and Lepor, 2007). With the 
inception of radiotherapy and chemotherapy, surgical option is restricted to special cases 
with a clear resection margin (Ohlsson et al., 1998). However, over time neither 
chemotherapy or radiotherapy has shown promising results due to lack of selectivity 
since both cancer and normal cells are killed (Johnstone et al., 2002). Since the multiple 
side effects of chemotherapy and radiotherapy have limited the extension of the duration 
of therapy, development of novel approaches that are more selective and less toxic was 
needed.  
A revolution in cancer treatment was reached with advancement in the field of 
cellular and molecular biology, which revealed that cancer is a genetic disease caused by 
genome instability that leads to abnormal cell progression. This discovery has created a 
novel framework for researchers to repair the molecular defect in tumor cells, beginning 
the era of targeted therapy.  
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Targeted Therapy 
 Targeted agents are mainly molecules that attack cancer cells but cause less 
damage to normal cells. Multiple targeting approaches have been investigated for their 
anti-tumor efficacy such as targeting angiogenesis and apoptosis. Improvements in 
understanding apoptosis, known as programmed cell death, has led to utilization of this 
system to eliminate cancer cells. Since the 1990s, many important discoveries of 
apoptosis related genes have opened new doors for development of apoptosis inducing 
drugs that are capable of triggering cell death (reviewed in Wong, 2011).   
 With the continuous discovery of novel cancer related genes, it has been 
observed that different tumors express different defective genes. The defects of these 
genes have attributed to the accumulation of mutations over time, which consequently 
results in destroying their function (Vogelstein and Kinzler, 1993). It was reported that 
mutation event actually occurs in the most documented key regulatory genes that are 
responsible for cancer occurrence and progression, tumor suppressor genes and 
oncogenes. These genes include tumor suppressor p53, p16INK4a (p53 stabilizer) and 
retinoblastoma protein (Rb) (Sherr, 1996). This finding suggests that if the expression of 
tumor suppressor genes in cancer cells is restored, cell growth might once again be 
modulated, restoring the anti-tumor effect, hence cancer gene therapy was proposed 
(Fujiwara et al., 1993). 
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Gene Therapy 
The term “Gene therapy” is used to describe a technology that involves 
transferring therapeutic molecules directly to the cells (Anderson, 1998). It has become 
one of the most rapidly developing areas in clinical research, and has the potential to treat 
numerous kinds of cancer. A number of alternative targeting strategies for cancer gene 
therapy have been developed. One approach aimed to increase drug selectivity towards 
cancer cells. As initial gene therapy focused on treating single gene defects, the 
identification in the early 1980s of critical tumor targets such as p53 and E2F from DNA 
tumor virus studies was essential (Lane and Crawford, 1979; Helin et al., 1992). Tumor 
suppressor p53 was the first target for cancer gene therapy, as it revealed potent tumor 
suppressor activity against cancer. Since most tumor cells have inactive p53 protein, 
scientists have suggested replacing the non-functional protein in tumor cells with the 
intact version to restore the function (Finlay et al., 1989; Levine et al., 1994). Since then, 
all potential anti-tumor gene therapy-based agents became putative targets for gene 
therapy. However, this process requires a vector to deliver the therapeutic gene to the 
target tumor cells. For this purpose, intensive efforts have focused on engineering 
delivery vehicles to improve gene and drug delivery including viral and non-viral based 
vectors. 
Although non-viral based vectors are a suitable system for gene therapy with 
respect to safety, easy development, and non-immunogenic features, they have limitations 
in gene size and show modest delivery efficiency (reviewed in Lundstrom and Boulikas, 
2003). In addition, viral based vectors excel for their efficient gene delivery. This is 
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because viruses can efficiently infect a broad range of cells and have the ability to target 
specific cells. They also possess strong promoters that generate a high expression level of 
the therapeutic gene (reviewed in Giacca and Zacchigna, 2012). Therefore, it is not 
surprising that a wide range of viruses is under development to achieve excellent 
delivery.  
Viruses in the field of gene therapy fall into one of two categories, either wild 
type viruses or recombinant viruses. Due to the safety concerns of using viruses in cancer 
gene therapy, two thirds of current clinical practices are using non-replicative viruses as 
part of their therapeutic strategies. These viruses are recombinant agents that have been 
engineered to be non-replicative through the deletion of genes responsible for viral 
replication. The non-replicative characterization allows the expression of therapeutic 
genes only in the cells they infect, providing high efficacy and clinical safety (Kurooka 
and Kaneda, 2007). A large variety of recombinant viruses have been developed for 
cancer gene therapy, including adenoviruses, Newcastle disease virus, retroviruses, and 
many other viruses (reviewed by Giacca and Zacchigna, 2012). Roth reached the first 
successful use of viruses in this field in 1996 when wild type p53-containing retrovirus 
was injected into non-small cell lung cancer (Roth et al., 1996). A few years later, the 
first recombinant non-replicative adenovirus lacking the E1 and E3 regions was 
engineered (Andrews et al., 2001). 
Among the recombinant vectors, adenovirus represents the ideal gene transfer 
vector. Its ability to transfer genes without integration in the genome has assured the 
safety of this vector (Harui et al., 1999). This characteristic, and several more such as its 
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capability of infecting dividing and non-dividing cells and stability of its genome have 
made significant advances in its path to clinical evaluation. To date, adenovirus-based 
vectors has accounted for a quarter (24.7%) of gene therapy clinical trials around the 
world (reviewed by Edelstein et al., 2007). A well-known example is Gendicine, an Ad-
p53 recombinant vector, which is the most popular approach in viral mediated gene 
therapy. In 2004, China’s State Food and Drug Administration approved Gendicine as a 
treatment for head and neck cancer.  
Although results of many studies using the strategies to treat different cancers 
agree with these findings, different recent in vitro and clinical studies have shown 
inconsistent results in terms of antitumor effect (Fujiwara et al., 2006). Thus although 
non-replicating vectors are more safe, the shortcoming of limiting replication prevents 
viral spread to the entire tumor, particularly for advanced tumors (Heise et al., 1999). 
Nevertheless, in the context of local disease, gene-vector-based therapy with repeated 
dosing would be a suitable choice when it is combined with other modalities such as 
chemo- and radio-therapy (Pan et al., 2009).  
Virotherapy 
 The concept of virotherapy is about 100 years old, and began when DePace 
observed a reduction in tumor size in cervical cancer after inoculation with attenuated 
rabies vaccine in 1912 (reviewed in Ring, 2002). In parallel with that observation, 
previous report in 1904 when Dock documented tumor regression from cancer patients, 
while suffering from viral infection. These historical records suggest the notion that 
viruses may be able to eradicate cancer, and therefore may be used as cancer therapy 
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agents, otherwise known as oncolytic viruses. Shortly after, Levaditi and Nicolau 
conducted an animal experiment on mouse tumors in the 1920s to report the first 
oncolytic vaccinia agent for cancer therapy. They noticed impaired tumor growth of 
virally infected tumor whereas no noticeable reduction in uninfected tumors. Since then, 
during the 1950s and 1960s, a series of studies to investigate the effect of oncolytic 
viruses in humans have been established. These investigations have provided the 
scientific community with a hint that these viruses might possess a unique mechanism of 
anti-tumor effect that explains their capacity of tumor regression (reviewed in Kelly and 
Russell, 2007). 
Several animal studies were conducted by several groups to test the antitumor 
effect of number of viruses. Among the tested viruses, the first generation of potential 
oncolytic viruses, which were then chosen for human clinical trials (reviewed in Meerani 
and Yao, 2010). Many human clinical trials with different oncolytic viruses were carried 
out to treat several cancers such as cervical cancer (Smith et al., 1956). Despite the 
observations of partial and complete tumor regression, first generation naturally oncolytic 
viruses have elicited infectious complications that ultimately ended the trials in the late 
1960s. In addition, a severe immune response has elicited as a result of expression of wild 
type viral proteins, which limited their success. The latter drawbacks have caused 
significant decline in viral oncotherapy for decades (reviewed in Kelly and Russell, 
2007).  
As years passed, a better understanding of virology combined with the advent of 
gene therapy and biotechnology concepts in the 1990s has increased the interest in 
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mutated viruses as cancer treatment, giving rise to the second generation of oncolytic 
viruses. Today, oncolytic virotherapy is the most rapidly growing area in cancer 
treatment. It is considered a formidable therapy option for cancer in combination with 
chemo- and radio-therapy (Taneja et al., 2001).  
Oncolytic Viruses 
 The term oncolytic virus refers to viruses that have the capability to selectively 
replicate in and destroy cancer cells (Alemany et al., 2000). To date, around 675 cancer 
gene therapy clinical trials, where more than half of the trials have been focused on 
oncolytic viruses (reviewed by Aghi and Martuza, 2005). Viruses are small parasites that 
have the natural ability to spread, grow and kill the infected cells. Since cancer has 
certain molecular defects in multiple signaling pathways, such as the p53 and the 
interferon (IFN) pathway, these viruses can be genetically manipulated and designed to 
exploit the aberrant cellular and molecular pathways in cancer cells resulting in selective 
replication. This means that the replication and destruction ability of oncolytic viruses is 
restricted to cancer cells rather than normal cells (Morley et al., 2004).  
The mechanism of viral oncolysis relies on the lytic replication cycle. Upon 
infection of one cancer cell, the genetically engineered virus begins to multiply and 
replicate to lyse the infected cell resulting in the release of new virions that are capable of 
targeting and infecting the adjacent cancer cells in a tumor. After a number of cycles, the 
virus spreads within the cells facilitating the destruction of all tumor cells as seen in 
(Figure 1) (Biederer et al., 2002). Beside its efficient targeting property, the replication 
event of many oncolytic viruses has triggered strong immune response towards the 
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infected cancer cells, thus functioning as an adjuvant. Therefore, viral oncolysis is 
considered a two-pronged strategy, oncolytic from one side and immunotherapeutic from 
the other side (Benencia et al., 2008). 
Figure 1: Mechanism of action of oncolytic viruses (Reported by Kasuya et al., 2005) 
Selection Criteria of Oncolytic Viruses for Cancer Therapy 
 Identification of the optimal virus for oncolysis is a challenging task. To consider 
an ideal virus species for oncolysis, it should demonstrate a number of specific 
characteristics. The virus needs to be safe with minimal side effects. It should be a 
genetically stable virus with a large gene carrying capacity and easy to engineer for both 
safety and manufacturing standpoints. It must be efficient by achieving complete 
destruction of tumor cells. It can infect dividing and non-dividing cells with available 
mechanisms for selective replication in cancer cells. The virus needs to be grown in high 
titers for clinical study production under Good Manufacturing Practice (GMP) guidelines. 
It should preferably not integrate in the host genome to avoid causing further mutations. 
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In addition, the virus must have its receptors expressed redundantly on cancer cells to 
facilitate viral internalization with the ability to trigger strong immune response against 
tumor cells, providing the two-pronged mechanism. Finally, the virus must be cost 
effective and easy to monitor (Vile et al., 2002). 
A number of viruses from many different families exhibited most of the 
characteristics and therefore were proposed for oncolytic development. Such viruses that 
were found to be safe oncolytic agents and have shown promising results in preclinical 
studies include adenovirus, herpes simplex virus, and vaccinia virus (Martuza et al. 1991; 
Zhang et al., 2007). However, adenovirus is a better candidate for therapeutic 
development. Beside its match to the above criteria for an ideal oncolytic agent, 
adenovirus is well characterized and much is known about its biology. Also, it has a long 
history of usage in gene therapy as a non-replicating vector (reviewed by Yamamoto, 
2004).  
Oncolytic Adenovirus 
 Conditionally replicative adenovirus (CRAD) is a genetically modified human 
adenovirus that can restrict its growth to only cancer cells. Ad-ONYX-015 is the first 
successful adenovirus mutant that was approved for clinic use. This virus was engineered 
with deletion in E1B gene region to target and replicate in cells that have a defective 
tumor suppressor p53 pathway (Bischoff et al., 1996). As a result of its efficient 
reduction of tumor size and inducing only mild flulike symptoms, it was approved in 
China in 2005 to treat head and neck squamous cell carcinoma (HNSCC) patients and 
nasopharyngeal cancer combined with standard therapy (Garber, 2006).  
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Adenoviruses 
 In 1953, adenovirus was first isolated from human adenoidal tissue sample in 
culture as was found to exist in 62% of adenoid specimens, thus named “adenovirus” 
(Rowe et al., 1953). The different virus serotypes predominantly cause limited respiratory 
and gastrointestinal illnesses as well as ailments in the conjunctiva of the eye. Adenovirus 
serotype 5 is the most widely used in research because it belongs to the non-oncogenic 
sub group C. Therefore, it does not induce cancer, which makes it the most favorable for 
cancer research.  
Classification 
Adenoviruses are small DNA viruses that belong to Adenoviridae. The latter is 
subdivided into five groups according to their host as follows: Atadenovirus, 
Aviadenovirus, Siadenovirus, Ichtadenovirus and Mastadenovirus, in which human 
adenoviruses fall into. The genus Mastadenovirus is categorized into six subgroups, based 
on their agglutination property and their oncogenic activity, named A to F. These species 
are in turn divided into 51 serotypes (Benko et al., 1999).   
Structure 
Adenovirus consists of non-enveloped icosahedral capsid with diameter of 
approximately 80-110 nm. The outer capsid is composed of structural proteins, hexon, 
pentone, and fiber, as major capsid proteins along with several minor ones (V, VI, VII, 
VIII, IX, IIIa and IVa2) as shown in (Figure 2). Each viral particle consists of 252 
capsomers, in which 240 are hexons and 12 are pentons. Hexon is the largest, as it is the 
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building block of 20 faces of the viral particle. Penton and fiber proteins are essential for 
viral internalization, in which penton binds integrins and fiber binds coxsackie 
adenovirus receptor (CAR) to facilitate the entrance (Russell, 2009). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Structure of adenovirus. A schematic depiction of the structure based on cryo-electron 
microscopy and crystallography. The locations of the capsid and minor components are 
reasonably well defined and are not to scale. The disposition of the core proteins and the virus 
DNA is largely conjectural. Reported by (Russell, 2009) and the symbols for IIIa and VIII are 
based on the structures defined by Saban et al. (2006). 
Genome 
The genome of adenovirus is linear double-stranded DNA with a size of about 36-
38kb. The genome is flanked by inverted terminal repeats (ITRs) protected by two 
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terminal proteins at the 5′ ends (Rekosh et al., 1977). The interaction of both terminal 
proteins is essential to maintain the genome in a quasi-circular state, therefore facilitating 
the replication of viral DNA (Seth, 1999). The adenovirus genome encodes proteins 
whose genes are divided into two groups according to their stage in transcription. The 
viral genes transcripts and translated proteins are shown in Figure 3.  
 
 
 
 
 
 
Figure 3: Genome structure of adenoviruses (From Shenk, 1996). 
Life Cycle 
Adenovirus type 5 infection cycle is divided into two distinct phases: early and 
late. The early phase begins with viral internalization into the cell by integrin binding 
through CAR-mediated endocytosis. After that, the viral genome enters the nucleus, 
followed by transcription and translation of early viral genes to drive infected cells into 
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unscheduled replication. Then, the late phase begins by a series of transcription of genes 
encoding structural capsid proteins, facilitating the production of large quantities of new 
viruses that induce cell lysis (Mathias et al., 1994; Russell, 2009). As a tremendous 
amount of information is available on every gene and network, this review will focus 
only on genes that are directly related to replication and oncolysis, which is the focus of 
our study.  
Early Genes 
E1 
Transcription of early genes, E1, E2, E3, and E4 begins as soon as viral DNA 
enters the nucleus. E1 is the first gene that is transcribed upon viral infection. It consists 
of two genes, E1A and E1B. E1A gene is the most essential element, as it is responsible 
of stimulation of viral DNA synthesis and transcription activation of other early genes 
(Berk et al., 1979). Both genes work together to regulate apoptosis and to force the cell to 
enter S phase in favor of virus replication. These genes are the primary targets of 
modification for creating tumor selective replicative adenoviruses (Moran, 1993).  
Immediate early (E1A) 
E1A is the first protein produced immediately upon infection. The processing of 
E1A transcript yields five different products, 13S, 12S, 11S, 10S, and 9S. Their mRNAs 
encode for different proteins in which the major ones, 13S that encode for 289R and 12S 
that encode for 243R, are responsible for major functions of E1A including the 
transcriptional regulation of several cellular and viral proteins. Between these amino acid 
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residues, there are three conserved regions named, CR1, CR2, and CR3 that act to 
promote the multiple functions of E1A (Shenk, 2001). One critical function of E1A is 
regulating the transcription of other early and late genes in the infection cycle.  For this 
reason, E1A is considered a master regulator of the adenovirus replication process.  
During viral replication, adenovirus utilizes its own polymerase and other proteins 
required for DNA replication to synthesize its viral DNA. At the same time, E1A 
transforms the cell into S phase and stimulates the cell cycle progression, thus providing 
an optimal environment for efficient viral DNA synthesis  (Whyte et al., 1988; Howe et 
al., 1990). The latter is achieved through the ability of CR1 and CR2 to bind to certain 
tumor suppressor proteins including retinoblastoma protein (Rb) and preventing its 
binding to E2F transcription factor, which controls the entry into S phase, resulting in 
activation of cell cycle progression genes (Hiebert, 1993). The release of E2F will lead to 
stabilization of tumor suppressor p53 protein that is required to implement apoptosis. 
This reveals another activity of E1A expression in which it can induce p53-dependent 
apoptosis, which must be inhibited to avoid host cell death during viral infection (White 
et al., 1992).  
The fact that CR3 is not involved in the cell transformation process does not 
cancel its importance. CR3 is a critical transcriptional activator of E1B, E2E, E3, and E4 
and stimulates the activity of major late promoter (MLP) for efficient progression (Bruton 
et al., 2007, 2008). Together, the E1A protein products provide a powerful mechanism 
for efficient viral replication through deregulating cell cycle genes.  
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E1B  
 E1B is the product of an mRNA 2,200 nucleotides in length. It contains two major 
proteins, as a result of translation of two distinct start codons, E1B19kDa and E1B55kDa. 
Both proteins contribute to cellular transformation mediated by E1A; however, they 
prevent the unwanted apoptosis, unlike E1A (Debbas and White, 1993). Despite the 
differences in their sequences and their functions, two overlapping frames encode both 
proteins (Esche et al., 1980). 
The E1B19kDa protein is found to be a homolog of Bcl-2 anti-apoptotic family in 
sequence as well as function. It has an anti-apoptotic effect that has shown to block 
apoptosis induced by multiple pro-apoptotic genes including E1A, TNF-a, Fas, p53, Bid, 
Bax, and pro-apoptotic mitochondrial proteins that thus inhibit caspase activation. 
E1B19K deleted adenovirus has shown DNA degradation as well as strong cytopathic 
effect in the infected cells (White et al., 1984).  
 The larger E1B55kDa protein carries out multiple functions. The major function 
presents in its ability to interact with tumor suppressor protein p53 and inhibit its function 
on different levels. E1B55kDa binds to p53 domains and counteracts its transactivation 
activity such as inhibiting p53-mediated apoptosis, disrupting cell cycle checkpoint 
control, and losing the DNA repair system (Martin and Berk, 1999). In addition, 
E1B55kDa together with viral protein E4orf6 has another function, in which both form a 
complex with E3 ubiquitin ligase that targets p53 for proteasomal degradation. However, 
the absence of E4orf6 does not affect the p53 repression ability of E1B55kDa (Querido et 
al., 1997). The mechanisms of apoptosis of E1B55kDa and E1B19kDa are shown in 
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(Figure 4). 
 
 
 
 
 
 
Figure 4: E1B protein anti-apoptotic mechanisms. The two region proteins, E1B55 kDa and 
E1B19 kDa, both result in apoptotic prevention mechanism to help ensure successful viral 
infection and spread. The E1B55kDa predominantly functions to sequester and inhibit p53 but 
can also indirectly act through E4orf6 to ubiquitinate and degrade p53 to prevent p53-activated 
apoptosis. The E1B19 kDa protein acts as Bcl-2 analog and inhibits Bax and/or Bak from 
signaling mitrochonderial rupture, cytochrome c release, activation, and ultimate apoptosis (from 
Jounaidi et al., 2007).  
 
The complex of E1B55kDa and E4orf6 also results in the degradation of Mre11 to 
stop the damage response towards viral genome, thus preventing the viral genome end-
joining in cooperation with ataxia telangiectasia mutated (ATM) protein kinase 
expression (Stracker et al., 2002). Moreover, the E1B55kDa/E4orf6 complex promotes 
the transportation of viral mRNA from the nucleus through E4 nuclear localization and 
transport signalling (Dobner et al., 1996). However, the same complex retains the host 
specific mRNA, thus blocking cellular protein synthesis (Dobbelstein et al., 1997). The 
deletion of adenovirus E1B region restricts viral growth in the intact p53-infected cells, 
as allowing p53-mediated apoptosis.   
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E2 
Expression of the E2 gene is associated with expression of E1A, as the latter 
activates E2 and the other early genes. E2 gene comprises about 20kb of the viral genome 
that is transcribed under the control of two promoters early and late to form two mRNA 
products from different splicing signals, E2A and E2B. Despite their differential 
functions, both genes encode three main proteins that are essential for initiating viral 
DNA replication, which are DNA binding protein (DBP), terminal protein, and viral 
DNA polymerase. A sufficient concentration of these proteins is required to start the 
replication process, which begins 5 to 8 hrs post infection. Viral DNA replication will 
lead to productive replication of the virus resulting in production of new virions (Shenk, 
2001). 
The E2A gene encodes DBP, which is about 72kDa. It has high binding affinity to 
single stranded DNA, which is required to achieve all functions. DBP has major 
functions during replication. It prevents the formation of a DNA duplex structure leaving 
unwinding the douple stranded DNA for chain elongation (Brenkman et al., 2001). It also 
protects against DNA degradation by nucleases, thus increasing the stability of single 
stranded DNA. In addition, DBP has a role in enhancing the interaction of terminal 
protein with DNA and the binding of polymerase to the origin of replication (Van 
Breukelen et al., 2003). 
E2B gene encodes two distinct proteins: terminal protein (TP) and viral DNA 
polymerase (Pol), 55kDa and 140kDa, respectively. Both proteins are involved in the 
initiation of replication from one parental strand of DNA. The adenovirus polymerase 
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uses protein primer pTP to produce douple stranded DNA via a protein-priming 
mechanism (Parker et al., 1998). Then, viral polymerase will perform the addition of 
nucleotides in a specific manner until the elongation step is finished. The other parental 
single strand forms a ‘pan-handle’ structure, annealed inverted terminal repeats (ITRs), 
for the second round of DNA replication using the same mechanism. These ITRs are 
located at the ends of each parental strand to serve as an origin of replication (Brenkman 
et al., 2002). When the replication process is done, viral polymerase will perform the 
cleavage of pTP resulting in its mature form (TP) (Smart and Stillman, 1982) (Figure 5).  
 
 
 
 
 
 
 
Figure 5: Adenovirus DNA replication model  
E3 
The region of E3 is essential to counteract the host immune response against the 
virus. The translation of E3 gene results in generation of several proteins with 
immunomodulatory functions, E311.6kDa, E3 14.5kDa, E3 10.4kDa, and E3-gp 19kDa. 
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They all participate together to reach one goal, hindering the recognition of virus proteins 
and eliminating the targeting of infected cells by cytotoxic T lymphocytes (CTLs). 
(Burgert et al., 1987; Dimitrov et al., 1997), thus, facilitating persistent infection of 
adenovirus in the infected cell. For efficient replication of oncolytic adenovirus, E3 
11.6kDa death gene deletion is required. The deletion is essential for avoiding premature 
death during the productive adenovirus infection cycle (Tollefson et al., 1996a). E3 
region is dispensable for virus replication in vitro; therefore it is deleted in the majority of 
adenovirus vectors. 
E4 
E4 protein is a product of 18 different mRNAs, as a result of alternative splicing, 
that are activated by E1A-13S. E4 different transcripts, encode several open reading 
frames (ORFs), which are named according to their arrangement within the region as 
(E4orf1, E4orf2, E4orf3, E4orf4, E4orf5, E4orf6, and E4orf7) (Virtanen et al., 1984). 
Some of the E4 proteins are functionally known whereas others lack a clear function 
(reviewed in Leppard, 1997).  
Late Genes 
The transcription of late genes begins after DNA replication under the control of 
the MLP. In the late phase of infection, MLP becomes fully active which results in 
producing a transcript of 29kb nucleotides in length. The alternative splicing of this 
transcript results in five distinct groups of genes. These genes are categorized based on 
different poly-A sites, into L1 to L5 (Nevins and Darnell, 1978). Late genes encode viral 
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structural proteins (IV, VI, VII, VIII, Mu) that are essential for virion assembly (Smith et 
al., 2010). 
Mechanism of Antitumor Efficacy 
Adenovirus mediates oncolytic activity and tumor killing by an array of different 
mechanisms (reviewed by Mullen and Tanabe, 2002). The first mechanism is the result of 
viral replicative cycles that cause direct lysis of infected cells. The new virions then infect 
neighboring cancer cells resulting in subsequent destruction using the same mechanism. 
These cycles can be constantly repeated providing a continuous amplification of the 
initial dose until they are stopped by either of immune response or a rareness of 
susceptible cells. 
The second mechanism involves direct toxicity of the infected cells through the 
expression of toxic viral proteins. In this regard, adenovirus can generate certain proteins 
during replication, which are E3 11.6kD and E4ofr4 protein. Both proteins are toxic and 
able to damage the cell (Shtrichman and Kleinberger, 1998). The third mechanism 
depends on the induction of antitumoral immune response. This can be achieved via 
expressing toxic peptides encoded in the viral genome on the surface of the cell through 
antigen presenting cells triggering inflammatory cytokines as well as CTLs. These 
cancer-infected cells will then be recognized in the future, thus providing long-term 
protection against tumor recurrence.  
The final mechanism of adenovirus mediating antitumor effects, which can also 
be considered as combined therapy, relies on arming adenovirus with therapeutic 
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proteins. This mechanism can be achieved via insertion of anti-cancer genes in the viral 
genome. Therefore, the continuous repetition of replicative cycles will result in longer 
transgene expression. Thus, recompensing the defect of such protein in cancer cell 
leading to eradicate tumor mass (Van Beusechem et al., 2002). Despite all the above 
mechanisms, the approach of combining oncolytic adenovirus with chemotherapy is 
recommended for optimal oncolytic activity if it ensures limited toxicity to normal cells, 
which is already under clinical evaluation (reviewed in Ferguson et al., 2012). 
Mechanism of Antitumor Selectivity 
Reaching appropriate antitumor efficacy requires viruses that are tumor selective, 
but the concern is how to make these viruses specific and only target tumor cells. 
Currently, by understanding cancer and virus microbiology, scientists have successfully 
developed a number of different approaches to achieve tumor selective adenovirus 
replication (reviewed by Mullen and Tanabe, 2002). Each approach has shown various 
degrees of success, however, one approach that depends on targeting defective pathways 
has made it not just into clinical trials but also into approval for clinical use in China in 
2005 (Yu and Fang, 2007). This review will focus on this approach since it has been also 
used in this study with a brief highlight on the other approaches. 
Targeting Tumor Receptors  
Cancer cells usually express their own unique receptors on the surface of the cell, 
known as tumor specific receptors. One tumor selectivity approach is to redirect oncolytic 
adenoviruses to target only these receptors, thus facilitating selective internalization to 
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only tumor cells. This strategy involves the genetic modification of the viral fiber protein 
that is responsible for viral attachment and cell entry such as incorporation of an RGD 
motif in adenovirus fiber knob. However, finding these motifs has proven to be difficult. 
Many attempts have been made for finding motifs with high affinity of binding to 
receptors on the target cells, but few have successfully provided sufficient affinity 
(reviewed inYamamoto and Curiel, 2010). 
Targeting Tissue Specific Promoters  
Adenoviruses normally express their genes under their own promoters in a wide 
range of cell types. One attempt to achieve tumor selectivity is to place viral replicative 
genes under specific promoters that restrict their expression to cancer cells rather than 
normal cells, which is missing the activator proteins of these promoters (Saukkonen and 
Hemminki, 2004). These promoters are known as cancer/tumor specific, which are found 
to be highly active in cancer cells. For example, the prostate-specific antigen gene (PSA), 
which was inserted in the viral genome upstream of the E1A sequence to control its 
expression in CV706 virus-infected cells. As a result, the expression of E1A protein was 
correlated with the expression level of this promoter in a given cell (Rodriguez et al., 
1997). Although this approach has provided a proof of selective viral growth, it has major 
drawbacks. First, it is limited by the absence of such specific promoters in many cancers. 
Second, tumor specific promoters are much weaker compared to viral promoters, 
therefore they result in attenuated E1A expression (Gu et al., 2002). 
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Targeting Defective Pathways 
Cancer cells have much in common with viruses. Both final goals are to drive 
cells to proliferation, which is the favor of maximum virus replication. Tumor cells are 
subjected to many genetic features such as loss or gain of function properties that make 
them fertile ground for virus replication. Fascinatingly, a number of regulatory proteins 
that are targeted by adenovirus for inactivation are also found to be inactivated during 
tumorgenesis. Thus, these viral genes become dispensable in cancer cells that have lost 
the target proteins. This raised the idea of engineering mutant adenoviruses that have a 
deletion in genes critical for viral replication in normal cells but expendable in cancer 
cells to eradicate them, thus obtaining a mechanism of tumor selectivity mechanism 
(reviewed in Morley et al., 2004). 
Adenoviral Vectors Targeting the Rb Pathway 
In normal cells, both tumor suppressor proteins pRb and p53 are the key 
regulators of cancer signaling pathway that control cancer progression. In response to 
adenovirus infection, pRb and p53 are expressed in high levels to stop virus production. 
However, adenovirus inactivates this cellular defense mechanism through the expression 
of E1A (Whyte et al., 1988) and E1B (Yew and Berk, 1992) viral proteins that counteract 
their function in favor of virus replication.   
It is evident that tumor suppressor protein pRb is altered in many cancers due to 
the phosphorylation process. For example, about 30% of malignant gliomas have reported 
inactive Rb (Fueyo et al., 1998). In addition, as it is previously mentioned, E1A viral 
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region has the ability to target Rb for inhibition to facilitate the entrance of the cell into S 
phase (Nemajerova et al., 2008). Thus, a defective pRb pathway in tumor cells will 
provide a favorable environment for mutant virus replication, whereas the intact pathway 
will hinder replication. Therefore, it is suggested that deletion or mutation in the E1A 
viral gene will result in selective replication of E1A mutant adenovirus in pRb defective 
cells. Several E1A deleted adenoviruses have been engineered for oncolysis. As early as 
2001, Ad-24 oncolytic adenovirus has shown promising results and is currently being 
tested for safety and efficacy (Suzuki et al., 2001).  
Adenoviral Vectors Targeting the P53 Pathway 
P53 tumor suppressor protein is the most frequently altered gene in cancer. About 
50% to 70% of human cancers have reported mutations in p53 gene (Petitjean et al., 
2007). The inactivation usually occurs through various ways including presence of 
mutations in the gene, and loss of p14/19ARF, which functions as an indirect stabilizer of 
p53 protein (Zhang and Xiong, 1999). Inactivation of p53 leads to expression of 
dysfunctional protein resulting in a p53 defective pathway. The latter resulted in 
uncontrolled cellular checkpoints and failure in induction of apoptosis.  
P53 is also the major target of adenovirus E1B55kDa region. Their interaction 
will inhibit p53 function that normally hinders virus replication (Yew and Berk, 1992; 
Yew et al., 1994). The defective p53 pathway in most cancers gives adenovirus the green 
light to replicate efficiently and take over the cell cycle. Therefore, it was hypothesized 
that deletion of adenoviruses E1B55kDa region would result in selective replication in 
p53-deficient tumor cells, as E1B55kDa viral gene become superfluous in this case. Since 
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then, several replication selective adenoviruses have been generated. In 1996, Frank 
McCormick and his group engineered the first E1B deleted adenovirus (ONYX-015) that 
entered clinical trials to treat tumors lacking p53 function. ONYX-015 is a competent 
replicative adenovirus type 5 with a deletion of 827 bp in the viral E1B55kDa gene, p53-
binding region (Bischoff et al., 1996).  
After the construction of adenovirus with E1B deletion, a series of studies were 
conducted to evaluate its efficacy and selectivity. One of the initial studies was performed 
in two cancer cell lines, RKO and H1299. The study’s results reported significant 
reduction in virus replication efficiency in both cell lines with positive p53 status 
compared to the matched cell lines with negative p53 status (Harada and Berk, 1999; 
Rogulski et al., 2000). Another study demonstrated the ability of E1B mutant adenovirus 
to selectively replicate in p53 mutated tumor cells and exhibited cytopathic effects 
(Bischoff et al., 1996; Heise et al., 2000). Moreover, adenovirus with E1B deletion 
revealed significant antitumor effect and demonstrated tumor regression in various mouse 
models (Rogulski et al., 2000). Based on these data, human clinical trials were initiated. 
Subsequently, E1B deleted adenovirus (ONYX-015) has undergone a series of 
clinical trials. Fifteen clinical trials from phase I to III have been conducted, spanning 
from 2001 to 2005, for treating 250 participants of different cancer types. Different 
methods of administration were tested beginning with intratumoral injection followed by 
other route utilized during the trials (reviewed in Kirn, 2001). E1B deleted adenovirus has 
shown success in the early stage with low toxicity rate and well tolerance in several trials’ 
results including pancreatic cancer, liver tumor, prostate cancer, and ovarian cancer.  
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However, the available data from phase I and phase II of head and neck clinical 
trials have shown limited efficacy of E1B deleted adenovirus, as 50% of the cases have 
shown reduction in the treated tumor in combination with chemotherapy. Also, E1B 
deleted adenovirus as a single agent exhibited a low degree of efficacy with 13-14% 
complete tumor regression in another clinical setting (Ganly et al., 2000; Nemunaitis et 
al., 2001). Moreover, some in vitro studies have shown conflicting results, which did not 
come as a surprise due to the lack of consistent cell system between the studies 
(Rothmann et al., 1998). 
It has been suggested that the mechanism of selectivity of this oncolyic virus was 
more complex than was originally assumed. First, different mechanisms of p53 
inactivation result in various degrees of viral selectivity. Second, most of the data that 
showed the effect of inactive p53 in supporting virus replication came from different in 
vitro cell systems and no study has been done in matched cells (Rothmann et al., 1998). 
Third, it was suggested that deletion of E1B55kDa region might hinder its function in the 
exportation of viral RNA. Too soon, it became clear that tumor cells have the ability to 
compensate RNA export by unknown mechanism (O’Shea et al., 2004). Fourth, 
hindering the virus spread by neutralizing antibodies that are produced from active 
adaptive immune response, which has been solved through the intratumoral injection of 
viral particles; this is most likely due to the difficulties of antibodies to penetrate tumors 
(Baxter et al., 1994). Finally, one explanation for these contradictions has been ascribed 
to a lack of significant correlation between p53 genotype status and E1B deleted 
adenovirus replication ability (reviewed in Ganly and Singh, 2003). This indicates a need 
for more extensive work on identifying the role of p53 genotype in modulating E1B 
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deleted adenovirus replication. Also, there is a need for understanding the molecular 
mechanism underlying virus selectivity.  
Despite all challenges above, ONYX-015 is the most utilized oncolytic virus in 
clinical and experimental studies and is now, since 2003, under evaluation in phase I and 
phase II clinical trials of many cancers (reviewed in Aghi and Martuza, 2005). In 
addition, FDA in China has approved H101, an oncolytic virus with the same ONYX-015 
approach and an additional E3 deletion, since 2005 to treat head and neck cancers in 
combination with chemotherapy after the success of 4 years clinical trials (Yu and Fang, 
2007). H101 is even more potent than ONYX-015 since it showed 79% overall response 
rate. This means that E1B deleted adenovirus is still a promising approach despite the low 
efficacy in some cancers, but if it is well optimized or combined with other 
modifications.  
Tumor Suppressor P53  
P53 was discovered in 1979 when it was found in a complex with viral 
oncoproteins SV40 T-antigen (Lane and Crawford, 1979) and later on with adenovirus 
E1B55K in 1982 (Sarnow et al., 1982). It first came to attention when it demonstrated 
overexpression level in tumor cells rather than normal cells with oncogenic activity 
(Rotter, 1983). Ten years later, it finds its legitimate place within the family of tumor 
suppressor genes in the late 1980s (Finlay et al., 1989).  
Since p53 is a tumor suppressor protein, it provides a cellular defense mechanism 
against tumor formation and cancer development (Levine, 1997). It acts as a central 
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regulator of cell division and growth through its ability to make a decision whether 
genomic DNA will be repaired or if the cell will undergo apoptosis in response to DNA 
damage, eliminating cancer-prone cells from the replicative pool. It is therefore the key 
molecule to maintain the DNA integrity of the cell, thus deserved the nickname "guardian 
of the genome" (Lane, 1992). 
P53 is localized in the nucleus, as it is a nucleoprotein that binds directly to DNA 
for full activation and optimal function as a transcription factor. The wild type functional 
protein has short half-life, 6–20 min, and is usually maintained in low levels in normal 
cells. If only one functional copy of p53 gene is inherited from the parents, the individual 
will be prone to cancer development in future. This condition in which wild type (wt) p53 
allele is lost due to germline mutations is known as Li-Fraumeni syndrome (Srivastava et 
al., 1990). However, the vast majority of tumor types result from somatic mutations in 
the p53 gene that led to loss of tumor suppressor function. This was clearly confirmed in 
studies of different tumors when each clone of ectopic, missexpressed or overexpressed, 
p53 cDNA has shown different sequence from the others (Piaskowski et al., 2010).  
P53 protein is also a crucial target for multiple viral oncoproteins that promote its 
inactivation as well as degradation. This incudes E6 protein of human papillomavirus 
(HPV) as shown in cervical cancer (Scheffner et al., 1990), Adenovirus E1B55kDa 
protein that bind to p53 protein through sequence specific mechanism (Yew and Berk, 
1992), and adenovirus E1B55kDa/E4 34kDa proteins complex (Roth et al., 1998).  
The p53 protein belongs to a family of three members, p53, p63, and p73 proteins. 
They all share a homologous gene sequence for three main domains of their structures, 
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transactivation domain (TAD), DNA binding domain (DBD), and oligomerization 
domain (4D) resulting in similarities in their functions (Irwin and Kaelin, 2001). 
However, the p63 and p73 are not as common targets for viral oncoproteins as p53 (Roth 
et al., 1998). Also, p73 is also not a target of mdm2 degradation as p53 (Zeng et al., 
1999). Although p73 can partially compensate for the p53 DBD function, mutant (mt) 
p53 is still able to interact with its family member through the core domain DBD, 
repressing their activation (Gaiddon et al., 2001).  
Feedback Loops 
Under normal conditions p53 is tightly regulated through multiple feedback loops, 
positive and negative, that are initiaed by p53 itself. The positive loops are essential in 
modulating up p53 activity in response to activation signals as well as connecting p53 
activity to other signal transduction pathways. In contrast, negative feedback loops serve 
as p53 inhibitors, as they can modulate down p53 activity resulting in very low steady 
state p53 level in the normal cell (Blagosklonny, 1997).  
Mouse double minute 2 (mdm2) is the main negative regulator under non-stressed 
conditions (Momand et al., 1992). In normal condition, p53 and mdm2, an E3 ubiquitin 
ligase, autoregulate each other through feedback loop known as p53-mdm2 negative 
feedback loop to control its functionality (Lev Bar-Or et al., 2000). This inactivation by 
mdm2 is mediated through two distinct mechanisms: one mechanism is by repressing p53 
transcriptional activity through mdm2 binding to two adjacent p53 binding sites (p53BS) 
in the transactivation regions of p53 protein (Momand et al., 1992). The other mechanism 
is that mdm2 and mdm4 proteins form a complex that can target p53 for degradation by 
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the proteasome (Parant et al., 2001).  
Elevated level of p53 results in increasing mdm2 levels that in turn shut off p53 
activity and lower p53 level to be in a low steady state (Figure 6) (Piette et al., 1997). 
However, under stress, both p53 and mdm2 became phosphorylated by ATM protein 
kinase. This phosphorylation activity blocks the binding of p53 and mdm2 proteins, thus 
enhancing p53 level and function (Siliciano et al., 1997). On the other hand, in cancer, 
when p53 is mutated, it loses its ability as a transcriptional activator and therefore it 
cannot induce mdm2 expression, which in turn results in stabilizing p53 (Terzian et al., 
2008).  
 
 
 
 
 
Figure 6: p53–mdm2 autoregulatory loop. Mdm2 protein binds to p53 and inactivates it through 
at least two distinct mechanisms: physical blockage of the transcriptional activities of p53, and 
promotion of p53 ubiquitination and subsequent proteasomal degradation (Reported by Oren, 
2003). 
P53 Protein Structure 
Although p53 has complex gene structure, its sequence is conserved in all 
vertebrates (Jin et al., 2000).  Human p53 is mapped on the short arm of chromosome 17, 
17p13.1 (Isobe et al, 1986). It is a product of 393 amino acid protein that is translated 
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from one open reading frame. It consists of five highly conserved domains: the N-
terminal transactivation domain (TAD), a proline rich domain (PRD), a DNA binding 
domain (DBD), a tetramerization domain (4D) and a C-terminal regulatory domain 
(Soussi et al., 1990). This protein includes 12 isoforms as a result of multiple translation 
sites and alternative splicing sites (Bourdon et al., 2005). 
Transactivation Domain (TAD) 
TAD is localized in the amino terminus of the protein, which is full of acidic 
residues and it is the target region for phosphorylation activity by kinases (Meek, 1994). 
Ligases and some co-activator proteins are responsible for the regulation of this domain 
(Mavinahalli et al., 2010). It includes block I, which is highly conserved. This domain 
contains one of two transactivation subdomains, which is TAD1. This subdomain 
contains around 40 residues starting from residue 1 to residue 40 (Chang et al., 1995); 
and more specificly two of these residues, Leu 22 (Lin et al., 1994) and Trp 23 (Venot et 
al., 1999), are critical for the transactivation activity and mutations in these residues 
(L22Q/W23S) would not abolish the transactivation capability.   
Proline-Rich Domain (PRD) 
PRD consists of about 12 proline residues and contains the second transactivation 
subdomain, TAD2. TAD2 is the region between residues 43 and residue 73 (Chang et al., 
1995). Two amino acids, Trp 53 (Zhu et al. 1998) and Phe 54 (Venot et al. 1999), are 
critical for transactivation activity. Mutated amino acid residues to amino acid 
(W53Q/F54S) can result in loss of transactivation capability. However, other single point 
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mutations cannot abolish the transactivation activity, but loses the ability to interact with 
mdm2 protein (Lin et al., 1994). This means that both TADs are sufficiently stable unlike 
DBD, which is highly sensitive to point mutations.  
In addition to transactivation activity, TAD1 and TAD2 are able to bind to 
multiple cellular and viral proteins through binding sites such as TATA binding protein 
(Chang et al., 1995) and adenovirus E1B protein (Kao et al., 1990), respectively. They 
also can interact with several regulators such as mdm2 (Kussie et al., 1996). However, 
the amino terminal region of the transactivation domain is not specific, as it can be 
compensated by other regions from various transcription factors (Pietenpol et al., 1994).  
DNA Binding Domain (DBD) 
Based on the crystallographic studies of p53 DBD, it contains a sandwich of two 
anti-parallel β-sheets that serve as scaffold for the domain surface, which is composed of 
two structural motifs with three large loops. The first motif includes loop1 that binds to 
DNA major groove and known as loop-sheet-helix motif.  The other structural motif has 
two loops L2 and L3, which bind to DNA in the minor groove. Both L2 and L3 large 
loops can be stabilized by zinc ion (Cho et al., 1994).  
DBD is the most essential domain in wild type p53 protein function for several 
reasons. First, it contains four highly conserved blocks that are found within all p53 
proteins to date (Soussi et al., 1990). These blocks are found within exons 5 through 8; 
block ii (codons 117 to 142), block iii (codons 171 to 181), block iv (codons 234 to 258), 
and block v (codons 270 to 286) (Soussi, et al., 1990). Second, it is the most targeted 
	   48	  
domain for mutations in most cancer types (Caron de Fromentel and Soussi, 1992). Third, 
it has the binding site of one hundred of its target genes in blocks IV and V to mediate 
DNA binding activity and also SV40 T-antigen binding site (Tan et al., 1986).  
DBD mediates p53 transcriptional function of the target genes through binding to 
DNA in sequence-specific manner (Melero et al., 2011). The p53 sequence that 
determines its degradation by oncoprotins is most likely located between residues 92 and 
112 and it is crucial for determining p53 stability through an unknown mechanism (Gu et 
al., 2001). DNA must have the p53-responsive element (p53RE) to facilitate the binding. 
This consensus sequence for p53 binding is composed of two sequences of 
RRRCWWGYYY separated sometimes by a variable length spacer of 0–13 nucleotides, 
where R is a purine, W is A or T and Y is a pyrimidine (El-Deiry et al., 1992).  
Tetramerization Domain (4D) 
In order for wild type p53 to function properly as a transcription factor, it needs to 
bind to DNA as a tetramer (Melero et al., 2011). This form is assembled when the protein 
is organized in two stably folded domains, the tetramerization and the DNA-binding 
domains that are linked and flanked by intrinsically disordered segments, most likely 
amino acid residues 323 to 355 (Melero et al., 2011). Simply put, the interaction of two 
β-strands form a dimer and two dimers form a tetramer through the interaction with α-
helices.  
C-terminal Regulatory Domain 
The carboxy-terminus is a highly conserved leucine-rich domain that has two 
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main functions: nuclear localization and as a DNA damage sensor. There are three 
nuclear localization signals founded in this domain. Mutations in these signals will lead 
to the production of cytoplasmic p53 protein (Shaulsky et al., 1990). The C-terminal 
domain has shown its capability to form a complex with damaged DNA through the last 
75 amino acid residues with a high degree of affinity to facilitate the recognition of DNA 
damage (Reed et al., 1995). P53 structure and domains are shown in Figure 7.  
 
 
 
 
 
 
Figure 7: Schematic representation of the p53 protein. a) the functional domains. B) regions of 
sequence conservation, and c) structural domains. L1, L2, and L3 indicate loops, and LSH 
indicates a loop-sheet-helix structure (reported by Soussi and Béroud, 2001). 
Function of P53 Pathway 
Wild type p53 acts as a potent transcription activator of large set of responsive 
genes known as p53 target genes. These genes work together in a network in the p53-
signaling pathway. P53 activates the expression of these genes by its binding to their 
promoters through its DBD.  The binding occurs in a sequence specific manner via p53 
(p53RE) that exists in the p53 binding sites (El-Deiry et al., 1992). The target genes are 
involved in many biological outcomes as a result of p53 tumor suppressor activity 
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including cell cycle arrest, DNA repair, microRNA processing, and apoptosis (Figure 8). 
The latter activity is the most crucial for tumor suppression, as shown in cancer p53 
based therapies (Levine, 1997).  
Normally, the p53 pathway remains in standby mode until it gets activated due to 
stress signals that are detected by regulatory kinases. Most stress signals are associated 
with cancer initiation and progression including oncogenic activation (Pauklin et al., 
2005), hypoxia (Graeber et al., 1996), and direct DNA damage such as ultraviolet (UV) 
irradiation (Giaccia and Kastan, 1998). When kinase enzymes detect the signals, it causes 
posttranslational modifications to p53 protein at different residues to promote its 
activation, such as phosphorylation of serine residues in N- and C-domains and 
acetylation at Lys370, Lys372, Lys373, Lys381, and Lys382 (reviewed in Bode and 
Dong, 2004).  
Once p53 is activated, the p53 pathway undergoes two-step responses to be fully 
functional. These steps are stabilization and transcriptional activation. Firstly, the binding 
ability of p53 and mdm2 is diminished due to ATM kinase phosphorylation of both p53 
and mdm2. This results in an accumulation of p53 protein up to 3-10 fold and 
stabilization for hours in the cell with the aid of multiple posttranslational modifications 
as well. Secondly, once stabilized, it activates the transcription of downstream target 
genes to induce cell cycle arrest, DNA repair, and apoptosis as final outputs, hence 
preventing the proliferation of cells genome damage (Kastan et al., 1991; Giaccia and 
Kastan, 1998).  
Beside the transactivation activity of p53 protein, it also has the ability to trans-
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repress number of viral oncoproteins such as adenovirus E1A protein and some cellular 
promoters including Myc and Ras, and can also induce transcription independent 
apoptosis, an alternative route to cell death (Subler et al., 1992; Serrano et al., 1997).  
Figure 8: Downstream targets of the p53 transcription factor mediate its different biological 
outcomes (Reported by Harris and Levine, 2005).  
 
Cell Cycle 
The cell cycle is an ordered set of events leading to cell division. It consists of two 
main phases mitotic (M) and interphase. The latter contains three phases, G1, S and G2, 
which are the transition states for checkpoint. Normally, DNA replicates during S phase 
and afterwards is delivered into the two newly divided cells in the M phase. One of p53’s 
roles in the cell division of normal cells is controlling cell cycle progression. When p53 is 
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activated in response to stress, it pauses the cell cycle and the progression of cell division 
in G1 and G2 to make the decision whether to repair the DNA damage and complete the 
cell cycle or to undergo apoptosis depending on the severity of the damage (reviewed in 
Haupt et al., 2003).  
Cell cycle arrest is achieved with the aid of p14ARF, a p53 stabilizer. P14ARF is 
induced as a result of the activation of E2F transcription factor (Bates et al., 1998), to 
bind to mdm2 and inhibits its ubiquitin ligase activity and thus preventing the 
degradation of p53 (Honda and Yasuda, 1999). Once p53 level has risen, it 
transcriptionally activates a number of cell cycle genes to promote growth arrest. The 
genes involve Cyclin-dependent kinase inhibitor p21, 14-3-3 sigma, IGF-BP3 and BTG 
(El-Deiry et al., 1993).  
Cyclin-dependent kinase inhibitor p21 is the major player of cell cycle arrest 
response. Simply put, p53 protein binds to p21 protein to stimulate its expression and 
interaction with cdk2 cell division stimulating protein. This interaction results in the 
inhibition of the cdk2 kinase activity that is an essential requirement for cell cycle G1-S 
transition, thus stopping cell division (El-Deiry et al., 1993). Moreover, p53 can also 
control G2-M transition via GADD45 and 14‐3‐3 sigma. When p53 is mutated or 
attenuated, it cannot function, therefore the cell divides uncontrollably and forms a tumor.  
DNA Repair 
P53 mediates DNA repair as a response to mild DNA damage, thereby enabling 
the cell to fix the damage (reviewed in Vogt Sionov and Haupt, 1999). There are a set of 
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genes that are involved in the DNA repair pathway, including p48 protein and p53R2, 
which is a ribonucleotide reductase gene that is directly involved in the p53 checkpoint 
for DNA damage repair (Tanaka et al., 2000). Although GADD45 gene is already 
involved in the growth arrest outcome, it also shows a controversial role in mediating 
DNA repair (Kazantsev and Sancar, 1995). Once DNA repair is done, the cell cycle can 
resume, allowing damage-free DNA replication.   
Apoptosis 
Apoptosis, programmed cell death, has the most critical role in fighting cancer, 
which can be achieved by p53 protein. When a cell prefers to promote apoptosis rather 
than growth arrest and DNA repair, it means that it underwent severe damage such as 
viral oncogenic stress. Phosphorylation of p53 at serine46 residues by mediators such as 
kinases is a potent indicator of severe damage (Oda et al., 2000). Upon that, p53 regulates 
the expression of pro-apoptotic genes in the apoptotic cascade to eliminate damaged 
infected cells (Kerr et al., 1972).  
Apoptosis involves two main pathways: extrinsic and intrinsic as shown in Figure 
9. The extrinsic pathway involves the production of cell surface receptors such as Fas and 
DR5 proteins (Bennett et al., 1998). These proteins with PIDD protein are responsible for 
the activation of caspase 8 and Bid, pro apoptotic protein, resulting in cytochrome c 
release. The latter activates the caspase, proteases cascade followed by apoptosis. On the 
other hand, the intrinsic pathway promotes the secretion of cytochrome c directly from 
the mitochondria through the expression of pro-apoptotic proteins Bax, Noxa, Puma, Bid 
and p53AIP1, resulting in apoptosis (Miyashita and Reed, 1995; Schuler et al., 2000).  
	   54	  
 
 
 
 
 
 
 
 
Figure 9:  A model for p53-mediated apoptosis. This model depicts the involvement of p53 in the 
externsic and internsic apoptotic pathway. P53 target genes are showen in red. The convergence 
of the two pathways through Bid is shown (reported by Haupt et al., 2003). 
Other P53 Functions 
Despite the main functions of p53, it also has other responses that contribute to 
safeguarding the cellular genome integrity. These responses involve other p53 inducible 
genes that fall into several functional categories such as differentiation, senescence, 
angiogenesis and metastasis inhibitors. When p53 is mutated or absent, the cell loses the 
ability to induce the target genes, thereby lose the capability to maintain genome stability.   
Inactivation of P53 
Normally, loss of p53 function results in uncontrolled cell proliferation and 
survival of tumor cells. Therefore, p53 plays a crucial role in carcinogenesis, since most 
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cancers have actively attenuated or lost p53, resulting in its stabilization in the cell. P53 
inactivation and stabilization are achieved through array of mechanisms either directly or 
indirectly (reviewed by Vogelstein et al., 2000). One of the direct mechanisms is the 
existence of mutations, including point mutation and small insertions/deletions (Nigro et 
al., 1989). In contrast, one of the indirect mechanisms is by up-regulation of p53 
inhibitors such as mdm2 or down-regulation of p53 stabilizer such as p14ARF (Zhang and 
Xiong, 1999).  Another mechanism is found in virus-associated cancers, as they express 
viral proteins that bind to p53 for inhibition and degradation such as E6 of HPV in Hela 
cells. Similarly, E1B55kDa and SV40 T-antigen in other cell lines (Thomas et al., 1999; 
Wienzek et al., 2000). As a consequence, mutant p53 protein loses its sequence specific 
binding ability and its transcription factor activity. 
P53 Mutations 
P53 tumor suppressor protein is damaged in 50% - 70% of cancers (Wang et al., 
2004a). This damage is mostly due to mutations in the gene caused by several exogenous 
and endogenous events, including deletion, insertion, and base substitutions, either 
transition (purine to purine or pyrimidine to pyrimidine) or transversion (purine to 
pyrimidine or vice versa) (Baker et al., 1990; Petitjean et al., 2007; MUTP53LOAD data 
base). According to the International Agency for Research on Cancer (IARC), p53-
associated tumors have wide spectrum of mutations reaching around 28,717. Over 98% 
are high frequency somatic mutations (reviewed by Hollstein et al., 1991). 
P53 mutations can be divided into three distinct classes based on their impact on 
stabilization and DNA contact as well as structure. The three classes are: (i) class I, 
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missense mutation that affect protein-DNA binding; (ii) class II, missense mutations that 
disrupt the conformation of the protein; and (iii) class III, null mutations (deletions, 
insertions, and nonsense) that caused complete destruction of p53 protein (Cho et al., 
1994).  
In fact, 95% of documented cancer associated mutations in p53 are point 
mutations. About 75% of them are missense that result in single amino acid changes. The 
latter causes alteration of the protein features and affects its functional activities as well 
(reviewed in Hussain and Harris, 1998). The most common missense mutations include 
R175H, R249S, R273H, G245S and R282W (Hernandez-Boussard et al., 1999; Petitjean 
et al., 2007). 
Loss of wild type p53 transcriptional activity as a result of loss of p53 alleles is 
the main effect of point mutations. For complete loss, both alleles of p53 gene need to be 
lost or mutated, which is required for cancer initiation (Knudson et al., 1975). This loss 
affects the transcriptional activity of DBD to various degrees because not all mutations 
have equal effect on p53 function. Even if they are at the same position, different amino 
acids have different effects. This has been confirmed in many studies, as loss of apoptotic 
activity of p53 due to point mutations has been reported (Chao et al., 2000).  
However, some mutant forms have shown novel properties that are absent in the 
wild type version (Frazier et al., 1998). These properties are accompanied by two 
phenomena of different degrees of dominance (Frebourg, et al., 1994). Firstly, by 
exerting dominant negative (DN) effect, which means that mutant p53 allele is able to 
inactivate the wild type p53 allele function. This inactivation involves a change in the 
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wild type p53 protein conformation to the mutant form, therefore loses its transcriptional 
activity (De Vries et al., 2002). However, mutant p53 cannot be stabilized since wild type 
allele is still existent. This type of mutant is found in some human cancers such as Li-
Fraumeni syndrome (Srivastava et al., 1990).  
Secondly, possessing dominant-positive effect that can be described as gain of 
function or acquiring new function. In this phenomenon, mutant p53 must have both 
alleles mutated to be able to acquire new functions, the same requirement for the loss of 
function (Gualberto et al., 1998). Although, the mechanism of gain of function remains 
unclear, it results in enhanced tumorigenic potential. Several studies on some mutants 
have demonstrated alteration in the transcriptional activities as gain of function (Shaulian 
et al., 1992). This type includes mutation at codons 143, 175, 248 and 281 (reviewed in 
Dittmer et al., 1993). 
There are around 280 somatic missense mutations distributed over 90 codons. 
Nearly 98% fall within 110 to 307 codons and mutations outlying exon 5-8 is rare (Nigro 
et al., 1989; Petitjean et al., 2007). Many of them are at hotspot codons including, 175, 
248, 249, 273, 179, 157, 217, 213, 181, 195 and 280 (Figure 10). Each cancer type has 
different spectra of mutations and frequency as well (reviewed in Olivier et al., 2010). 
Here, we will review the major mutations that are present in each domain, with a 
particular focus on the mutations that are present in high frequency in the hotspots and 
possess critical function as well.  
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Figure 10: A diagram to show the functional domains of p53 and some of the sites that are 
frequently mutated in human tumors (Slee et al., 2004).  
 
P53 Mutations in the Transactivation Domain (TAD)  
TAD contains multiple mutations including the first two in p53, Leu 22 and Trp 
23, but these mutations mostly have no or mild alterations in p53 function (Zhu et al., 
1998). However, TAD contains the mdm2 interaction site, so mutations (L22Q and 
W23S) would cause site disruption. The latter will result in p53 stabilization and a 
decrease in p53 transactivation capacity (Lin et al., 1994).  
P53 Mutations in the Proline-Rich Domain (PRD) 
Numerous single nucleotide polymorphisms (SNPs) are present at the TP53 locus. 
PRD is the most targeted domain for SNPs, which affect the response to therapies as well 
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as increase cancer development (Zhou et al., 2007). PRD is also the target of several 
transcription binding sites such as mdm2 and p300, therefore SNPs in these binding site 
will prevent their interaction and abolish their function as well (Dornan et al., 2003). The 
most common polymorphism in PRD is the variation of proline/arginine (CCC or CGC) 
at codon 72 (rs1042522), which results in either of two residues that are differing in their 
functional outcome.  
Mutant p53 expressing proline allele is more efficient in transcription activation 
of p21 than p53 expressing arginine allele, whereas p53 arginine is a more potent inducer 
of apoptosis than p53 proline (Salvioli et al., 2005). In addition, several studies have 
reported the p53 proline association with the risk of lung adenocarcinoma (Fan et al., 
2000), but p53 arginine mutation occurred with more frequency compared to p53 proline 
especially in squamous cell cancers since it is more susceptible to missense mutations 
than proline. Furthermore, p53 arginine showed a decreased response to chemotherapy in 
clinical studies. Other p53 PRD mutants and deletions have been illustrated in in vitro 
studies as they have little effects on p53 stability and function upon DNA damage, but the 
mutant protein remained as active as wild type p53 (Edwards et al., 2003). 
P53 Mutations in the DNA-Binding Domain 
As previously mentioned, DBD is the main core domain in p53 protein. In fact, it 
is the target of more than 80% of p53 missense mutations that are clustered between 
amino acids 100 to 300. Each residue in this area has been found to be mutated in human 
tumors, and the resulting proteins display a marked heterogeneity in terms of loss of 
structure and function. Seven hot spot mutations, which are the most frequently mutated 
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in cancers, have been founded in DBD (Walker, et al., 1999). Since this domain is 
essential in p53 main function, presence of mutations would lead to both p53 stabilization 
as well as loss of its transcriptional capability at various degrees such as partial activation 
of targets genes  (Nenutil et al., 2005). Depending on the nature of the mutation, they can 
be classified as contact mutants or structural mutants. 
Contact Mutants 
Mutations that are located in the protein-DNA contact region (amino acids 100–
300) are referred to as contact mutants. They occurred in either the L3 loop of p53 or the 
nearby loop-sheet-helix motif (Cho et al., 1994) and they affect the DNA-interacting 
residues. Some contact mutants directly interact with the DNA at the minor groove and 
some with the DNA phosphate backbone through the RE-p53 binding site. As a result, a 
protein that fails to transcribe p53-responsive genes will be produced. Mutants such as 
R248W, I195T, A293, N268D and R273H are examples of this type of mutation, named 
class I mutations. Many contact mutants were studied in vivo and in head and neck cancer 
and shown failure in the induction of cell cycle arrest and apoptosis including R248 
(Erber et al., 1998). A study performed by Wong et al. (1999) showed that contact 
mutants might reveal some local changes in the protein conformation and folding but in a 
small degree.  
Structural Mutants 
The other type of mutants that are not in the DNA contact region, but involved in 
the protein folding and conformation are termed structural mutants. They are caused by 
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structural perturbations within the core domain resulting in disruption of the protein 
folding, and thus indirectly affect DNA-binding (Cho et al., 1994). They occur in the L2 
loop in the zinc region leading to a local or global change of the protein conformation 
into an inactive form (Milner and Medcalf, 1991; Cho et al., 1994). This category 
includes, R175H, Y220C, G245S, R249S and R282W mutations that are also known as 
class II mutations.  R175H is the third most frequently mutated residue in cancers that has 
an altered conformation with intense binding to hsp70 heat shock protein.  
P53 Mutations in the Tetramerization and Regulatory Domain 
Although this domain is crucial for p53 activity as a tetramer, only few mutations 
have been documented in this area. Up to date, none of the reported mutation has shown 
any noticeable effect on p53 function. A study was performed on a mouse model 
expressing mutation S312A, which is equal to mutation S315A in humans has confirmed 
the previous reported statement (Lee et al., 2011). Also, in response to stress, another 
study was conducted in fibroblasts and demonstrated no effect of this mutation on p53 
function. However, multiple mutations, double or triple, in this domain may inhibit p53 
activity, as shown in the mutational analysis by Waterman et al. (1995). 
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AIM OF THE STUDY 
As seen in the review, there is a lack of real correlation between p53 genotype 
status and E1B deleted adenovirus replication ability. Therefore, the aim of this study is 
to understand the relationship between p53 status and the replication sensitivity of 
Ad5dlE1b55kDa at the molecular level. This objective was achieved by examining the 
following:  
1- The effect of the quantity of wild type p53 expression and cellular backgrounds 
on the replication efficiency of Ad5dlE1b55kDa by evaluating the viral DNA 
replication ability under the expression of various levels of p53.  
2- The effect of p53’s functional activity on the sensitivity of Ad5dlE1b55kDa 
replication by evaluating the effect of active wild type p53 and mutant p53 on 
viral replication.  
3- Assessing the functional status, transcriptional activity, of mutant p53 that 
supported viral growth to reveal what transcript rescued viral growth and whether 
this transcript lost the complete p53 function. 
4- Determining the viral rescuing mechanism underlying selectivity and oncolysis on 
the basis of gene expression.  
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MATERIALS AND METHODS 
Plasmid Construction and Cloning 
Bacterial strain 
Escherichia coli DH5α was utilized in this study for cloning and propagation of 
plasmid DNA. This strain contains specific characteristics in its genome as follows: 
ΔM15, Δ(lacZYA-argF), U169, recA1, endA1, hsdR17 (rK-mK+), supE44, thi-1, phoA, 
deoR, gyrA96, relA1, providing efficient transformation (Woodcock et al., 1989).  
Competent cells 
Competent cells were prepared according to Inoue et al. (1990). The procedure 
was conducted as follows: a stock of cell population from New England Biolabs (NEB) 
was used as a source to propagate the cells. An antibiotic-free LB agar plate was utilized 
for growing the colonies and from the grown colonies; a single colony was used 
afterwards to inculcate 5 mL of antibiotic-free LB medium. After inoculation, the culture 
was incubated overnight in a 37°C adjusted shaker. The inoculum was then transferred 
into a 2L flask containing 250 mL of SOB medium. This medium consists of 0.5% (w/v) 
bacto-yeast extract, 2% (w/v) bacto-tryptone, 10 mM MgCl2, 10 mM NaCl, 2.5 mM KCl, 
10mM MgSO4 and 20mM glucose. The culture was then grown by shacking at 250 rpm 
and 18°C until it reached OD600= 0.6, which was measured using a spectrophotometer. 
Once the OD was reached, the culture was placed on ice for 10 minutes and then 
subjected to centrifugation for 10 minutes at 3000x g and 4°C in a Beckman GPR 
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centrifuge. The supernatant-free pellet was then resuspended in 80mL of pre-prepared 
ice-cold transformation buffer (TB: 10 mM Hepes, 55 mM MnCl2, 15 mM CaCl2, 250 
mM KCI, at pH 6.7) and placed on ice for 10 minutes. Resuspended cells were subjected 
to a second centrifugation for 10 minutes at 3000x g and 4°C. The supernatant was then 
decanted leaving the pellet for another resuspention step in 12-15 mL of ice-cold TB. 
During incubation on the ice, dimethyl sulfoxide (DMSO) was added to a final 
concentration of 7%. The competent cells were frozen immediately in liquid nitrogen and 
transferred to -80°C.  
Bacterial culture 
Luria-Bertani broth (LB) was prepared for growing bacterial cultures. The 
medium contents, 0.5% (w/v) bacto-yeast extract, 1% (w/v) bacto-tryptone and 1% (w/v) 
NaCl were mixed together and autoclaved to sterilize the medium. The medium was kept 
in 50cc tubes and stored at 4°C. until further use. When the medium was used for 
growing cultures, the cultures were maintained at 37°C.  
Luria-Bertani plates were also prepared for growing bacterial colonies by 
adding 2% (w/v) agar to LB medium components. For selection purposes, after 
autoclaving, the LB was cooled down to 45°C and 0.1 mg/mL ampicillin was added 
since, all plasmid constructs contain the ampicillin gene as a selection marker. 
Ampicillin-containing agar was poured into ten milliliter Petri dishes until it completely 
solidified and then stored at 4°C.  
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Transformation and inoculation 
Ligated plasmid or plasmids isolated from bacterial cells were prepared prior 
transformation. One hundred microliter aliquots of frozen competent cells were used for 
each plasmid DNA. Cells were placed on ice and inoculated with plasmid DNA mixture. 
The mixture was kept on ice for 30 minutes and then subjected to heat shock at 42°C for 
45 seconds. Immediately after the heat shock, the cells were placed back on the ice again 
for 2 minutes only. Once removed from ice, 700 µL of antibiotic-free LB was added to 
the mixture and incubated in the shaker for 45-50 minutes at 37°C after which 100 µL of 
this mixture was plated on 2X ampicillin (0.1 mg/mL) LB agar plates. This selects for 
growth of positively transformed colonies. After incubating the plates overnight at 37°C, 
the selected colonies were picked and inoculated in 2-3mL of 2X ampicillin LB and 
shaken overnight at 37°C.  
Plasmid DNA preparation 
Small-scale isolation of plasmid DNA was carried out using a commercial Kit 
(Plasmid DNA Miniprep Kit, Norgen Biotek Corp.), according to the manufacturer’s 
instructions. After the isolation, the plasmid DNA was stored at -20°C for further 
analysis.  
Large-scale isolation was also carried out for plasmid DNA using the Plasmid 
DNA Maxiprep Kit (Norgen Biotek Corp.), according to manufacturer’s directions. The 
purified plasmid was then stored at -20°C and screened at a later time by restriction 
enzyme confirmation analysis. 
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Mammalian Cell Culture 
Cell lines maintenance 
 Human Non-small-cell lung carcinoma (H1299) cells were used in this study as 
a p53 null cell line. They are the subclones of ATCC CRL-5803, which is derived from the 
metastatic site of a lymph node. Cells were maintained and cultured as a monolayer in 
RPMI-1640 Medium (Life Technologies, Gibco®), supplemented with 10% (v/v) fetal 
bovine serum (FBS, Innovative Research, Inc.) and 1% (v/v) penicillin/streptomycin 
(Invitrogen Corp., Gibco®). Cells were incubated in a water-jacketed incubator (Fisher 
Scientific, Pittsburgh PA) at 37°C with 96% relative humidity and 5% CO2. 
Cells were passaged twice weekly until they reached 90% confluencey using 
ethylenediaminetetraacetic acid-trypsin (EDTA-trypsin) and 0.05% phenol red solution 
(Life Technologies, Gibco®), according to ATCC’s instructions. Briefly, the medium 
was aspired and cells were washed with 6 mL phosphate buffered saline (PBS at pH 7.4) 
(Life Technologies, Gibco®) to remove all traces of trypsin inhibitors containing-serum. 
Two milliliters of EDTA-Trypsin was then added to the cell monolayer of a 150 mm 
plate. After 2-3 minutes, cells were lifted by gently tapping the plate’s sides and 4-6 mL 
of complete growth medium, RPMI-1640 medium, was added to stop the trypsin effect. 
A new culture plate was then filled with the medium and 2 mL of the cell suspension was 
added and cultures were incubated at 37°C.  
HeLa cells, derived from cervical cancer cells of Henrietta's tumor (ATCC CCL-
2) were also used in this study. The maintenance and handling of these cells was done in 
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Dulbecco’s Minimum Essential Medium (DMEM, Invitrogen Corp., Gibco®), 
supplemented with 5% (v/v) fetal bovine serum (FBS, Innovative Research, Inc.) and 1% 
(v/v) penicillin/streptomycin (Invitrogen Corp., Gibco®). EDTA-Trypsin and PBS were 
used to rinse and lift the cells and two milliliters of the cell suspension was added to 
medium containing-culture plate. The cultured cells were then incubated at 37°C in the 
same incubator conditions as was stated above.  
Human embryonic kidney (HEK) 293 (Microbix Inc., ATCC CRL-1573) was 
the third cell line used in this study. Cells were maintained in autoclavable Minimum 
Essential Medium (MEM, Invitrogen Corp., Gibco®) supplemented with 3% (v/v) 
sodium bicarbonate (Invitrogen Corp., Gibco®), 10% (v/v) fetal bovine serum (FBS, 
Innovative Research, Inc.), 1% (v/v) Antibiotic-Antimycotic (10,000 units/mL of 
penicillin, 10,000µg/mL of streptomycin, and 25µg/mL of Fungizone Antimycotic, 
Invitrogen Corp., Gibco®) and 1% L-glutamine (Invitrogen Corp., Gibco®). The same 
splitting procedure that was described in the cell lines above was carried out in HEK293 
cells but with different solution. Cells were washed and lifted with saline citrate and 
appropriate aliquots of cell suspension were then added to new culture plate and cultured 
cells were then incubated at 37°C.  
Cell counting 
After lifting the cells from the plates, the number of cells was counted using a 
hemocytometer. A volume of 15µL was placed on the notch of the hemocytometer and 
then covered with a cover slip. The sample was visualized under the light microscope and 
the average number of the cells was counted in each defined field of the hemocytometer. 
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Based on the average number, the total number of cells in the original sample was then 
calculated.  
Plasmid transfection using Lipofectamine 2000  
The introduction of plasmid DNA into mammalian cell lines was done using 
Lipofectamine 2000 transfection reagent (Invitrogen Corp., Gibco®) according to the 
manufacturer’s instructions. Briefly, when the cells were 80-90% confluent, the culture 
medium was replaced with antibiotic-free medium to avoid toxicity an hour prior to the 
transfection. For a 24-well plate, 100µL of transfection mixture (a mix of plasmid DNA 
and transfection reagent) was prepared for each well. A known amount of plasmid DNA 
was diluted in 50 µL Opti-MEM I Reduced Serum Medium (Invitrogen Corp., Gibco®). 
Similarly, 2 µL of Lipofectamine 2000 was diluted in 50 µL Opti-MEM I Reduced Serum 
Medium (Invitrogen Corp., Gibco®). Both mixtures were incubated for 5 minutes at 
room temperature (RT) and then mixed together and incubated again for 20 minutes at 
RT. The 100µL-combined mixture was then added dropwise onto the well and shaken for 
fair distribution. The cells were then incubated at 37°C for 5-6 hours. Following 
incubation, the medium was changed with complete growth medium containing an 
antibiotic. 
Freezing and thawing  
All cell lines were preserved and frozen using the same method except for the 
lifting step, in which HEK293 cells were lifted using saline citrate and the other cell lines 
used EDTA-Trypsin. When the cells reached 80-90% confluence, they were rinsed and 
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lifted and then centrifuged at 1200 rpm for 5 minutes at RT (Eppendorf centrifuge 5810). 
The supernatant was aspirated and the cell pellet was resuspended in 3 mL of freezing 
medium, composed of complete growth medium with 5% FBS and 10% (v/v) DMSO. 
Aliquots of cell suspension were then transferred to 1mL sterile cryogenic tubes 
(Sarstedt). The tubes were frozen immediately in dry ice and then stored at -80°C 
overnight. The next day, the cryovials were transferred to the liquid nitrogen tank for 
long-term storage.  
Cell thawing was done by retrieving the vials from liquid nitrogen and pouring 
the content in 15 mL falcon tubes containing 5mL of the appropriate growth medium. 
The tubes were then centrifuged at 1200 rpm for 3 minutes at RT. The medium was 
aspirated and the cell pellet was resuspended in 2-3 ml of the growth medium. The cell 
suspension was then poured into a 150 mm cell culture plate containing 20 mL of 
complete growth medium and incubated at 37°C overnight. The next day, the medium 
was changed to remove DMSO and the cells were monitored until they became confluent. 
Adenovirus production 
 Ad5dlE1b55kDa, is a type 5 adenovirus with a deletion in the E1B region. This 
was generously provided by Dr. Yousef Haj-Ahmad (Haj-Ahmad, 1986). The production 
of this virus was done in HEK 293 cells since it is transformed with the adenovirus E1 
gene, making it a permissive cell line for adenovirus production (Graham et al., 1977). 
Briefly, 2mL of viral inoculum was diluted in 8mL PBS++infection medium (0.01% 
CaCl2.2H2O and 0.01% MgCl2.6H2O dissolved in PBS). At 90% confluency, the culture 
medium was aspirated and the infection medium was added to the cells and incubated at 
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37°C for an hour while rocking the plate. Following incubation, 20mL of growth medium 
was added and incubated at 37°C overnight. Cells were monitored for the cytopathic 
effect (CPE) for days and when they displayed complete CPE, the cells were removed 
with a cell scraper (BD Falcon). The cells and medium were then transferred to 50cc tube 
and centrifuged at 1000xg for 5 minutes. The supernatant was collected and stored at -
80°C whereas the cell pellet underwent several freeze and thaw cycles to release the 
virus. The crude virus stock was supplemented with 10% sterile glycerol and stored at -
80°C.  
Ad5wt, wild type adenovirus type 5, was also provided by Dr. Yousef Haj-
Ahmad (Haj-Ahmad, 1986). AdGFP, adenovirus type 5 with a deletion in E1 region, was 
kindly provided by Dr. Vanja Misic (Misic, 2013). Both virus stocks were provided in a 
generous amount and ready for infection of mammalian cell lines. 
Adenovirus titration 
Two different methods of titration were utilized to titer Ad5dlE1b55kDa: RT-
qPCR and end-point titration assay according to Gustafsson et al., (2012) and Ibrahim et 
al., (2003). RT-qPCR measures the viral DNA copies per µL whereas end point dilution 
determines the plaque-forming unit (PFU) per mL. The end point dilution method was 
carried out using serial dilutions of the desired virus to infect HEK293 cells with 80-90% 
confluency. A ten-fold dilution of viral stock was prepared in 1 mL PBS++. The cell 
monolayer of a 24-well plate was infected with 100µL aliquot of each dilution and a 
growth medium was added afterwards. After the incubation period, 4 days post-infection, 
the displayed plaques that represent the number of viral particle were measured by 
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counting the area of cells in a monolayer that displayed a cytopathic effect. They 
appeared round and darker than other cells under the microscope. They were 
approximately 21 plaques. The viral concentration was determined in PFU/mL as 
follows: titer = (number of plaques)(dilution factor)/(infection volume).  
Adenovirus infection 
 Adenovirus infection was carried out in 24-well plates by using a viral volume 
equivalent to the desired multiplicity of infection (MOI). This volume was then mixed 
with PBS++ in a total volume of 100 µL/well. Then, it was added to the cell monolayer 
after aspirating the medium. The plate was then incubated for an hour, with swirling 
every 15 minutes, at 37°C in an incubator using 5%CO2 and 96% humidity. Two 
milliliters of growth medium was then added to each well and the plate was maintained in 
the incubator.  
DNA/RNA Manipulation 
DNA isolation 
Total DNA and total RNA were isolated from the same sample by using the 
RNA/DNA/Protein Purification Kit (Norgen Biotek Corp.), according to the 
manufacturer’s instructions. The purified DNA and RNA were examined for quality by 
agarose gel electrophoresis. 
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DNA quantification 
Total DNA samples were quantified using NanoDrop™ 2000 Spectrophotometer 
(Thermo Scientific) in which the absorbance was measured at wavelengths 260 nm (A260) 
and 280 nm (A280). According to Glasel (1995), the value of A260/A280 ratio was used as 
determinant of sample purity. A sample’s ratio value between 1.8 and 2.0 is considered 
pure.  
Cleaning of PCR product 
The amplified fragments that were obtained from a PCR reaction were cleaned 
using the PCR Purification Kit (Norgen Biotek Corp.), according to the manufacturer’s 
instructions. Breifly, the amplified DNA product was subjected to clean up and 
purification step, which is based on spin column chromatography that bind DNA in an 
ionic concentration manner, to remove PCR by-products. The purified samples were then 
used as inserts for the subsequent step of cloning.  
Restriction enzymes digestion 
Multiple digestions with restriction enzymes were carried out for downstream 
cloning purposes. The restriction enzymes were obtained from New England Biolabs 
(NEB) and used according to the manufacturer’s directions. Restriction enzyme digestion 
was used for either digesting the fragments of vectors and inserts for the ligation step or 
in the confirmation of the desired clone. In digestion preparations used for confirmation 
purposes, 2 to 5 µg of DNA was digested using one to ten units of restriction enzyme; 
2µL provided buffer and Nuclease-free water was added to complete the 20µL reaction 
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volume. This reaction was then incubated for two hours followed by agarose gel 
electrophoresis. 
However, in digestion preparations used for obtaining vectors and inserts 
fragments, larger volumes and longer incubation times were performed according to 
NEB’s protocol. In this digestion type, multiple enzymes were required, equal amount of 
enzymes were used and the reaction was done in the most suitable buffers for optimal 
enzyme activity. In the case of incomplete digestion, the amount of DNA and enzymes 
were adjusted. Also, a sequential digestion was conducted to ensure the activity of the 
enzymes and to avoid incompatible enzymes. In addition, enzyme inactivation at 70°C 
for 20 minutes was performed when required.  
DNA ligation 
The digested and cleaned fragments of vectors and inserts were then ligated in a 
20µL reaction volume. One microliter of T4 DNA ligase (New England Biolabs) that 
contains 400 units was used for this purpose, according to the manufacturer’s 
instructions. The reaction was done at RT for 2-3 hours to ligate the sticky ends of the 
two DNA fragments. However, when ligating blunt ends, reactions took 8 hours at RT or 
occasionally overnight at 16°C.  
Synthetic oligonucleotides annealing 
Two oligonucleotides were used for the construction of poly-A signal and 
p53R72P fragments. All were purchased from Integrated DNA Technology (IDT) flanked 
with restriction enzyme sites for cloning purposes. The fragments were mixed and 
	   74	  
annealed through the use of the iCycler PCR machine (Bio-Rad). The PCR program used 
was as follows: the mixed oligonucleotides were heated to 94°C and the temperature was 
lowered in increments of 0.5°C every 10 seconds until it reached 18°C and with a final 
cooling down to 4°C. 
Oligonucleotide ligation 
 The two annealed oligonucleotides were then ligated together in a 20µL reaction 
volume containing 1X Taq DNA ligase buffer and using 40 units of Taq DNA ligase 
(New England Biolabs), according to the manufacturer’s instructions. The reaction was 
then incubated at 45°C for 15 minutes. The ligation process was dependent on forming a 
phosphodiester bond between 5`phosphate and 3` hydroxyl end of the two annealed 
oligonucleotides.  
DNA sequencing 
DNA sequencing of all cloning steps starting from the PCR product continuing 
until the desired constructs was done using Applied Biosystem 3130x Genetic 
Bioanalayzer DNA sequencer. This instrument can provide real time detection of DNA 
sequences using dideoxy DNA sequencing method that was developed by Sanger et al. 
(1977). Cycle sequencing reaction was carried out along with BigDye Terminator 
chemistry using the BigDye Terminator v1.1 Sequencing Standard Kit (Applied 
Biosystems). Multiple forward and reverse primers (Table 1) that are specific for each 
construct were utilized to amplify 800-1000 long fragments. These data were directly 
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analyzed for their sequence as well as mutation detection using Finch TV software as 
base calling program.   
Table 1: List of sequencing primers used in this study 
Name Sequence 
P72-F 5`CAGACCTATGGAAACTACTTCC3` 
P175-F 5`ACTGAAGACCCAGGTCCAGATGAAG3` 
P175-R 5`AGGGGCCGCCGGTGTAGGAGCTGC3` 
P53-F 5`TCCCTTCCCAGAAAACCTACC3` 
P53-R 5`CTAGATGGCGCCTCAGTCTGAGTCAGGCCCTTC3` 
P268-F 5`CGCCTGAGGTTGGCTCTGACTGTACCACCAT3` 
MARI-F 5`TCCCCGGGTTAGTAAGACATCACCTTGCATTT3` 
MARII-R 5`TGCTCGAGAGCCATAGTTTGAGTTACCCTTT3` 
HPRE-F 5`CTAGATGGCGCCTTGCTCGGCAACGGCC3` 
BGH-F 5`TCGAATTCTGTGCCTTCTAGTTGCCAGC3` 
Total RNA isolation 
The isolation of total RNA was carried out using the Total RNA Purification Kit 
(Norgen Biotek Corp.), according to the manufacturer’s directions.  
RNA quantification 
All purified total RNA samples were quantified using NanoDrop™ 2000 
Spectrophotometer (Thermo Scientific). The quantification of RNA sample was 
dependent on measuring the absorbance at wavelengths 260 nm (A260) and 280 nm (A280) 
(Glasel, 1995).   
Analysis of RNA on Agilent 2100 Bioanalyzer  
RNA samples were analyzed for their quality using the Agilent RNA 6000 kit 
with the Agilent 2100 Bioanalyzer (Agilent Technologies Inc.), according to the 
manufacturer’s instructions. Simply, Bioanalyzer uses a lab on a chip approach to 
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determine RNA integrity using the same principles as agarose gel electrophoresis.   
DNase treatment of RNA samples 
For pure isolated RNA samples, the residual DNA in the RNA sample was 
digested using TURBO DNase (Ambion). In a total reaction volume of 100 µL, 50 µL of 
RNA sample was mixed with the provided buffer and four units of TURBO DNase. The 
prepared reaction was then incubated at 37°C for 30 minutes. 
RNA cleaning 
The cleaning of RNA samples was done using the RNA CleanUp and 
Concentration Kit (Norgen Biotek Corp.), according to the manufacturer’s instructions. 
DNA/RNA Agarose Gels 
Agarose gels for DNA samples 
Agarose gels were made according to the procedure of Sambrook et al., (1989). 
DNA samples were run on various percentage agarose gels depending on the size of the 
fragment to be analyzed and the amount of DNA in the sample. Agarose gels were then 
visualized under ultraviolet (UV) light. The pictures were then captured using the 
AlphaImager 2200 (Alpha Innotech).  
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Agarose gel extraction 
The extraction of DNA fragments for cloning, either vector or insert, after running 
on agarose gel was carried out using the DNA Gel Extraction Kit (Norgen Biotek Corp.,), 
according to the manufacturer’s directions. 
Formaldehyde agarose gels for RNA samples 
The integrity of isolated and cleaned RNA was determined using formaldehyde 
agarose gel electrophoresis. The gel was prepared according to Sambrook et al. (1989). 
Gels were then exposed to UV light and pictures were captured using the AlphaImager 
2200 (Alpha Innotech).  
PCR  
Polymerase chain reaction (PCR) (Mullis et al., 1986) was performed according 
to the manufacturer’s instructions of the polymerase. All of the forward and reverse 
primers (Table 2) that were used in PCR reactions were carefully designed and also 
ordered through the IDT. These primers were utilized at a concentration of 50µM by 
diluting them in Nuclease-free water (Ambion) and then stored as aliquots at -20°C.  
 All end point PCR reactions were performed in a Bio-Rad iCycler thermal 
cycler. A volume of 20µL was prepared for each reaction consisting of 1-2µL of DNA or 
complementary DNA (cDNA) template, 0.12 µL of each primer (50µM stock), 1µL 
deoxynucleotide triphosphates (dNTPs) (10mM), 2µL of the supplied 10X reaction 
buffer, 0.2 µL (2.5 units/ µL) of pfu polymerase or Taq DNA polymerase (5 units/ µL), 
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and the reaction volume was completed with distilled water (dH20). The PCR reaction 
program was as follows: 94°C for 3 minutes for template denaturation. Next, annealing 
was done for 15 seconds. The applied annealing temperature was variable, but it was 5°C 
lower than melting temperature (Tm). Following that, extension at 72°C for 1/2 minute 
per 1kb and a denaturation at 94°C for 30 seconds. The number of cycles was between 
thirty and forty cycles finishing with a hold for 5 minutes at 72°C and a final incubation 
at 4°C.  
Real-time PCR 
Probe-based qPCR reactions were performed in the CFX Connect Real-time PCR 
Detection System machine (Bio-Rad) to evaluate the gene expression level of p53 as well 
as viral DNA level. For the reverse transcriptase reaction, known concentrations of 
DNA/cDNA in which the initial RNA volume was equivalent to 200-300 ng were used. 
Specific probes for the p53 gene, adenoviral hexon gene and housekeeping genes along 
with specific primers were utilized to amplify the desired region (Table 2&3). In addition, 
plasmid copy number was determined through the use of a standard curve of known 
plasmid concentration. The reaction mixture contained 3µL of cDNA/DNA template, 10 
µL of 2X PCR master mix (Norgen Biotek Corp.) 2 µL of primer mix (5µM stock), 1µL 
of specific probe for each gene (10µM) in a 20µL reaction. The TaqMan qPCR program 
was performed on the reactions as follows: the mixture was heated to 95°C for 3 minutes 
followed by denaturation at 95°C for 15 seconds. Then, the reaction underwent annealing 
followed by extension for 30 seconds at 60°C. The last cycle was repeated for 40 cycles. 
 On the other hand, SYBR GREEN-based Real-time PCR using CFX Connect 
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Real-time PCR Detection System machine (Bio-Rad) was carried out to evaluate the gene 
expression of p53 target genes. Specific forward and reverse primers for each gene were 
used (Table 2). The reaction contained 7.5 µL of 2X SYBR GREEN master mix (Bio-
Rad), 0.12 µL of each primer (50µM stock) and 3µL of cDNA/DNA template in 15µL 
reaction. The mixture was heated to 94°C for 15 minutes for the activation of the hotstart 
enzyme. The cycling reaction was performed as follows: the temperature was set at 95°C 
for 15 seconds, then 30 seconds for annealing at a temperature that is 5°C lower than the 
primer melting temperature and then reduced to 72°C for one minute. This was repeated 
for 40 cycles. Following this, the temperature returned to the annealing temperature for 1 
minute and the melting curve was carried out by lowering the temperature by 0.5°C 
increments every 10 seconds for 80 rounds.  
Table 2: List of primers and oligonucliotides used in this study 
Name Sequence 
P53pro-F 5`CTAGATGACGTCCCTAGGAGATCTCGAGGGGAGAAAACGTTAGGGTGTG3` 
P53pro-R 5`GTCGAGCATATGGGCAGTGACCCGGAAGGCAG3` 
TP53-F 5`CTAGATCATATGGTCTAGAGCCACCGTCCAGG3` 
TP53-R 5`CTAGATGGCGCCTCAGTCTGAGTCAGGCCCTTC3` 
MARI-F 5`TCCCCGGGTTAGTAAGACATCACCTTGCATTT3` 
MARI-R 5`AACAGCCATAGTTTGAGTTACCCTTT3` 
MARII-F 5`TGCCTAGGTTAGTAAGACATCACCTTGCATTT3` 
MARII-R 5`TGCTCGAGAGCCATAGTTTGAGTTACCCTTT3` 
HPRE-F 5`CTAGATGGCGCCTTGCTCGGCAACGGCC3` 
HPRE-R 5`CTGAATTCGACATTGCTGGGAGTCCAAGAG3` 
BGHpolyA-F 5`TCGAATTCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTG 
CCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAG 
GAAATTGCAT3` 
BGHpolyA-R 5`TCCCCGGGGCCTGCTATTGTCTTCCCAATCCTCCCCCTTGCTGTCCTGCCCACC 
CCCCAGAATAGAATGACACCTACTCAGACAATGCGATGCAATTTCCTCATTTTA 
TTAGGA3` 
PUC19-F 5`GCAGAAAAAAAGGATCTCAAGAAG 
PUC19-R 5`TAACTGTCAGACCCAGTTTACTC3` 
Adeno-F 5`CGGGTAATATGGGTGTTCTGG3` 
Adeno-R 5`GCTCTGTGTTTCTGTCTTGC3` 
GAPDH-F 5`AAATTCAACCTCTTGGGCCCTCCT3` 
GAPDH-R 5`AGGCGCCCAATACGACCAAATCTA3` 
S15-F 5` CTACAACGGCAAGACCTT CA 3` 
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S15-R 5` GGCTTGTAGGTGATGGAGAAC 3` 
Fas-F 5`AAGTGACTGACATCAACTCC3` 
Fas-R 5`CACTTCTAAGCCATGTCC3` 
BAX-F 5`AGGGTTTCATCCAGGATCGAGCAG3` 
BAX-R 5`ATCTTCTTCCAGATGGTGAGCGAG3` 
MYC-F 5`TACCCTCTCAACGACAGCAG3` 
MYC-R 5`TCTTGACATTCTCCTCGGTG3` 
ZEB2-F 5`GGCGCAAACAAGCCAATCCCA3` 
ZEB2-R 5`TTCACTGGACCATCTACAGAGGCTT3` 
PRB53-F 5`TAACAGTTCCTGCATGGGCGGC3` 
PRB53-R 5`AGGACAGGCACAAACACGCACC3` 
Mega-F 5`GACTTGCACGTACTCCCCTGC3` 
Mega-R 5`TAAGATGCTGAGGAGGGGCCAG3` 
E1B-F 5` GAATGAATGTTGTACAGGTGGCT3` 
E1B-R 5` AGGAAAACCGTACC GCTAAAATTG3` 
BGH-F 5`TCGAATTCTGTGCCTTCTAGTTGCCAGC3` 
BGH-R 5`TCCCCGGGGCCTGCTATTGTCTTCCCA3` 
5S-F 5`GCCATACCACCCTGAACG3` 
5S-R 5`AGCCTACAGCACCCGGTATT3` 
ATM-F 5` TGAAGAAGGAAGCCAGAGTACA3` 
ATM-R 5` CCCCACATTGCTTCGTGTTC3` 
CASP2-F 5` CAAAGTGGGCAGTTTCAGCC3` 
CASP2-R 5` ACATATCCTCCAGGTGGCCT3` 
ATR-F 5` ACACTGAGAACTGGCCTTCG3` 
ATR-R 5` ATGATCCAGGCAGCGAACAA3` 
CHEK-F 5` TTTGCCAATCTTGAATGTGTGA3` 
CHEK-R 5` AGGTTCCATTGCCACTGTGAT3` 
MDM2-F 5` AGGAGATTTGTTTGGCGTGC3` 
MDM2-R 5` TGAGTCCGATGATTCCTGCTG3` 
 
Table 3: List of probes used in this study 
Probe Name Sequence 
P53 5`/56-FAM/CGGAGGCCC/ZEN/ATCCTCACCATCATCA/3IABkFQ/3` 
GAPDH 5`FAM-AGGAGATGC/ZEN/TGCATTCGCCCTCTTAA/3IABkFQ3` 
Adeno. 5`FAM-CATTCAACT/ZEN/GCGATGCTTGGCCC/IABkFQ3` 
5S 5`/56-FAM/TT AGT ACT T/ZEN/G GAT GGG AGA CCG CCT /3IABkFQ3` 
S15 5` /56-FAM/AGG TGG AGA /ZEN/TCA AGC CCG AGA TGA /3IABkFQ/3` 
Site directed mutagenesis PCR 
The introduction of mutations in the p53 wild type sequence was achieved 
through the use of mega primer strategy that was developed by Tyagi et al. (2004). In this 
strategy, two rounds of PCRs were conducted using two intact flanking primers and one 
mutagenic primer to generate the required fragment. Since one of the constructed plasmid 
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(pHPRE) contains the p53 wild type sequence, it was used as a template of the first PCR 
reaction to amplify the target region. In the first round, two primers (forward and 
reverse), of which one of them is mutated, were used to generate the first PCR product 
that contains the desired mutation. Then, the first product was used as a template for the 
second round of PCR reaction using intact forward and reverse primers to amplify the 
mutant fragment thus generating the final mutant p53 PCR fragment. This was then used 
in subsequent cloning steps. Primers are listed in Table 4.  
Table 4: List of mutated primers used in this study 
Name Sequence 
72R-F 5'AGGTCCAGATGAAGCTCCCAGAATGCCAGAGGCTGCTCCCCGCGTGGCC CCTGCAC 
CAGCAGCTCCTACA3` 
72R-R 5'CCGCCGGTGTAGGAGCTGCTGGTGCAGGGGCCACGCGGGGAGCAGCCTCTGGCATTCT 
GGGAGCTTCATCTGGACCTGGGTCTTCAG3' 
175H-F 5`TGCACGTACTCCCCTGCCCTCAACAAGATGTTTTGC3` 
175H-R 5`GATGCTGAGGAGGGGCCAGACCATCGCTATCTGAGCAGTGCTCATGGTG3` 
 
Reverse transcription PCR 
Reverse transcription PCR was performed on RNA samples to generate cDNAs 
that were used as template for end point PCR and qPCR reactions. The mixture contained 
300-500 ng of total RNA mixed with 0.5µL of 100mM oligo (dT)18 primer (IDT) and the 
reaction volume was then brought up with RNase/DNase-free water to 5µL. The reaction 
program was as follows: the mixture was heated to 70°C for 5 minutes and then held at 
4°C.  During the hold, 15µL of RT reaction solution was added to the mixture. This 
solution contained 4µL of 5X First Strand Buffer (250mM Tris-HCl [pH 8.3 at RT], 
375mM KCl, 15 mM MgCl2), 1µL of 10mM dNTPs, 2µL of 0.1 M dithiothreitol (DTT), 
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0.2µL Superscript III reverse transcriptase (Invitrogen) and 7.8 µL RNase/DNase-free 
water (Ambion). The synthesis of cDNA was then continued at 25°C for 5 minutes, 42°C 
for 90 min and 70°C for 15 minutes followed by maintaining the temperature at 4°C.  
Gene expression profiling by microarray 
The transcriptome expression analysis was performed on selected RNA samples 
using Affymetrix Genechip Human transcriptome array 2.0 (HTA 2.0) (Affymetrix, CA, 
USA) at Sick Kids Hospital, (Genomic Facility, Toronto, Ontario). The GeneChip system 
is comprised of 25-mer oligonucleotide probes synthesized on quartz chips and 
assembled into cartridges. Hybridization and scanning was performed according to the 
manufacturer’s instructions (Affymetrix, CA, USA).   
Data analysis 
All statistical analysis was performed in Excel (Microsoft Corp., USA). Two 
tests, the analysis of variance one-way ANOVA and the Student t test, were utilized in 
this study to calculate the level of significance. P values <0.05 were considered 
significant.  
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RESULTS 
ENGINEERING AND EVALUATING P53 EXPRESSION 
VECTORS IN MAMMALIAN CELLS  
Efficient gene expression requires a vector that remains in the cell for a prolonged 
period of time. Therefore, a plasmid DNA (pDNA) vector was designed to maximize 
survival and to enable high p53 expression level. There are a number of DNA and RNA 
cis-acting regulatory elements that can increase plasmid stability and stabilize transgene 
expression in vitro. These elements include matrix attachment regions (MARs) that are 
able to enhance and maintain transgene expression over an extended period of time as 
well as enhancing pDNA stability (Jenke et al., 2002; Allen et al., 2000; Wang et al., 
2008), hepatitis B virus posttranscriptional regulatory element (HPRE) that promotes 
RNA accumulation and thus enhancing transgene expression (Huang and Liang, 1993; 
Huang and Yen, 1994, 1995; Huang et al., 1996; Smith et al., 1998) and bovine growth 
hormone poly-A signal (BGH poly-A) that increases plasmid resistance as a result of a 
reduction in enzyme activity and enhanced mRNA posttranscriptional efficiency (Pfarr, 
1986; Azzoni et al., 2007). These elements were utilized to construct various transient 
p53 expression vectors. These vectors were then evaluated for their stability in vitro in 
three different cell lines, H1299, HEK293, and HeLa.   
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Plasmid construction 
To construct various p53 expression vectors that contain the transgene and all the 
regulatory elements, six plasmids were engineered through a series of cloning steps and 
strategies. All vectors are based on the PUC19 backbone. The first expression vector was 
engineered to contain the p53 promoter only (p0). The second plasmid contained the p53 
promoter in addition to a p53 transgene (pA). Another four plasmids were constructed as 
follows, pB (contains p53 promoter, p53 transgene and MAR element), pC (contains p53 
promoter, p53 transgene and two copies of MAR elements, one is upstream the transgene 
and one is downstream). pD (contains p53 promoter, p53 transgene, two copies of MAR 
elements and HPRE) and pE (contains all above components in addition to BGH poly-A 
signal). The cloning strategy and final engineered plasmids are shown in Figure 11. 
Furthermore, restriction enzyme digestion confirmation of constructed plasmids was done 
and the expected bands were observed on the gel as shown in Figures 12, 13 and 14.  
Table 5: Engineered p53 expression vectors in this study  
Plasmid 
name 
Contents Figures Plasmid abbreviation 
used in transfection 
P0 P53 promoter Figure 12 - 
PA P53 promoter + P53 gene Figure 12 A 
PB P53 promoter + P53 gene + MARI Figure 13 B 
PC P53 promoter + P53 gene + MARI + MARII Figure 13 C 
PD P53 promoter + P53 gene + MARI + MARII + 
HPRE 
Figure 14 D 
PE P53 promoter + P53 gene + MARI + HPRE + 
MARII + Poly-A 
Figure 14 E 
PF Negative control - F 
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Figure 11: Design scheme used for the construction of the various p53 expression vectors 
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Table 6: Restriction enzyme analysis of p53 expression vectors (P0 and PA) 
 
 
 
 
                                           
 
 
 
 
 
Figure 12: Schematic diagrams of p53 expression vectors (P0 and PA) and confirmation of test 
plasmids by restriction enzymes digestion. MR: Norgen’s MidRanger ladder. 
Plasmids Enzyme Expected band size (bp) 
P53 promoter (P0) ZraI/NdeI 2435/543 
P53 promoter p53 gene (PA) NdeI/EcoRI 2766/1483 
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Table 7: Restriction enzyme analysis of p53 expression vectors (PB and PC) 
 
 
 
 
 
 
 
 
 
 
Figure 13: Schematic diagrams of p53 expression vectors (PB and PC) and confirmation of test 
plasmids by restriction enzymes digestion. MR: Norgen’s MidRanger ladder. 
Plasmids Enzyme Expected band size (bp) 
P53-MARI (PB) PsI/NsI 4688/330 
P53-MARI-MARII (PC) NdeI/EcoRI 4489/1862 
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Table 8: Restriction enzyme analysis of p53 expression vectors (PD and PE) 
 
 
 
 
 
 
 
 
 
 
Figure 14: Schematic diagrams of p53 expression vectors (PD and PE) and confirmation of test 
plasmids by restriction enzymes digestion. MR: Norgen’s MidRanger ladder.  
Plasmids Enzyme Expected band size (bp) 
P53-MARI-MARII-HPRE (PD) BamHI 4129/2038 
P53-MARI-MARII-HPRE-PolyA (PE) BamHI 4317/2038 
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Evaluation of p53 expression vector stability in H1299, HEK293, and 
HeLa cell lines 
The impact on p53 transgene expression was evaluated by determining the 
plasmid stability as well as p53 mRNA level over time. Plasmids A, B, C, D, E and F as 
shown in Table 5 were used in this experiment. In order to assess their stability over time, 
equal copy number from each of the plasmids was transfected into three cell lines H1299, 
HEK293, and HeLa. Transfection was conducted in triplicate and cultured in a 24-well 
plate using cationic liposome transfection reagent (Lipofectamine 2000) and the medium 
was replaced 6 hours post-transfection. Following transfection, samples were collected at 
various time points dependent on the cellular growth rate of each cell line. Total DNA 
and RNA were isolated, quantified and processed for further analysis. The data were 
analyzed using a one-way ANOVA test as well as a Student t test. P values <0.05 were 
considered significant. 
Plasmid stability in H1299 cells 
Equal amounts of DNA from each point (day 1, day 4, day 8 and day 13) were 
used as templates for qPCR to assess plasmid stability. The actual plasmid copies per cell 
were obtained from a standard curve of known plasmid concentration using specific 
primers for p53 gene since this cell line is p53-null. From the data illustrated in Figure 
15, plasmid copy numbers were shown to reach the highest point at day 1 post-
transfection and they decreased sharply at day 8 post-transfection, reaching the basal 
level at day 13 post-transfection. Plasmid D revealed the highest copy number (5 copies 
per cell) at day 13 post-transfection compared to test and negative control plasmids (one-
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way ANOVA, p values <0.05), although it showed insignificant difference with plasmid 
E at day 8 post-transfection (Student t test, p values 0.225) 
 
 
Figure 15: Plasmid stability in H1299 cells. A) Average plasmid copy number of test plasmids 
(A, B, C, D and E) and the negative control plasmid (F) (n=3) at 1, 4, 8 and 13 days post-
transfection. B) Average plasmid copy number at 13 days post-transfection. Plasmid D obtained 
the highest copy number (5 copies per cell) at day 13 post-transfection compared to test and 
negative control plasmids (one-way ANOVA, p values <0.05). Error bars represent standard 
deviation (SD). 
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Plasmid stability in HEK293 cells 
Equal amounts of isolated DNA from each collection point (day 1, day 6 and 
day16) were analyzed by quantitative PCR (qPCR) using specific primers for PUC19 
backbone. Actual plasmid copy number per cell was determined from a standard curve of 
known plasmid concentration. There was insignificant difference in plasmid copy number 
between test plasmids at day 1 post-transfection and day 16 post-transfection as p values 
were >0.05 (one-way ANOVA). However, plasmid F showed a significant reduction in 
copy number at day 1 compared to the others. Despite the fast drop at day 6 post-
transfection, plasmid D is significantly the most stable among the others (one-way 
ANOVA, p values <0.05), however, it showed insignificant results compared to plasmid 
C copy number at p values 0.147 (Student t test) (Figure 16).  
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Figure 16: Plasmid stability in HEK293 cells. A) Average plasmid copy number of test plasmids 
(A, B, C, D and E) and the negative control plasmid (F) (n=3) at 1, 6 and 16 days post-
transfection. B) Average plasmid copy number at day 6 post-transfection, plasmid D is 
significantly the most stable among the others (one-way ANOVA, p <0.05). Error bars represent 
SD. 
Plasmid stability in HeLa cells 
QPCR was performed on equal amounts of DNA from each time point (day 6, day 
9, day 12 and day 16) to determine the exact plasmid copy numbers in each sample.  
Absolute copy number of each plasmid per cell was obtained using PUC19 backbone 
specific primers and a standard curve of known plasmid concentration. From the data, 
there was no statistically significant change between plasmids copy numbers of the test 
plasmids and the negative control at all days post-transfection (one-way ANOVA, p 
values >0.05) except day 6 post transfection. Although plasmid E was the highest copy 
numbers at day 12 post-transfection, it is still insignificantly higher than plasmid C and 
plasmid D (Student t test, p values 0.356 and 0.081, respectively) (Figure 17).  
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Figure 17: Plasmid stability in HeLa cells. A) Average plasmid copy number per cell of test 
plasmids (A, B, C, D and E) and the negative control plasmid (F) (n=3) at 6, 9, 12, 16 days post-
transfection. B) Average plasmid copy number at day 12 post-transfection, plasmid E is 
significantly the highest (one-way ANOVA, p <0.05), however it is insignificantly higher than 
plasmid D (Student t test, p values >0.05). Error bars represent SD.  
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Evaluation of p53 expression level in H1299, HEK293, and HeLa cell 
lines 
To assess p53 transgene expression level and correlate it with pDNA stability, the 
same plasmids A, B, C, D, E and F as shown in Table 5 were used in this experiment. 
Since each plasmid has a different molecular size, equal copy numbers from each of the 
plasmids were transfected into the same three cell lines H1299, HEK293, and HeLa for 
reliable results. Transfection was done in a 24-well plate with three biological replicates 
for each plasmid using Lipofectamine 2000 and at 6 hours post-transfection the medium 
was replaced. Different time course transfections for each cell line were conducted since 
they differ in their growth rate. The collected samples were utilized to isolate DNA and 
RNA from a single sample. Then both were quantified and used afterwards for further 
analysis. The data were analyzed using a one-way ANOVA test as well as Student t test. 
P values <0.05 considered significant. 
P53 expression level in H1299 cells 
 All isolated and quantified RNAs samples were treated with DNase and cleaned 
up afterwards. Equal amount of cleaned RNAs were then subjected to reverse 
transcriptase PCR  (RT-PCR) reaction to generate corresponding synthesized first 
complementary DNAs (cDNAs) that were used as a template for qPCR. Relative p53 
mRNA abundance per cell was obtained at each time point (day 1, day 4, day 8 and 
day13) by the ΔΔCT comparative threshold method using a housekeeping gene that is 
constantly expressed in the cell for normalization. The levels of p53 were measured based 
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on the equation 2^(Ct S15- Ct P53). As shown in Figure 18, the p53 expression level that 
was obtained from plasmid D at day 1 post-transfection was insignificant compared to 
plasmid E (Student t test, p values 0.595). The same insignificant difference was 
observed at 13 post-transfection compared to plasmid D (Student t test, p values 0.068), 
although it was significantly higher compared to the others at the same named days (one-
way ANOVA, p values <0.05). While on 4 and 8 days post-transfection, plasmid D 
revealed significant superiority over all the other plasmids with the highest transgene 
expression level among the others (one-way ANOVA, p values <0.05). 
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Figure 18: P53 expression in H1299 cells. A) Relative p53 expression level per cell of test 
plasmids (A, B, C, D and E) (n=3) at 1, 4, 8 and 13 days post-transfection. B) Relative p53 
expression level per cell at 13 days post-transfection. P53 mRNA levels were normalized with 
endogenous control S15 gene and calculated using the equation 2^(Ct S15 – Ct P53). Plasmid D 
was showed significant increase in p53 expression relative to cells transfected with the other test 
plasmids and negative control plasmid at days 4 and 8 post-transfection (one-way ANOVA, p 
values <0.05). Error bars represent SD.  
P53 expression level in HEK293 cells 
The isolated RNAs were treated with DNase for DNA digestion of any residues in 
the samples. They then underwent DNase clean up to remove the remaining enzyme. 
Equal amounts of total RNA from each sample were used as a template for reverse 
transcriptase PCR reaction. Then, qPCR was performed on equal amounts of cDNA using 
p53 specific primers. The relative measurement of p53 mRNA level was obtained at each 
time point (day 1, day 6 and day16) by the ΔΔCT comparative threshold method using a 
housekeeping gene for normalization.  
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As HEK293 cells already express cellular p53, we subtracted the expressed p53 
that was obtained from each test plasmid from the expressed p53 that was obtained from 
the negative control sample to achieve the actual level of exogenous p53 expression. This 
subtraction was done after they were both normalized with the housekeeping gene. P53 
expression that was obtained from the negative control represents the p53 cellular basal 
level. The equation used was 2^- ((Ct S15test sample - Ct P53test sample) – (Ct S15 negative 
control - Ct P53 negative control)), where Ct S15 is the PCR threshold cycle of S15 
amplified by S15 specific primers and Ct P53 is the PCR threshold cycle of p53 
amplification using specific p53 primers from the same sample.  
From the generated data, no significant change was noted in p53 mRNA level of 
plasmids tested at days 1 and 16 post-transfection, however; plasmid E was the lowest 
among them. Although the p53 expression level displayed a significant decrease at day 6 
post-transfection, plasmid D is still higher than plasmid C (Student t test, p values <0.05). 
Also, it is significantly the highest compared to the others (one-way ANOVA, p values 
<0.05) (Figure 19).  
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Figure 19: P53 expression in HEK293 cells. A) Relative p53 expression level per cell of test 
plasmids (A, B, C, D and E) after normalization with p53 cellular background at 1, 6 and 16 days 
post-transfection (n=3). B) Relative p53 expression level per cell at 6 days post-transfection. P53 
mRNA levels were normalized with endogenous control S15 gene and calculated using the 
equation 2^-((Ct S15 - Ct P53) – (Ct S15 - Ct P53)). At day 6, Plasmid D is significantly the 
highest among the others (one-way ANOVA, p values <0.05). Error bars represent SD. 
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P53 expression level in HeLa cells 
All RNAs that were isolated underwent DNase treatment and clean up afterwards 
to achieve DNase-free RNAs samples. Equal amount from each sample was then used in 
a reverse transcriptase PCR reaction to obtain cDNAs that were to serve as a template for 
qPCR. Actual p53 mRNA level was measured at each time point (day 6, day 9, day 12 
and day16) by ΔΔCT comparative threshold method using a housekeeping gene for 
normalization. Since HeLa cells express p53 at a specific basal level, the level of 
exogenous p53 mRNA was calculated by subtracting the expressed p53 that was obtained 
from each test plasmid after normalization with a housekeeping gene form the expressed 
p53 that obtained from negative control sample after normalization with housekeeping 
gene as well. The used equation is 2^- ((Ct S15test sample - Ct P53test sample) – (Ct S15 
negative control - Ct P53 negative control)), where Ct S15 is the PCR threshold cycle of S15 
amplified by S15 specific primers and Ct P53 is the PCR threshold cycle of p53 
amplification using specific p53 primers from the same sample. 
From the analyzed results, it was found that no significant change was observed 
between the plasmids at days 6 and 16 post-transfection (one-way ANOVA, p values 
>0.05). In contrast, at day 9 post-transfection, plasmid D has shown to obtain the highest 
expression among the plasmids reaching below the significant level, which is 0.05. Also, 
at day 12 post-transfection, plasmid D is still revealed to be superior over all of the other 
plasmids (one-way ANOVA, p values <0.05), whereas compared to plasmid E it showed 
insignificant change at p values 0.145 (Student t test) (Figure 20). 
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Figure 20: P53 expression in HeLa cells. A) Relative p53 expression level per cell of test 
plasmids (A, B, C, D and E) after normalization with p53 cellular background at 6, 9, 12, 16 days 
post-transfection (n=3). A) Relative p53 expression level per cell at 6 days post-transfection. P53 
mRNA levels were normalized with endogenous control S15 gene and calculated using the 
equation 2^-((Ct S15 - Ct P53) – (Ct S15 - Ct P53)). At day 12 post-transfection, plasmid D is 
still revealed to be superior over all of the other plasmids (one-way ANOVA, p values <0.05) 
with less significance compared to plasmid E. Error bars represent SD. 
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EVALUATING REPLICATION EFFICIENCY OF 
Ad5dlE1b55kDa MUTANT IN CELL LINES EXPRESSING 
VARIOUS LEVELS OF P53 
In order to evaluate the replication of Ad5dlE1b55kDa in various cell lines 
expressing either endogenous or exogenous wild type p53 at various levels, plasmids that 
expressed different p53 levels (described in chapter I) were used to obtain different p53 
bagrounds. To facilitate this experiment, three different viruses were used as shown in 
Table 9: (i) Ad5dlE1b55kDa (Ad5dlE1b), an Ad with a deletion of E1B55kDa region 
(827bp) and E3 region, that lacks the ability to interact with p53 but still contains E1B 
19kDa to prevent premature death of host cell through apoptosis and to achieve 
transformation, (ii) E1 deleted Ad (AdGFP), an Ad with a deletion of E1 and E3 regions 
and encoding the GFP reporter gene, that lacks the ability of replication, and (iii) wild 
type Ad (Ad5wt), an Ad with a deletion of E3 region only. Since the E3 region expresses 
the death protein, it was deleted in all viruses to avoid the early death of the infected cell 
and to facilitate viral replication. Both AdGFP and Ad5wt vectors were used as controls, 
in addition to PUC19 transfected cells that were used as negative controls in the 
experiment.  
In this chapter, two distinct cell lines with and without p53 expression: HeLa (wt-
p53) and H1299 (null-p53) were used. Before evaluating the effect of different p53 levels 
on viral replication, we tried to assess viral growth in the two cell lines. Therefore, the 
replication kinetics was characterized for each virus listed in Table 9 in both cell lines 
through viral infection of (Ad5dlE1b, AdGFP and Ad5wt) at MOI of 10 PFU/cell, which 
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was optimized in another experiment for the higest number of viral particles that didn’t 
cause cell detachment from the monolayer (Data not shown). Viral DNA synthesis was 
used as an indicator of replication efficiency. 
Then, the viral replication efficiency in cells expressing various levels of p53 was 
determined. An in vitro transfection of different molar ratio from each plasmid (A, B, C, 
D, E and F) to establish different p53 levels in both cell lines was conducted in a 24-well 
plate using Lipofectamine 2000 reagent and medium was replaced six hours post-
transfection. Following transfection, viral infection of adenoviruses (Ad5dlE1b, AdGFP 
and Ad5wt) was performed at 24 hours post-transfection. Triplicate samples were 
collected at different time points 2, 24, 48 and 72 hours post-infection and total DNA and 
RNA were isolated from the same sample to assess viral DNA replication efficiency as 
well as p53 expression level. The data were analyzed using the one-way ANOVA test as 
well as the Student t test. 
Table 9: List of adenoviruses and p53 plasmids used in this chapter 
Virus Contents Source Reference 
Ad5dlE1b dl E1b 55kDa + dl E3 Dr. Haj-Ahmad (Haj-Ahmad, 
1986) 
AdGFP dl E1 + dlE3 + GFP gene Dr. Misic (Misic, 2013) 
Ad5wt dl E3 Dr. Haj-Ahmad (Haj-Ahmad, 
1986) 
 
Plasmid 
abbreviation 
Plasmid name Contents Reference 
A PA P53 gene Figure 12 
B PB P53 gene +MARI Figure 13 
C PC P53 gene +MARI+MARII Figure 13 
D PD P53 gene +MARI+MARII+HPRE Figure 14 
E PE P53 gene 
+MARI+HPRE+MARII+Poly-A 
Figure 14 
F PF Negative control - 
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Characterization of Ad5wt, AdGFP and Ad5dlE1b55kDa replication in 
H1299 and Hela cells 
To compare viral replication kinetics of Ad5wt, AdGFP and Ad5dlE1b55kDa in 
relation to cell types, the replication phenotype of each virus was characterized in both 
H1299 and HeLa cell lines. Replication efficiency was determined by measuring relative 
DNA levels of all viruses by qPCR, which was performed on the same amounts of DNA 
samples using adenovirus probe and primers specific for the hexon gene. Delta CT (ΔCT) 
threshold method was applied afterwards on the raw PCR CT using glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and 5S as housekeeping genes for normalization to 
calculate the viral DNA level per cell. The measurements were assessed using the 
equation 2^(Ct cellular gene - Ct hexon). Moreover, viral cytopathic effect (CPE) of 
different adenoviruses was determined morphologically using the inverted microscope. 
The results show that growth rate of Ad5wt and Ad5dlE1b55kDa was 
significantly higher in H1299 that is null for p53 expression than HeLa cells, which 
contains wt p53 expression at all time post-infection (Student t test, p value >0.05). Also, 
the same result was found in the case of AdGFP at 48 hrs post-infection, however, a 
reverse was true at 2 hrs post-infection. This was demonstrated through the calculation of 
viral relative growth percentage in H1299 to HeLa cells. Also it was observed in the 
cellular morphology of both cells using the microscope, as CPE causes changes in the 
structure of the infected cells reaching cell detachment depending on the efficiency of 
viral production (Figure 22). These results showed the effect of p53 on viral replication 
efficiency. The viral DNA replication was greatest at 72 hours post-infection (Figure 21).  
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B                                                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Growth rate of Ad5wt, AdGFP and Ad5dlE1b in H1299 and HeLa cells. A) Relative 
viral DNA levels in both H1299 and HeLa cellular backgrounds over 2, 24, 48 and 72 hours post-
infection. Relative DNA levels were measured after normalization with cellular gene using the 
equation 2^(Ct cellular gene - Ct hexon). Error bars represent SD. B) Ad5wt, AdGFP and 
Ad5dlE1b relative growth percentage in H1299 to HeLa cells. 
Ad5wt % 
2 hours 53 
24 hours 119 
48 hours 412 
72 hours 439 
AdGFP % 
2 hours 32.2 
24 hours 132 
48 hours 254 
72 hours 63 
Ad5dlE1b % 
2 hours 345 
24 hours 128 
48 hours 4907 
72 hours 10431 
* 
* 
* 
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H1299                 HeLa 
 
Figure 22: Cellular morphology of infected H1299 and HeLa cells with Ad5wt, AdGFP and 
Ad5dlE1b55kDa at 72 hours post-infection. A) cells infected with Ad5wt at MOI of 10 PFU/cell, 
B) AdGFP infection of both H1299 and HeLa at MOI of 10 PFU/cell, C) Ad5dlE1b55kDa 
infected cells at MOI of 10 PFU/cell, and the control (non-infected).  
A 
C 
Control 
B 
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Effect of p53 levels on Ad5wt, AdGFP and Ad5dlE1b55kDa replication 
efficiency in H1299 cells 
As mentioned above, in this part, H1299 cell line was first transfected with 
multiple p53 expression vectors to obtain various levels of p53. Second, viral infection 
using the three viruses was carried out at 24 hours post-transfection. Viral DNA 
replication efficiency of all viruses was determined using isolated DNA of the different 
samples. In addition, isolated RNA from the same sample was converted to cDNA 
through the use of RT reaction and then used in determining p53 expression level. Probe 
based-TaqMan qPCR was performed on equal amounts of both DNA and cDNA using 
specific probe and primers for adenovirus hexon gene and p53gene, respectively. Relative 
viral DNA levels were assessed by ΔCT method through normalization with cellular 
GAPDH gene at different collection points, whereas relative p53 expression per cell was 
obtained using the same ΔCT method but with the S15 housekeeping gene for 
normalization. The level of viral DNA and p53 mRNA were measured according to the 
equations 2^(Ct GAPDH - Ct hexon) and 2^(Ct S15- Ct P53), respectively.   
Determination of Ad5wt replication efficiency  
From the plotted data in Figure 23, a relative relationship between the expression 
of wild type p53 that obtained from different plasmids (A-E) and Ad5wt DNA replication 
was observed. However, variant amount of p53 didnot affect the ability of viral 
replication. Viral DNA reached the highest level in H1299 cells that lacked p53 
expression (F). However, the increase was insignificant compared to viral DNA levels in 
H1299 cells with different p53 expression backgrounds from plasmids (A-E) at p values 
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0.837 (one-way ANOVA). The highest obtained peaks of p53 expression differ between 
the plasmids as some were at 2 hours whereas the others were at 24 and 48 hours post-
infection, which is not the case of negative control (F).  
Figure 23:   Effect of p53 levels on Ad5wt replication efficiency in H1299 cells. Relative Ad5wt 
DNA levels in different p53 expression levels that btained from plasmids (A, B, C, D, and E) and 
(F serve as PUC19 negative control) (n=3) over 2, 24, 48 and 72 hours post-infection. Relative 
DNA levels were measured after normalization with 5S using the equation 2^(Ct GAPDH - Ct 
hexon). Relative p53 expression levels were normalized using the expression of S15 gene and 
measured using the equation 2^(Ct S15- Ct P53). Error bars represent SD. 
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Determination of AdGFP replication efficiency  
As seen in Figure 24, there was a weak correlation between AdGFP replication 
and wild type p53 expression level that expressed from different plasmids (A-E) in 
H1299 cells. Viral DNA level reached the highest under p53 level that expressed from 
plasmid B. However, this increase in the replication capacity was insignificant compared 
to viral replication in the other different p53 backgrounds that obtained from plasmids 
(A-F), as the p values was >0.05 (one-way ANOVA) at 72 hours post-infection. On the 
other hand, there was a significant difference in DNA levels of AdGFP compared to 
Ad5wt. P53 expression was shown to reach its maximum at 2 and 24 hours post-infection 
in all cases (A-E). Although plasmid (F) does not encode a p53 transgene, a very little 
amount of p53 expression was observed at 24 hours post-infection for unknown reason.  
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Figure 24:   Effect of p53 levels on AdGFP replication efficiency in H1299 cells. Relative 
AdGFP DNA levels in different p53 expression levels that obtained from plasmids (A, B, C, D, 
and E) and (F serve as PUC19 negative control) (n=3) over 2, 24, 48 and 72 hours post-infection. 
Relative DNA levels were measured after normalization with 5S using the equation 2^(Ct 
GAPDH - Ct hexon). Relative p53 expression levels were normalized using the expression of S15 
gene and measured using the equation 2^(Ct S15- Ct P53). Error bars represent SD. 
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Determination of Ad5dlE1b55kDa replication efficiency 
Figure 25: Effect of p53 levels on Ad5dlE1b replication efficiency in H1299 cells. Relative 
Ad5dlE1b DNA levels in different p53 expression levels that obtained from plasmids (A, B, C, D, 
and E) and (F serve as PUC19 negative control) (n=3) over 2, 24, 48 and 72 hours post-infection. 
Relative DNA levels were measured after normalization with 5S using the equation 2^(Ct 
GAPDH - Ct hexon). Relative p53 expression levels were normalized using the expression of S15 
gene and measured using the equation 2^(Ct S15- Ct P53). Error bars represent SD. 
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The trend of Ad5dlE1b55kDa replication was in correlation with the trend of p53 
expression in all p53 backgrounds that obtained from different plasmids (A-E). In H1299 
transfected with negative control (F), viral DNA level increased to the highest in the 
absence of p53 expression. In the same case, it started to increase earlier at 24 hours post-
infection whereas it increased significantly at 48 hours post-infection in all cases, but 
Ad5dlE1b55kDa DNA level in the case of plasmid B was significantly higher than this 
window (A, C, D, E and F) at p value <0.05 (one way ANOVA). However, at 72 hours 
post-infection, there was insignificant difference in viral DNA levels under different p53 
expression levels from plasmids (A-E) (one-way ANOVA, p value was 0.194) whereas 
when compared to the negative control, the viral DNA level reached the highest among 
the others with a p values <0.05 (one-way ANOVA). Generally, Ad5dlE1b55kDa DNA 
level was significantly lower than Ad5wt and actually significantly higher than AdGFP. 
P53 expression level reached its peak at 2 hours post-infections in all cases and then 
started to decrease until it reached zero at 72 hours post-infection. This observation was 
not applied to the negative control (F).  
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Effect of p53 levels on Ad5wt, AdGFP and Ad5dlE1b55kDa replication 
efficiency in HeLa cells 
To examine if the same trend of viral replication was observed in HeLa cells, 
relative DNA levels of all viruses were determined. QPCR was performed on the DNA 
samples using adenovirus probe and primers against the hexon gene. ΔCT threshold 
method was utilized afterwards on the raw PCR CT using the 5S gene for normalization 
to calculate the viral DNA level. The measurements were done through the equation 
2^(Ct 5S - Ct hexon). On the other hand, relative p53 expression level was also 
determined using previously cleaned RNAs from the same sample. cDNA was generated 
through the use of RT reaction and then subjected to qPCR using specific p53 probe and 
primers. The level of expressed p53 per cell was measured by applying ΔCT threshold 
method using the equation 2^(Ct S15- Ct P53).  
Determination of Ad5wt replication efficiency  
From Figure 26, a relative relationship was observed under all p53 backgrounds 
that obtained from endogenous and exogenous expression. Viral DNA level started to 
increase at different time points and thus reached various levels at 72 hours post-infetion. 
However, insignificant difference of viral DNA levels was obtained from cells expressing 
endogenous and exogenous p53 (plasmids A-E) and cells endogenously expressing p53 
(F, negative control) at 48 hours post-infection (one-way ANOVA, p values >0.05). The 
p53 expression reached its peak at 2 and 24 hours post-infection and then started to 
decrease until it reached the cellular basal. 
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Figure 26:   Effect of p53 levels on Ad5wt replication efficiency in HeLa cells. Relative Ad5wt 
DNA levels in different p53 expression levels that obtained from HeLa cells transfected with 
plasmids (A, B, C, D, and E) and (F serve as PUC19 negative control) (n=3) over 2, 24, 48 and 72 
hours post-infection. Relative DNA levels were measured after normalization with 5S using the 
equation 2^(Ct 5S - Ct hexon). Relative p53 expression levels were normalized using the 
expression of the S15 gene and measured using the equation 2^(Ct S15- Ct P53). Error bars 
represent SD. 
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Determination of AdGFP replication efficiency  
Figure 27: Effect of p53 levels on AdGFP replication efficiency in HeLa cells. Relative AdGFP 
DNA levels in different p53 expression levels that obtained from HeLa cells transfected with 
plasmids (A, B, C, D, and E) and (F serve as PUC19 negative control) (n=3) over 2, 24, 48 and 72 
hours post-infection. Relative DNA levels were measured after normalization with 5S using the 
equation 2^(Ct 5S - Ct hexon). Relative p53 expression levels were normalized using the 
expression of S15 gene and measured using the equation 2^(Ct S15- Ct P53). Error bars represent 
SD. 
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From the data plotted in Figure 27, AdGFP showed a significant difference in 
DNA level between the cases. Although AdGFP obtained the highest DNA level in all 
cases (A-E) at 72 hours post-infection, this increase was insignificant at p values >0.05 
(one-way ANOVA). Viral DNA replication in the case of the plasmid B was significantly 
higher than the negative control (F) at p values <0.05 (Student t test), although p53 
expression pattern of plasmid B was almost the same compared to other plasmids. 
Different peaks that show the maximum p53 expression were obtained at different time 
points. When the data were compared to the previous results in H1299, AdGFP showed 
greater replication efficiency, as it reached a similar Ad5wt level but to a lesser extent.  
Determination of Ad5dlE1b55kDa replication efficiency  
Ad5dlE1b55kDa DNA level in HeLa cells was significantly lower than Ad5wt 
and AdGFP. As shown in Figure 28, the highest level was reached at 2 hours post-
infection and it sharply reduced after this point reaching either the basal level or zero at 
72 hours post-infection. No significant difference of viral DNA level per cell was found 
under all cases (A-F) that express exogenous (A-E) and endogenous (F) p53. The level of 
p53 expression in all plasmids was almost the same with insignificant difference at all 
time post-infection.  
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Figure 28:   Effect of p53 levels on Ad5dlE1b replication efficiency in HeLa cells. Relative 
Ad5dlE1b DNA levels in different p53 expression levels that obtained from HeLa cells 
transfected with plasmids (A, B, C, D, and E) and (F serve as PUC19 negative control) (n=3) over 
2, 24, 48 and 72 hours post-infection. Relative DNA levels were measured after normalization 
with 5S using the equation 2^(Ct 5S - Ct hexon). Relative p53 expression levels were normalized 
using the expression of S15 gene and measured using the equation 2^(Ct S15- Ct P53). Error bars 
represent SD. 
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Comparison and characterization of Ad5wt, AdGFP and 
Ad5dlE1b55kDa growth in H1299 and HeLa cells 
To compare viral growth kinetics of Ad5wt, AdGFP and Ad5dlE1b55kDa in 
relation to different p53 levels, the same above experiment data were plotted and 
expressed in a different way for comparison purposes. The results represent the 
replication phenotype of each virus, which was characterized in both H1299 and HeLa 
cell lines expressing exogenous p53 from p53 expression vectors and also in matched cell 
lines without exogenous p53 expression.  
Ad5wt growth in H1299 and HeLa cells 
From the results, there was insignificant difference in viral growth ability of 
Ad5wt in both H1299 and HeLa cells with or without respect to p53 expression at all 
times post-infection (Student t test, p values >0.05). The viral DNA replication was 
greatest at 72 hours post-infection (Figure 29).  
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Figure 29: Ad5wt growth in H1299 and HeLa cells. Relative Ad5wt DNA levels in different p53 
expression levels that obtained from both cell lines transfected with plasmids (A, B, C, D, and E) 
and (F serve as PUC19 negative control) (n=3) over 2, 24, 48 and 72 hours post-infection. 
Relative DNA levels were measured after normalization with housekeeping genes using the 
equation 2^(Ct cellular gene - Ct hexon). Error bars represent SD. 
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AdGFP growth in H1299 and HeLa cells 
AdGFP growth kinetics differed in H1299 and HeLa. A significant viral DNA 
level at various degrees was observed in HeLa cells compared to H1299 cells at all times 
post-infection (Student t test, p values <0.05). The viral DNA replication was started at 
24 hours post-infection until it reached its peak at 72 hours post-infection, the highest 
replication point (Figure 30). 
Figure 30: AdGFP growth in H1299 and HeLa cells. Relative AdGFP DNA levels in different 
p53 expression levels that obtained from both cell lines transfected with plasmids (A, B, C, D, 
and E) and (F serve as PUC19 negative control) (n=3) over 2, 24, 48 and 72 hours post-infection. 
Relative DNA levels were measured after normalization with cellular gene using the equation 
2^(Ct cellular gene - Ct hexon). Error bars represent SD. 
* 
* 
* 
* 
* 
* 
0 
50 
100 
150 
2hrs 24hrs 48hrs 72hrs Re
la
tiv
e
 
A
dG
FP
 
D
N
A
 
le
v
e
l /
c
e
ll 
H
u
n
dr
ed
s 
Time post infection 
A 
H1299 
HeLa 
0 
50 
100 
150 
2hrs 24hrs 48hrs 72hrs Re
la
tiv
e
 
A
dG
FP
 
D
N
A
 
le
v
e
l /
c
e
ll 
H
u
n
dr
ed
s 
Time post infection 
B 
H1299 
HeLa 
0 
50 
100 
150 
2hrs 24hrs 48hrs 72hrs Re
la
tiv
e
 
A
dG
FP
 
D
N
A
 
le
v
e
l /
c
e
ll 
H
u
n
dr
ed
s 
Time post infection 
C 
H1299 
HeLa 
0 
50 
100 
150 
2hrs 24hrs 48hrs 72hrs Re
la
tiv
e
 
A
dG
FP
 
D
N
A
 
le
v
e
l /
c
e
ll 
H
u
n
dr
ed
s 
Time post infection 
D 
H1299 
HeLa 
0 
50 
100 
150 
2hrs 24hrs 48hrs 72hrs R
el
a
tiv
e
 
A
dG
FP
 
D
N
A
 
le
v
e
l /
c
e
ll 
H
u
n
dr
ed
s 
Time post infection 
E 
H1299 
HeLa 
0 
50 
100 
150 
2hrs 24hrs 48hrs 72hrs R
el
a
tiv
e
 
A
dG
FP
 
D
N
A
 
le
v
e
l /
c
e
ll 
H
u
n
dr
ed
s 
Time post infection 
F 
H1299 
HeLa 
	   120	  
Ad5dlE1b55kDa growth in H1299 and HeLa cells 
The growth kinetics of Ad5dlE1b55kDa in different cell lines was different, as the 
viral DNA level of Ad5dlE1b55kDa in H1299 was higher than HeLa reaching a 
significant p value level of <0.05 (Student t test) under all plasmid conditions at 48 and 
72 hours post-infection (Figure 31). The replication of viral DNA reached its maximum 
at 72 hours post-infection. 
Figure 31: Ad5dlE1b growth in H1299 and HeLa cells. Relative Ad5dlE1b DNA levels in 
different p53 expression levels that obtained from both cell lines transfected with plasmids (A, B, 
C, D, and E) and (F serve as PUC19 negative control) (n=3) over 2, 24, 48 and 72 hours post-
infection. Relative DNA levels were measured after normalization with a cellular gene using the 
equation 2^(Ct cellular gene - Ct hexon). Error bars represent SD. 
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EVALUATING THE IMPACT OF P53 FUNCTIONAL STATUS 
ON THE REPLICATION EFFICIENCY OF ONCOLYTIC 
AD5dlE1b MUTANT 
To test whether the replication efficiency of oncolytic Ad5dlE1b55kDa mutant 
was dependent on the functional activity of p53, the growth of Ad5dlE1b55kDa was 
determined in cells expressing various p53 forms, wild type and mutants. Since the 
existence of such mutations influences the activity of p53 at various degrees (depending 
on the mutation site), we constructed multiple mutant p53 plasmids that express various 
mutant forms of p53 along with a wild type p53 plasmid to generate matched pair p53-
expressing cells. The introduced mutations were chosen based on a bioinformatics 
analysis of cancer-associated p53 mutation sites. Then, we evaluated the growth of 
Ad5dlE1b55kDa in various mutant-p53 transfected cells. Lastly, we investigated the 
functional status of mutant p53 that rescued viral growth as well as determined the viral 
rescuing mechanism underlying tumor selectivity by transcriptome profiling.  
The H1299 (p53-null) cell line was chosen based on literature to perform a fair 
and unbiased comparison. It was transiently transfected with the engineered plasmids that 
expressing wild type and mutant p53 versions along with the controls (mock transfected) 
and then infected with Ad5wt and Ad5dlE1b55kDa at day 1 post-transfection. Viral MOI 
and infection conditions were optimized for little variation and high consistency. Viral 
DNA level was determined as an actual indicator of viral replication efficiency at various 
times post-infection. 
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Bioinformatics analysis of p53 mutation sites 
Since more than 90% of cancer-related p53 mutations are found distributed within 
the DNA binding domain affecting its stability and DNA binding ability as well as 
protein conformation, in this study we chosed different mutations within DBD and PRD 
that may affect the function of the p53 protein differently to ensure diversity in the 
functional impact. The process of choosing the mutations was actually based on literature 
reviews and bioinformatics analysis of each mutation individually (Petitjean et al., 2007). 
Missense mutation at codons 72, 175 and 268 were chosen for the study’s purpose 
(Figure 32 & Table 10).  
Mutant R72P locates in the PRD, which is required for apoptosis and growth 
suppression, was chosen based on a common polymorphism where amino acid 72 is 
arginine (R) instead of proline (P). P53 arginine is a more potent inducer of apoptosis and 
occurred with more frequency compared to p53 proline (Dumont et al., 2003; Salvioli et 
al., 2005). When p53 has an arginine at this position, it can modify the mutant protein’s 
ability to bind and interact with other proteins such as MDM2 and p73, a p53-like protein 
inhibiting their function and also affecting the response to therapies (Dornan et al., 2003). 
Mutant R175H (arginine to histidine) is structural mutant that belonges to class I 
mutants and locates in the L2 loop of structural DNA binding motif p53. This missense 
point mutation substitution alters the conformational state of the p53 protein, yielding 
indirect disruption of DNA-binding ability (Cho et al., 1994). It possesses critical 
function in stabilizing the loops that are involved in DNA binding. R175H is the third 
most frequently mutated residue associated with human cancer.  
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Mutant N268D (asparagine to aspartic acid) is a contact mutant that belonges to 
class II mutants and locates in the DBD. It is the most stable missense point mutation 
substitution that can occur in cancer (Petitjean et al., 2007). It acts on different regions of 
the core domain of p53 affecting its stability and its DNA binding activity resulting in 
hindring the tumor suppressor functions, the most important of which are the cell-cycle 
arrest and apoptosis (Cho et al., 1994).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: The chosen p53 mutations in this study (Modified from May and May, 1999). 
  
 
Table 10: Mutations codons, amino acid substitutions, and locations. 
 
Mutations Mutated codon Mutated amino acid Location 
Residue 
72 
CCC→CGC Pro → Arg PRD 
Residue 
175 
CGC→CAC 
 
Arg → His 
 
DBD 
Residue 
268 
AAC → GAC Asn →Asp DBD 
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Construction of mutant p53 plasmids 
 The construction of multiple mutant p53 vectors was achieved using a similar 
cloning strategy in all engineered plasmids. HPRE plasmid (pD) from phase I was 
utilized in this chapter as the backbone plasmid for all the constructs which share the 
same promoter and cis-acting elements but differ in the p53 gene sequence. The overall 
cloning strategy is shown in Figure 33.  
 
Figure 33: Schematic of overall cloning strategy of mutant p53 plasmids 
Generation of mutations in p53 coding sequence  
Site directed mutagenesis method 
 The introduction of R175H was achieved through the use of a site directed 
mutagenesis approach along with the mega primer strategy (Tyagi et al, 2004). In this 
method, two rounds of PCRs were conducted utilizing two external oligonucleotide 
primers and one internal mutagenic primer to obtain the required mutated fragment. 
HPRE plasmid (pD) was used as a template for the first round of PCR reaction since it 
contains the p53 wild type sequence that needs to be mutated. Two primers, in which one 
PD (HPRE)  	   PCR  PCR
  
Cloning into 
Pp53-HPRE 
P72 
P175 
P268 
72 
175 
268	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of them is the internal mutagenic primer, were used to generate the first PCR product that 
contains the desired mutation. Then, a second round of PCR reaction was performed on 
the first PCR product using the intact external primers (flanked with unique restriction 
enzymes for cloning purposes) to amplify a plentiful amount of mutated p53 fragment 
(Figure 34).  
 
 
Figure 34: Site directed mutagenesis approach with mega primer polymerase chain 
reaction technique (Modified from Tyagi et al., 2004) 
Construction of p53-P72R plasmid 
 The plasmid contains mutation in the p53 sequence at codon 72 in which 
proline is substituted with arginine (CCC       CGC). This mutated fragment was achieved 
by annealing of two mutated oligonucleotides. It is also flanked with unique restriction 
enzymes (the closest to the mutation site) to serve the cloning into HPRE plasmid as a 
replacement of the wild type p53 sequence as shown in Figure 35. 
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Figure 35: Schematic diagram showing the strategy for constructing the p53-P72R plasmid 
containing a mutation at codon 72 of p53 coding region. Mutant fragment was generated through 
annealing of two mutated oligonucleotides. 
p53-MARI-MARII-HPRE.gb
6163 bp
APr
Lac Promoter
p53 promoter
p53
MAR I
HPRE
MARII
P(BLA)
P(LAC)
ORI PshAI (1629)
SgrAI (1699)
TP53 gene 
72 
Pro                Arg          
GACNNNNGTC 
PshAI 
CRCCGGYG 
SgrAI 
PshAI/SgrAI*PshAI/SgrAI* liga.on*
p53-P72R
6163 bp
APr
Lac Promoter
p53 promoter
p53
MAR I
HPRE
MARII
72
P(BLA)
P(LAC)
ORI
PshAI (1629)
SgrAI (1699)
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The final plasmid was then confirmed by restriction enzyme digestion (Table 11 & Figure 
36) and sequencing analysis was also performed to confirm the presence of the desired 
mutation at the desired site as shown in Figure 37.   
Table 11: Restriction enzyme analysis of p53-P72R plasmid 
 
 
 
 
                                              
 
 
 
Figure 36: Restriction enzyme confirmation for p53-P72R plasmid.  Restriction enzyme 
digestion of p53-P72R plasmid on agarose gel. MR: Norgen’s MidRanger ladder.   
 
Figure 37: Confirmation of full-length sequence of p53-P72R fragment by sequencing 
analysis (n=3) to ensure 100% sequence accuracy and the presence of the desired 
mutation.  
gacccaggtccagatgaagctcccagaatgccagaggctgctcccCGCgtggcccctgcaccagcagctcctaca
ccggcg 
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Construction of p53-R175H plasmid 
 This plasmid contained a point mutation at codon 175 that changed the amino acid 
from arginine to histidine (CGC→CAC). This mutant form of p53 was accomplished by 
using site-directed mutagenesis as described above. The flanking restriction enzymes at 
the two ends of the fragment facilitate the cloning into the HPRE plasmid as a 
replacement of wild type p53 sequence (Figure 38). 
 
  
 
 
 
 
Figure 38: Schematic diagram showing the strategy for constructing the p53-R175H plasmid 
containing a mutation at codon 175 of p53 coding region. Mutant fragment was generated 
through site directed mutagenesis approach.  
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The final confirmation of digested plasmid is shown in Table 12 & Figure 39 and 
sequenced to determine which allele the mutation resided on (Figure 40).  
Table 12: Restriction enzyme analysis of p53-R175H plasmid 
 
 
 
 
 
 
 
 
Figure 39: Restriction enzyme confirmation for p53-R175H plasmid.  Restriction enzyme 
digestion of p53- R175H plasmid on agarose gel. HR: Norgen’s HighRanger ladder.   
 
Figure 40: Confirmation of full-length sequence of p53-R175H fragment by sequencing 
analysis (n=3) to ensure 100% sequence accuracy and the presence of the desired 
mutation.  
cacgtactcccctgccctcaacaagatgttttgccaactggccaagacctgccctgtgcagctgtgggttgattccacaccc
ccgcccggcacccgcgtccgcgccatggccatctacaagcagtcacagcacatgacggaggttgtgaggcgctgcccc
caccatgagCACtgctcagatagcgatggtctggcccctcctcagc 
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Construction of p53-N268D plasmid 
 The plasmid includes a mutation at 268 spot in p53 sequence. This mutation 
converted the asparagine amino acid into the aspartic acid (AAC → GAC). The gene-
constructed fragment was flanked at both ends with the nearest restriction enzymes to the 
mutation site. These restriction sites are essential in cloning this fragment into the HPRE 
plasmid to obtain the final p53-N268D plasmid. The construction strategy is shown in 
Figure 41. 
 
 
 
 
 
 
 
 
 
Figure 41: Schematic diagram showing the strategy for constructing the p53-N268D plasmid 
containing a mutation at codon 268 of p53 coding region. Mutant fragment was obtained from 
gene construction. 
p53-MARI-MARII-HPRE.gb
6163 bp
APr
Lac Promoter
p53 promoter
p53
MAR I
HPRE
MARII
P(BLA)
P(LAC)
ORI
BbvCI (2028)
StuI (2495)
TP53%gene%
268%
Asn           Asp %
CCTCAGC% AGGCCT%
BbvCI% StuI%
BbvCI/StuI*
BbvCI/StuI* liga/on*
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As shown in the gel (Figure 42), when the plasmid was digested with a restriction 
enzyme (Table 13), the observed bands were similar to what is expected. Also, the 
sequencing analysis showed the right sequence as required (Figure 43).   
Table 13: Restriction enzyme analysis of p53-N268D plasmid 
 
 
 
 
 
 
 
Figure 42: Restriction enzyme confirmation for p53-N268D plasmid.  Restriction enzyme 
digestion of p53-N268D plasmid on agarose gel. MR: Norgen’s MidRanger ladder.   
 
Figure 43: Confirmation of full-length sequence of p53-N268D fragment by sequencing 
analysis (n=3) to ensure 100% sequence accuracy and the presence of the desired 
mutation. 
Cctcagcatcttatccgagtggaaggaaatttgcgtgtggagtatttggatgacagaaacacttttcgacatagtgtggtggt
gccctatgagccgcctgaggttggctctgactgtaccaccatccactacaactacatgtgtaacagttcctgcatgggcggc
atgaaccggaggcccatcctcaccatcatcacactggaagactccagtggtaatctactgggacggGACagctttgagg
tgcgtgtttgtgcctgtcctgggagagaccggcgcacagaggaagagaatctccgcaagaaaggggagcctcaccacg
agctgcccccagggagcactaagcgagcactgcccaacaacaccagctcctctccccagccaaagaagaaaccactgg
atggagaatatttcacccttcagatccgtgggcgtgagcgcttcgagatgttccgagagctgaatgaggcct 
Lane number Enzyme Expected band size (bp) 
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Characterization Ad5 dlE1b55kDa growth in cells expressing mutant p53 
 To examine the effect of p53 functional activity on the replication efficiency of 
oncolytic Ad5dlE1b55kDa, the viral growth was examined under various mutants p53 
backgrounds assuming that each mutant transcript should differ functionally from the 
others. The previously engineered mutants and wild type p53 constructs (Table 14) were 
used to transfect H1299 cells generating different versions of wild type or mutant p53-
expressing cells. The reason for choosing these cells was the fact that it is a p53-null cell 
line, which serves the desired purpose. Two negative controls were included in the 
experiment: PUC19 plasmid and mock transfected cells. In addition, infection with wild 
type Ad (Ad5wt) was used as a control beside Ad5dlE1b55kDa (Ad5dlE1b) (Table 14). 
Briefly, H1299 cells’ monolayer was transfected with test and negative control plasmids. 
Transfection with plasmid conditions from G to L was conducted in triplicate in 24-well 
plate using Lipofectamine 2000 reagent and 6 hours post-transfection the medium was 
replaced. Twenty-four hours post-transfection, viral infection of Ad5wt and 
Ad5dlE1b55kDa was carried out at MOI of 10 PFU/cell. Samples were then collected at 
different times post-infection and total DNA along with total RNA were isolated for 
further analysis.  
Table 14: List of adenoviruses and mutant p53 plasmids used in this study 
Virus Description Source Reference 
Ad5dlE1b dl E1b55kDa + dl E3 Dr. Haj-Ahmad (Haj-Ahmad, 1986) 
Ad5wt dl E3 Dr. Haj-Ahmad (Haj-Ahmad, 1986) 
Plasmid abbreviation Plasmid name P53 genotype Figures 
G pHPRE Wild type p53 Figure 14 
H p53-P72R Mutant p53 (P72R) Figure 35 
I p53-R175H Mutant p53 (R175H) Figure 38 
J p53-N268D Mutant p53 (N268D) Figure 41 
K PUC19 Negative control - 
L - Negative control - 
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Ad5wt and Ad5dlE1b55kDa replication in mutant p53-transfected H1299 
 Relative viral DNA level was used as a determinant of viral replication 
efficiency. Equal amount of isolated DNA samples from Ad5wt-infected cells and 
Ad5dlE1b55kDa-infected cells were used as templates for TaqMan qPCR reaction. 
Specific adenovirus probe and primers were used to amplify the hexon gene. The 
obtained CTs were used to perform ΔCT threshold method to calculate viral DNA level per 
cell after normalization with GAPDH, a housekeeping gene. The measurements were 
done through the equation 2^(Ct GAPDH - Ct hexon). The data were analyzed using a 
one-way ANOVA test. P values <0.05 were considered significant. 
 From the data in Figure 44, Ad5wt showed significantly higher viral DNA 
levels than Ad5dlE1b55kDa over various times points post-infection. Both viruses 
reached the highest growth level at 72 hour post-infection. In the case of Ad5wt, there 
was insignificant difference in the viral DNA levels under this window (G, H, I, K and L) 
(one-way ANOVA, p values >0.05) although it showed a slightly higher level under 
mutant p53N268D (one-way ANOVA, p values <0.05). On the other hand, 
Ad5dlE1b55kDa reached the highest DNA level under mutant p53R175H with 
significant difference compared to other conditions (one-way ANOVA, p values <0.05). 
However, viral DNA levels that obtained from the other mutants showed the same results 
compared to the controls (one-way ANOVA, p values >0.05) whereas viral replication 
under wild type p53 was the lowest among the others. It is important to note that p53 
expression level was measured from the isolated RNA that was obtained from the same 
single sample and optimized for long-lived expression. Viral DNA levels of both viruses 
	   134	  
under all conditions did not show strong correlation with the level of p53 expression as 
was concluded in the previous chapter (Data not shown).  
 
Figure 44: Adenovirus replication in H1299 cells expressing various p53 mutants. A) Relative 
Ad5wt DNA levels in wild type p53 (G) and different mutants p53 (H, I and J) (K and L serves as 
PUC19 and mock transfected negative controls) (n=3) over 2, 24, 48 and 72 hours post-infection. 
B) Relative AdE1b 55kDadeleted DNA levels in wild type p53 (G) and different mutant p53 (H, I 
and J) (K and L serve as PUC19 and mock transfected controls) (n=3) over 2, 24, 48 and 72 hours 
post-infection. Relative DNA levels were measured after normalization with GAPDH using the 
equation 2^(Ct GAPDH - Ct hexon). Error bars represent SD. 
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Table 15: Relative amount of viral DNA in H1299 cell line at 2 hours and 72 hours post-
infection (replication ratio) in correlation with p53 status. 
A) Ad5wt 
P53 genotype P53 status 
Viral DNA 
copies/cell at 2 
hours 
Viral DNA 
copies/cell at 72 
hours 
Replication Ratio 
72/2 hours CPE 
Wild type  wt 1.0 7035 7147 +++ 
mutated P72R 1.2 6254 5272 +++ 
mutated R175H 1.1 6154 5612 ++ 
mutated N268D 2.6 9988 3897 +++ 
- - 1.0 5515 5720 ++ 
B) Ad5dlE1b55kDa 
Wild type  wt 1.5 62.80 41.9 - 
mutated P72R 1.9 105.1 55.3 + 
mutated R175H 2.1 144.0 68.6 ++ 
mutated N268D 3.5 97.10 27.7 + 
- - 3.0 95.50 31.4 + 
 
-Grade of visual cytopathic effect at 72 hours post-infection (the highest virus copy number). (- no CPE, + 
week CPE, ++ moderate CPE, +++ strong CPE) 
 
 
 
From the results in Figure 44, we found that mutant p53R175H successfully 
rescued Ad5dlE1b55kDa growth more than the other mutants in the study. It is assumed 
that this mutation functionally inactivated p53; therefore it supported the replication of 
oncolytic Ad5dlE1b55kDa mutant. Further investigation of the functional activity of this 
mutation is essential to reveal the nature of the relationship between oncolytic E1b 
deleted adenovirus replication efficiency and p53 status during infection in the context of 
cancer virotherapy.  
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Microarray- based gene expression profiling 
Mutant p53 (p53R175H) that showed successful rescuing of oncolytic 
Ad5dlE1b55kDa was further investigated at the transcriptional level to examine its 
functional activity. This was achieved by comparing gene expression profiles of both 
mutant p53 and wild type p53 in the context of p53 target genes that mediate its function.  
In this section, we also determined the rescuing mechanism of tumor selectivity of 
oncolytic Ad5dlE1b55kDa in the same context and revealed how this mutant p53R175H 
affected the cellular transcriptome and modulated Ad5dlE1b55kDa replication. This was 
accomplished by comparing the expression profiling of wild type p53 and mutant p53 
samples but after the infection with Ad5dlE1b55kDa to assess the relative importance of 
p53 target genes in mutant p53 transcript, a physiologic target of E1b55kDa deleted 
adenovirus. 
The same above experiment with Ad5dlE1b55kDa infection was conducted again 
and p53 expression was optimized for long-lived expression as well. In this study, we 
chose to control the cellular difference, infectibility, and the heterogeneity of p53 
induction by selecting one cell line to be the control cell line and a model system, with 
which we can perform the comparisons. This cell line is H1299 (p53-null) cell line.  
Microarray-based gene expression analysis was performed on the purified and 
DNase-treated RNA samples. The concentration of total RNAs was determined and the 
quality of the samples was also analyzed using the Agilent RNA 6000 Kit. Five RNA 
samples were sent for gene expression profiling. The first two RNA samples were 
isolated from H1299 cells that were transiently transfected with wild type and mutant p53 
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plasmids (mock-infected samples). The second two RNA samples were isolated from 
H1299 cells that were transiently transfected with wild type and mutant p53 plasmids and 
infected afterwards with Ad5dlE1b55kDa at day one post-transfection (infected samples) 
at MOI of 10 PFU/cell. The fifth RNA sample, which was incorporated in the comparison 
in order to obtain a meaningful result, was H1299 RNA cellular background and served 
as a control sample. The time point 72 hours post infection was chosen to examine the 
expression pattern of cellular genes because p53 gene expression and viral DNA 
replication efficiency were the highest at this time point. 
The transcriptome expression analysis of all RNA samples was performed using 
Affymetrix Genechip Human transcriptome array 2.0 (HTA 2.0). This platform provides 
gene expression profiling of all known transcripts. The GeneChip system is comprised of 
25-mer oligonucleotide probes synthesized on quartz chips and assembled into cartridges. 
The p53-dependent gene expression patterns of the four samples were analyzed using 
Transcriptome Analysis Console software to categorize the significant differentially 
expressed genes that are biologically meaningful. Theses genes should satisfy the modest 
level of statistical significance (Student t test p-values <0.05) and ranked by minimum 
fold-change cutoff of 2.0, which was calculated by dividing the signal intensity of each 
gene mRNA against the corresponding mRNA level of the control.  
More than fifty three thousand protein-coding genes and non-coding RNAs 
including the internal genes and controls were analyzed in all samples. Generally, 
between 500 and 800 genes showed up or down regulation among the tested samples. 
Since p53 target genes were the focus of this study, they were highlighted and analyzed 
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for their expression profile in the four samples. The basis of upregulation and 
downregulation of p53 target genes was based on a minimum fold change threshold. Two 
hundred and thirty-two target genes were analyzed for their expression. Of these genes, 
forty-two were found to share the same expression patterns among the four samples. 
Between the mock-infected samples, which are wild type p53 and mutant p53 transcripts, 
82 genes were commonly expressed and 65 genes were differentially regulated. On the 
other hand, between the two infected samples, 107 genes shared the same expression 
patterns and 45 genes were differentially expressed. Most of these genes, if not all, 
mediate p53 functions including INSR, MDM2, PIDD, Bak, ZEB2, CASP1, CASP2, 
CCNB1, E2F4, and more which are distributed between cell cycle, apoptosis, DNA 
repair, cell proliferation and growth, cell division and stemness. The detailed results are 
shown in Table 16.  
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Table 16: Microarray gene expression profiles of up and down regulated genes in the test 
samples after normalization with control sample (H1299 RNA). 
 
Action # Of genes Category Reference 
Mock infection Viral infection 
WTP53 MTP53 WTP53 MTP53 
Up regulation 369 303 439 475 Transcription, protein 
transport, gene expression, 
cell survival, cytokinesis, 
interferon pathway, 
pathways in cancer, 
stemness, mitochondrion 
distribution, organization, 
mitotic sister chromatid 
segregation, cell cycle, 
apoptosis, metabolism, 
immune response, 
oxidative stress, signal 
transduction, metabolic 
process, DNA repair, DNA 
replication, receptors, cell 
adhesion, cell growth, 
Damage response, 
Data not 
shown 
Down 
regulation 
202 267 413 428 As above Data not 
shown 
   P53 target genes (232) 
Commonly 
expressed 
among all (4 
conditions) 
42 Angiogenesis, cell cycle, 
DNA repair, Apoptosis, 
cell proliferation, stemness, 
metabolism, transcription, 
signal transduction targeted 
by p53, growth factors 
Shown in 
Appendix 
Commonly 
expressed (2 
conditions) 
82 107 Cell cycle, cell division, 
regulation of transcription, 
metabolism, DNA repair, 
apoptosis 
Shown in 
Appendix 
NO change 85 80 DNA replication, 
Transcription, Pathways in 
cancer 
Shown in 
Appendix 
Differentially 
expressed 
65 45 Cell proliferation, 
apoptosis, cell division, 
cell growth and 
differentiation, DNA 
damage response, cell 
cycle regulation 
Shown in 
Tables 17 & 
18 
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Figure 45: Venn diagram represents the commonly and differentially expressed genes in 
the four tested samples (wtp53, mtp53, E1b/wtp53, and E1b/mtp53). 
 
Assessment of functional activity of mutant p53 that rescued oncolytic 
Ad5dlE1b55kDa mutant  
In this part of the analysis the interest was in finding out the difference between 
the functional activity of wild type p53 and mutant p53. Again, since p53 is a 
transcriptional factor that regulates many genes in its pathway, p53 target genes that exert 
its function were highlighted throughout the study. Of note, p53 target genes were 
gathered and collected from International Agency for Research on Cancer (IARC), TP53 
database, TP53 website, P53 books, human p53 signaling pathway array panels and P53-
	   141	  
pathway related literature reviews using PubMed (Zambetti, 2005; Petitjean et al., 2007; 
Hainaut and Wiman, 2007; http://p53.free.fr/). The objective of this part was achieved 
when both mRNA transcripts of the two mock-infected samples were compared to each 
other after their normalization with the transcript of H1299 cellular background (control 
sample). Different kinetics of expression profiles of p53 target genes upon wild type and 
mutant p53 expression was obtained. 
Of 232 genes, eighty-two genes were found to share the same expression patterns 
between mock-infected wild type p53 and mutant p53 transcripts (Figure 45). On the 
other hand, the rest were distributed between differentially regulated and no change. 
Sixty-five genes were found to differ in their expression patterns between mock-infected 
wild type and mock-infected mutant p53 transcripts including: Apaf1, PERP, MDM2, 
CDC7, ZEB2, CASP3, CASP2, BCL-2, E2F3, and more as shown in Table 17 and 
Figures 46 & 47 as well as Figure 49 that represents the volcano plot. These genes are 
distributed between cell cycle, apoptosis, DNA repair, cell proliferation and stemness.  
In wild type p53 transcript, all genes that are responsible for mediating p53 
functions upon expression and in response to unscheduled cell proliferation were returned 
back to their function to suppress tumor spread. On the other hand, the same genes but in 
mutant p53 transcripts were upregulated, which means that mutant p53 could not return 
to its normal function as tumor suppressor as wild type form. This indicates that gene 
expression profile was changed in a p53-dependent manner. 
 
	   142	  
Table 17: P53 regulated genes in H1299 cells expressing wild type (wt) p53 and mutant 
(mt) p53. Grouping by functional category of genes whose average expression > or < 2 
fold change. NC indicates no change. 
 
Symbol 
Category 
Affymetrx 
gene ID 
number 
Gene Name Specific/Other Categories 
LOG2 fold change 
Wtp53     
/Mock 
MtP53  
/Mock 
 
Apoptosis 
AXL 16862439 AXL receptor 
tyrosine kinase 
Negative regulation of apoptotic    
process 
 -1          1.04 
Apaf1 
 
16755542 apoptotic 
peptidase 
activating factor 
1 
Intrinsic apoptotic signaling  
pathway 
1.07       -1.01 
Bak1 17018274  BCL2-
antagonist/killer  
Intrinsic mitochondrial apoptosis  
signaling pathway 
1.03          NC 
TRAF2 17091444 TNF receptor 
associated factor 
2 
Inhibitor of apoptotic process 
 
1 NC          1.06 
 
BCL-2 
  
16855673 B-cell CLL/ 
lymphoma 2 
Blocks the apoptotic death of  
some cells 
 -1.13       1.03 
TNFRS
F10D 
 
 
PIDD 
 
 
TP53I3 
 
 
PERP        
 
 
CASP3 
 
 
CASP1 
17075448 
 
 
 
16734119 
 
 
16895179 
 
 
17024187 
 
 
16982011 
 
 
16743890 
Tumor necrosis 
factor receptor 
superfamily 
member 10d 
P53 induced      
death domain 
protein 
Tumor protein 
p53 inducible 
protein 3 
P53 apoptosis 
effector related 
to PMP-22  
caspase 3, 
apoptosis related 
cystine peptidase 
caspase 1, 
apoptosis related 
cystine peptidase 
 Inhibitory role in TRAIL 
-induced cell apoptosis 
 
 
Apoptosis in response to DNA 
damage, effector of p53-dependent 
apoptosis.  
Involved in p53-mediated cell death  
 
 
Apoptosis, p53 signaling pathway 
  
 
Cleaves and activates caspases  
6, 7 and 9 
 
Regulation of apoptotic process-cell 
death-regulation of inflammatory 
response 
 -1.02        NC 
 
 
 
1.04         -1 
 
 
  1.17         NC 
 
 
-1.01      1.01 
 
 
  1.06      -1.09 
  
 
   1.13     -1.03 
SIAH1       16826356     siah E3 ubiquitin     implicated in induction of apoptosis             1.04       NC 
                                        protein ligase 1              
 SIAH2 
 
 
SIAH3 
 
 
16960517 
 
 
16778790 
siah E3 ubiquitin 
protein ligase 2           
 
siah E3 ubiquitin 
protein ligase 2           
Negative regulator of apoptosis 
process 
 
Ubiquitin-dependent protein catabolic 
process 
  1.06        -1 
 
 
  1.09       NC 
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NFKB1      16969300    nuclear factor of     Negative regulation of apoptotic         NC         1.02 
                                       kappa light              process-positive regulation of  
                                       polypeptide             transcription 
                                       gene enhancer            
 
HK2 
 
16881838 
 
hexokinase 2 
 
Apoptotic mitochondrial changes 
and transmembrane transport 
        
      -1.05        1.07 
  
MCL1 16692775 
 
 
bcl2 related/ 
myeloid cell 
leukemia 
sequence 1 
 
Two transcripts one promote 
apoptosis and one inhibits 
apoptosis. 
 
       1.06       -1.07 
 
 
 
 
PMAIP
1 
 
16852683 phorbol-12-
myristate 13 
acetate induced 
protein 1 
Positive regulation of apoptotic 
process- positive regulation of 
release of cytochrome c 
 
       1.01      -1.05   
BBC3        16873675     Bcl-2 binding           Induce mitochondrial dysfunction            -1.26        NC 
                                       component 3             and caspase activation 
BID           16932008     BH3 interacting       Mediator of mitochondrial                         1.04       -1.05 
                                       domain death            damage induced by caspase-8 
                                       agonist    
CASP2 
 
 
 
Cell  
KLF4 
 
HDAC1 
 
 
DNMT1 
 
SFN 
 
 
TSC1 
 
IGF1 
 
ZEB2 
 
 
 
Cell 
SESN1 
17052776 
 
 
 
Proliferation 
 
17096827 
 
16662077 
 
 
16868576 
 
16661314 
 
 
17099361 
 
16769250 
 
17117888 
 
 
 
Cycle 
17022362 
 
Caspase 2, 
apoptosis related 
cystine peptidase 
 
 
 
kruppel-like 
factor 4 
histone 
deacetylase 1 
 
DNA (cytosine5) 
methyltransfera1 
stratifin 
 
 
tuberous 
sclerosis 1 
insulin-like 
growth factor 1 
zinc finger E-
box binding 
homebox 
 
 
Sestrin1 
Function in stress-induced cell death 
pathways, cell cycle maintenance, 
and the suppression of tumorigenesis 
 
 
 
Negative regulation of cell 
proliferation 
Control of cell proliferation and 
differentiation/ modulates p53 effect 
on cell growth and apoptosis. 
Regulation of cell proliferation 
 
Regulation of cell proliferation-
intrinsic apoptotic signaling pathway 
 
Regulation of cell cycle- 
regulation of cell proliferation 
Positive regulation of cell     
proliferation 
DNA-binding transcriptional  
repressor and role in cell  
proliferation 
  
 
Cellular response to DNA damage     
and oxidative stress 
3     1.13       -1.03   
 
 
 
 
 
 -1.04         1.01 
 
  1.12       -1.01 
 
 
  NC         1.04 
 
  NC         1.02 
 
 
-1.01         1.03 
 
-1.15         1.01 
 
-1.06          NC 
 
 
   
 
  NC     1.06 
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HMGA2    16753641    high mobility           P53 signaling pathway, regulation      1       -1.03 
                                      group AT-hook 2     of cell cycle progression 
 CHEK2  
 
BRCA2  
 
 
 
CDC25
A 
CDC7 
 
 
CDC2 
 
E2F4 
 
 
E2F3 
 
CDK6 
 
 
 
MLH1 
 
ATR 
 
 
CCNA1 
 
CCND2 
 
CCNE1 
 
CCNG2 
CCNB1  
 
K-Ras  
 
 
 
 
MSH2   
 
 
DNA  
 
DDB2    
 
16933502 
 
16773840 
 
 
 
16953279 
 
16667037 
 
 
17016110 
 
16820041 
 
 
17005234 
 
17059756 
 
 
 
16938899 
 
16959985 
 
 
16774053 
 
16746992 
 
16860418 
 
16968077 
16985599 
 
16762399 
 
 
 
 
16879883 
 
 
Repair 
 
16724471 
 
Checkpoint 
kinase 2  
Breast cancer 2 
 
 
 
Cell division 
cycle 25A 
Cell division 
cycle 7 
 
Cell division 
cycle 2 
E2F transcription 
factor 4  
 
E2F transcription 
factor 4 
Cyclin 
dependent kinase 
6 
 
Mutl homolog 1, 
colon cancer 
Ataxia 
telangiectasia 
and Rad3 related 
Cyclin A1 
 
CyclinD2 
 
CyclinE1 
 
CyclinG2 
CyclinB1   
 
V-ki-ras2 kirsten 
rat sarcoma viral 
oncogene 
homolog    
 
mutl homolog 2, 
colon cancer 
 
 
 
Damage specific 
DNA binding 
P53 signaling pathway, regulation   
of cell cycle progression 
Cell cycle cytokinesis, negative 
regulation of mammary gland  
epithelial cell proliferation,  
nucleotide-excision repair  
Progression from G1 to the S phase  
of the cell cycle 
Critical for the G1/S transition 
essential for initiation of DNA  
replication as cell division occurs 
Essential for S phase 
 
Crucial role in the control of cell  
cycle and action of tumor  
suppressor protein 
Regulate the expression of genes 
involved in the cell cycle 
Catalytic subunit of protein kinase 
complex that is important for cell  
cycle G1 phase progression and  
G1/S transition.  
Cell cycle 
 
Negative regulation of DNA  
replication-cell cycle 
 
Regulate separate functions in  
Cell cycle, S phase and G2 phase 
Regulatory subunit of CDK4 or  
CDK6 kinases. 
Regulator and mediate phosphor- 
ylation NAPT 
Regulate cell cycle and cell division  
Regulatory protein involved in cell  
cycle and mitosis. 
Signal transduction by p53- negative 
regulation of apoptotic process-negative 
regulation of cell differentiation-positive 
regulation of cell proliferation-positive 
regulation of cell growth. 
Cell cycle arrest-Damage response. 
 
 
 
 
Necessary for the repair of damaged 
DNA. 
  1.06     -1.02 
 
  -1.02     1.38 
 
 
 
-1.01     1.14 
 
 -1         1.17 
 
 
-1.01      1.05 
 
1.14        NC 
 
 
 NC       1.09 
 
-1.03     1.06 
 
 
  
NC        1.08 
 
-1.1       1.01 
 
 
-1.12     1.05 
 
-1.09     1.04 
 
-1.05     1.17 
 
-1.02      1.07 
-1.12      1.11 
   
-1.05      NC 
 
 
 
 
 -1.1       1.18 
 
 
  
 
1.07     -1.04 
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BRCA1 
 
RRM2B  
 
PCNA 
 
 
Cell  
 
 
LIN28A 
LIN28B 
 
EGR1 
 
MYOD
1 
ZNF675 
 
 
P53  
 
MDM2  
 
 
SESN2 
 
MMP2  
 
GPR87  
 
 
ZNF7 
 
IGFBP3 
 
 
INSR 
HPRT1 
 
 
SCARA
3 
 
16845349 
 
17079808 
 
16916958 
 
 
Differentiat
ion  
 
16661155 
17011255 
 
16989736 
 
16722526 
 
16870978 
 
 
Signaling 
 
16767332 
 
 
16661544 
 
16819062 
 
16960567 
 
 
17073961 
 
17057478 
 
 
16867915 
17107045 
 
 
17067314 
 
 
protein 2 
Breast cancer 1 
 
Ribonucleotide 
reductase M2 B 
Proliferating cell 
nuclear antigen 
 
 
 
 
lin-28 homologA 
lin-28 homologB 
early growth 
response 1 
myogenic 
differentation 1 
zinc finger 
protein 675 
 
 
 
 
Mouse double 
minut2 
 
Sestrin2 
 
Matrix 
metaliopeptidas2 
G protein-
coupled receptor 
87 
Zinc finger 
protein 7 
Insulin-like 
growth factor 
binding protein 3 
Insulin receptor 
Hypoxanthine 
phosphoribosyltr
ansferase 1 
Scavenger 
receptor class A 
,member 3 
 
Play role in DNA repair of double-
stranded breaks 
Necessary for DNA synthesis-    
response to DNA damage stimulus. 
In response to DNA damage, is 
ubiquitinated and is involved in the 
RAD6-dependent DNA repair pathway.  
   
 
 
Negative regulation of glial cell 
differentiation 
 
Required for differentitation and 
mitogenesis. 
Regulate differentiation 
 
Cancer differentiation     
 
 
 
 
Promote tumor formation by targeting 
 tumor suppressor proteins, such as p53, 
 for proteasomal degradation. 
Regulate cell growth and survival  
 
Positive regulation angiogenesis 
 
Role in signal transduction 
 
 
Regulation of transcription 
 
Prolonging the half-life of IGFs and 
altering their interaction with cell surface 
receptors 
Cellular response to insulin stimulus 
Cellular response to insulin stimulus 
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Figure 46: LOG2 fold change of sixty-five differentially expressed p53 target genes from 
wtP53-H1299 and mtP53-H1299 transcripts. 
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Correlation of p53 Status with Viral growth 
After we examined the functional status of p53-R175H mutant, we wanted to 
know the correlation between the obtained result and the efficiency of Ad5dlE1b55kDa 
replication. Therefore, we compared the expression profiles of both RNA transcripts that 
were obtained from the infected samples, which were transfected with wild type and 
mutant p53 and infected with Ad5dlE1b55kDa, after their normalization with the cellular 
background (control sample) to identify which p53 responsive genes in the mutant p53 
transcript are potential targets for initiating viral replication. These results helped us to 
understand the rescuing mechanism underlying selective oncolysis of Ad5dlE1b55kDa at 
the basis of up and down regulation of gene expression.  
The results showed that from a total of 232 p53 target genes, 107 were common 
and shared the same expression patterns in both samples (shown in appendix). These 
genes have major functions in cell cycle regulation, DNA apoptosis, and cell 
proliferation. However, forty-five genes were differentially expressed by two fold or 
more and if these genes were not found in the previously examined mutant p53 transcript 
for the mock-infected sample, this means that differentially regulated genes in mutant p53 
transcript were potential targets for oncolytic Ad5dlE1b55kDa mutant. These genes are 
involved in cell cycle, apoptosis pathway, proliferation and p53 signaling. Eighty genes 
demonstrated no change in the expression pattern relative to cellular background. Results 
are shown in Table 18 and in Figures 48, respectively, as well as Figure 50 that represents 
volcano plot.  
 
	   149	  
Table 18: P53 regulated genes in response to Ad5dlE1b55kDa in wt/mt p53-transfected 
H1299 cells. Grouping by functional category of genes whose average expression > or < 
2 fold change.  
Symbol 
Caegory 
Affymetrix 
gene ID 
number 
Gene Name Specific/Other Categories 
 LOG2 fold 
 
E1bwtp53 /   
/Mock 
Change 
 
E1bmtp5
3/Mock 
 
Apoptosis 
FAS 
 
 
FASLG   
16707149 
 
 
16673928 
Fas cell 
surface death 
receptor 
Fas ligand 
Apoptosis signaling, p53 Signaling, 
 death receptor signaling, Myc  
Mediated Apoptosis Signaling. 
Interaction of FAS with this ligand is 
critical in triggering apoptosis 
   NC       -1.18 
 
 
  NC        -1.11 
ATM 16730845 Ataxia 
telangiectasia 
mutated 
Cdc25 and chk1 Regulatory Pathway  
in response to DNA damage, Cell  
Cycle, p53-signaling pathway. 
  NC         1.27 
Bax 16863922 BCL2-
associated X 
protein 
Induction of apoptosis, p53 Signaling,  
death receptor signaling, Myc  
Mediated Apoptosis Signaling,  
Interferon Signaling, promotes  
apoptosis by binding to and  
antagonizing the Bcl-2 protein. 
  NC         -1.01 
PIDD 
 
 
TRAF2 
 
 
NOXA 
16734119 
 
 
17091444 
 
 
16903356 
P53-induced 
death domain 
protein 
TNF receptor 
associated 
factor 2 
BH3-only 
member of the 
Bcl-2 family 
Induce cell apoptosis in response  
to DNA damage,  role as an effector  
of p53-dependent apoptosis. 
Inhibitor of apoptotic process. 
 
 
Pro-apoptotic protein 
 
1   1.0         -1.12 
 
-- 
--  -1.01        NC 
 
 
 NC            -1 
 
 
PERP  17024187 
 
P53 apoptosis 
effector 
related to 
PMP-22  
Apoptosis, Direct transcriptional  
target of p53, p53 signaling pathway. 
 -1.16      1.05 
CASP8 
 
 
 
 
CASP1 
 
 
 
 
TP53BP2 
 
 
 
16889475 
 
 
 
 
16743890 
 
 
 
 
16699706 
 
 
 
Caspase 8, 
apoptosis-
related 
cysteine 
peptidase 
Caspase 1, 
apoptosis-
related 
cysteine 
peptidase 
Family of p53 
inretactin 
proteins 
 
Caspase Cascade in Apoptosis,   
D4-GDI Signaling Pathway, FAS  
signaling pathway, involved in the 
programmed cell death induced by  
Fas and various apoptotic stimuli. 
Positive regulator of apoptotic caspases 
 
 
 
 
Regulates apoptosis and cell growth  
 
 
 
   1.03      -1.04 
 
 
 
 
-    NC       1.32 
 
 
 
 
  1.05       1.46 
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Cyc1 
 
BIRC5 
17073565 
 
16838359 
Cytochrome c  
 
Baculoviral 
IAP repeat 
containing 5 
Involved in Mitochondrial Dysfunction 
and transport 
Negative regulation of apoptotic process 
positive regulation of cell cycle. 
1.03      -1.02 
 
-2.4        2.42 
ITGB3         16835158     integrin, beta 3     Negative regulation of cell death-                NC         2.01 
                                                                       positive regulation of angiogenesis      
ESPL1         16751709    Extra spindle         Apoptotic process, mitotic cell cycle,           NC        -2.05 
                                        pole bodies             cytokinesis  
                                        homolog 1  
MAD2L       16979389   MAD2 mitotic       Negative regulation of apoptotic                  NC        -2.21 
 1                                     arrest deficient-     process, cell division 
                                        like 1 
Apaf1          16755542   apoptotic peptidase Intrinsic apoptotic signaling pathway          NC        1.01 
                           activating factor 1                 
 
 
Cell proliferation and growth 
 
EAF2 
 
 
ZEB2 
16944574 
 
 
17117888 
Associated 
factor 2 
Zinc finger E-
box-binding 
homeobox 2 
Regulation of cell growth-positive 
regulation of transcription-intrinsic 
apoptotic signaling pathway. 
Negative regulation of transcription, 
nervous system development,  
biosynthetic process 
 NC          2.4 
 
  
 NC           1.1 
  
K-Ras          16762399      V-Ki-ras2           Regulation of cell proliferation,                    NC        1.02 
                                          Kirsten rat          signal  sarcoma viral oncogene   
                                          homolog             transduction by p53. 
  
Cell cycle 
  
CDKN2
A/ARF 
17092881 Cyclin-
dependent 
kinase 
inhibitor 2A 
(inhibits 
CDK4) 
P53 signaling pathway, Cell Cycle: 
G1/S Checkpoint Regulation, Non-
Small Cell Lung Cancer Signaling, 
Cyclins and Cell Cycle Regulation 
         -1.11        NC   
MYC 17072669 V-myc 
myelocytomat
osis viral 
oncogene 
homolog 
Transcription factor of many genes, 
drive cell proliferation, regulating 
cell growth, apoptosis, 
differentiation, Cell Cycle: G1/S 
Checkpoint Regulation.   
          1.07       -1.0 
 
 
   
 
 
 
CDK20 17095525 Cyclin-
dependent 
kinase 20 
Cell cycle, multicellular  
organismal development,  
protein amino acid phosphorylation 
         -1.1         1.01   
CENPA       16877956      centromere         Mitotic cell cycle                                            NC       -2.04 
                                          protein A   
HMGA2      16753641      High-mobility     Chromatin organization, development,        1.12         NC 
                                          group AT-           cell cycle, regulation of Cyclin A  
                                          hook2                  transcription, cell division, regulation  
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                                                                       of growth, mitosis.                                                                                                                                                                           
CCNB1       16985599      cyclin B1             Response to DNA damage stimulus             NC        -2.19 
                                                                       mitotic cell cycle, spindle checkpoint 
CENPK       16996722      centromere           Mitotic cell cycle                                          NC       -2.27 
                                          protein K              positive regulation of transcription                         
KIF15         16939960      kinesin family     Mitosis                                                          NC        -2.37 
                                          member 15 
ASCL1       16755958       achaete-scute       Positive regulation of cell cycle                   NC         1.14 
                                          family bHLH       negative regulation of apoptotic  
                                          transcription         process 
                                          factor 1 
Cell differentiation 
MGP            16761820      matrix Gla            Involved in cell differentiation.                  NC          2.23 
                                           protein 
LIN28A     16661155      lin-28 homolog    Negative regulation of glial cell                  NC         -1.04 
                                           A                         differentiation. 
MYOD1      16722526      myogenic             Regulate differentiation.                              1.01       -1.05 
                                          differentation 1 
DNA repair  
RAD51        16799637      RAD51                 DNA repair/response to DNA                    NC         -2.04 
                                          recombinase          damage stimuli 
H2AFX       16745236     H2A histone          Positive regulation of DNA repair/            NC         -2.08 
                                          family, member     response to DNA damage stimulus 
                                          X    
GTSE1        16931384      G2 and S phase     DNA damage response                               NC        -2.14 
                                          expressed 1           
FANCI        16804559      Fanconi anemia,   Response to DNA damage stimulus,          NC        -2.21 
                                          complementation  DNA repair 
                                          group I  
SESN1        17022362     Sestrin1                 Cellular response to DNA damage             NC        -1.11 
 
 
P53 signaling pathway 
 
MDM2        16767332     Mouse double       An inhibitor of p53 transcriptional               1.09      -1.11 
                                         Minute 2                activation, ATM, signaling Pathway 
                                                                       cell cycle, cell, cycle: G2/M checkpoint, 
                                                                       negative effector of Fas and TNF.                                                                                                                                                                        
Tp53 
 
 
MDM4 
 
 
 
ZNF10                  
7 
 
16840732 
 
 
16676343 
 
 
 
17056470 
 
 
Tumor protein 
p53 
 
Mdm4 
binding 
protein  
homolog 
Zinc finger 
protein 107 
 
 Regulates cell cycle by arrest cell  
 growth, activate DNA repair proteins,  
initiate apoptosis. 
 inhibits p53 by binding its  
transcriptional activation domain. 
 
 
Regulation of transcription. 
 
 
3        3.02       1.4 
 
 
     -1.1       1.08 
 
 
     
     NC      -2.17 
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Figure 48: LOG2 fold change of forty-five differentially expressed p53 target genes from 
wtP53-H1299 and mtP53-H1299 transcripts infected with Ad5dlE1b55kDa that are 
critical and have major functions in cell cycle, DNA repair and apoptosis.   
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ZNF7 
 
GALE 
17067314 
 
 
 
17013809 
 
17073961 
 
16683397 
Scavenger 
receptor class 
A, member 3 
Estrogen 
receptor 1 
Zinc finger 
protein 7 
UDP-
Galactose 4 
epimerase 
Induced by oxidative stress.     
 
 
 
Activation of transcription. 
 
Activation of transcription. 
 
Metabolism 
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Figure 49: Volcano plot represents the LOG2 fold ratio of expression level of 
differentially regulated target genes that are < or > 2 fold change difference in mtp53 
transcripts and t-test p-values <0.05.  
 
 
 
 
 
 
 
 
 
Figure 50: Volcano plot represents the LOG2 fold ratio of expression level of potential 
target genes that are < or > 2 fold change difference in response of Ad5dlE1b55kDa 
replication and t-test p-values <0.05.  
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Validation of putative target genes expression from mock-infected samples 
and infected samples using RT-qPCR  
To confirm the microarray data, twelve RNAs of the putative target genes that 
showed differential expression were subjected for RT-qPCR in order to evaluate their up 
or down regulation. Five out of the twelve genes were chosen from the mock-infected 
comparison based on their involvement in distinct function. The relative expression of 
each gene was examined by using specific primers for each. The expression level of the 
identified target genes was measured through the normalization with 5S gene expression. 
Relative expression between mutant p53 transcript / wild type p53 transcript and control 
transcript was calculated afterwards as LOG2 fold change using the equation LOG2 (2-ΔCt 
(target gene)
 mutant p53/ 2-ΔCt (target gene) Control) and LOG2 (2-ΔCt (target gene) wild type p53/ 2-ΔCt 
(target gene)
 Control). The relative gene expression data of mock-infected mutant p53 
transcript showed three downregulated genes, one upregulated gene and one gene 
unchanged. However, PCR data for the mock-infected wild type p53 transcript showed 
three upregulated genes and two downregulated genes. These results, which are listed in 
Table 19, were in agreement with microarray data with small standard deviation values.  
Table 19: LOG2 fold change in the expression of the 5 target genes of mutant and wild 
type p53 transcripts relative to control cellular transcript. 
(Red – Two fold or more up-regulated, Green – Two fold or more down-regulated, and Black – Minimally 
Deregulated / Unchanged) 
 
Gene 
Symbol 
Gene Description  (Mutant p53/ Mock 
control) 
 (Wild type p53/ 
Mock control) 
CASP2 Caspase 2, apoptosis related cystine peptidase -1.20 0.90 
CHEK2 Checkpoint kinase 2 -1.10 1.00 
ATR Ataxia telangiectasia and Rad3 related 1.90 -0.7 
ZEB2 Zinc finger E-box-binding homeobox 2 - -1.5 
MDM2 Mouse double minute 2 -1.19 1.40 
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Figure 51: RT-qPCR validation of 5 putative p53 targeted genes relative expression in 
cells transfected with wild type p53 and mutant p53 transcripts relative to average mock 
control.  
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Table 20: LOG2 fold change in the expression of the 7 target genes of mutant and wild 
type p53 transcripts relative to control cellular transcript. 
(Red – Two fold or more up-regulated, Green – Two fold or more down-regulated, and Black – Minimally 
Deregulated / Unchanged. 
 
Gene Symbol Gene Description  (Infected mutant 
p53/ Mock control) 
 (Infected wild 
type p53/ Mock 
control) 
Fas Fas cell surface death receptor -0.8 0.1 
Bax BCL2-associated X protein -1.7 0.3 
ATM Ataxia telangiectasia mutated 1.7 -1.2 
ZEB2 Zinc finger E-box-binding homeobox 2 1.7 0.3 
MYC V-myc myelocytomatosis viral oncogene 
homolog 
- 1.6 
MDM2 Mouse double minute 2 -1.4 1.3 
TP53 Tumor suppressor p53 1.0 2.5 
 
 
 
Relative expression of the remaining seven genes between the infected mutant 
p53 transcript and the infected wild type p53 transcript relative to the control transcript 
was calculated as LOG2 fold change using the equation LOG2 (2-ΔCt (target gene) infected 
mutant p53/ 2-ΔCt (target gene) Control) and LOG2 (2-ΔCt (target gene) infected wild type p53/ 2-ΔCt 
(target gene)
 Control). The relative gene expression data of the infected mutant p53 transcript 
showed three down regulated genes, three upregulated genes and one gene unchanged.  
However, PCR data for infected wild type p53 transcript showed three up regulated 
genes, one downregulated gene and three unchanged genes. These results, which are 
listed in Table 20 and shown in Figures 52, were in agreement with microarray data with 
small standard deviation values.  
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Figure 52: RT-qPCR validation of putative p53 targeted genes’ relative expression in 
Ad5dlE1b55kDa infected wild type P53 and mutant P53 transcripts relative to average 
mock control. 	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DISCUSSION 
Oncolytic viral therapies have been an innovative approach for cancer therapy in 
the last century. The ability of selective replication of these viruses has gained them the 
property of tumor specificity over other cancer therapies. Oncolytic adenovirus was one 
of the first oncolytic agents that were developed to achieve selective oncolysis, the ideal 
sort of treatment for cancer. Since the disruption of the p53 tumor suppressor protein is 
the main target of the viral E1B55kDa oncoprotein and cancer progression, E1B55kDa 
deleted adenovirus is a promising agent in p53 defective cancers. However, the overall 
efficacy of oncolytic adenovirus has shown varying degrees of success even when using 
the same virus. The results have been ambiguous. Therefore, the relationship between 
p53 genotype status and E1B55kDa deleted adenovirus needs to be studied at the 
molecular levels. Clearly, increasing our knowledge is a necessity, so that oncolytic 
adenoviruses can achieve maximum efficiency in terms of clinical efficacy.   
The present study was designed to establish a correlation between the replication 
ability of Ad5dlE1b55kDa and the status of tumor suppressor p53. The strategy was to 
examine p53 activity after infection at different levels, both quantitatively and 
qualitatively, and then correlate that with the efficiency of oncolytic viral growth. First, 
we engineered a p53 transient expression system for examination purposes. Second, we 
tested the effect of different p53 backgrounds and levels on viral replication efficiency. 
Lastly, we assessed the functional status of mutant p53 that supports Ad5dlE1b55kDa 
replication in H1299 cell line and determined the tumor selective viral rescuing 
mechanism.   
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P53 transient expression system 
P53 mRNA in higher eukaryotes has a half-life as short as few minutes (Rogel et 
al., 1985). Transgene expression level of p53 in the transformed cells is usually low, and 
widely variable. Since p53 is a critical key in this study, achieving efficient and long-
lived transiently expressed p53 was the objective of this section. Therefore, an expression 
system was engineered with the purpose of increasing p53 mRNA stability in mammalian 
cells. Firstly, we tried to increase the chance of vector existence in the cell by improving 
plasmid DNA stability. Secondly, we tried to elevate the transgene expression level 
through enhancing posttranscriptional events.  
Plasmid DNA stability 
The data obtained from plasmid stability in H1299 and HEK293 cells indicates 
that the presence of different elements within them had different effects on the stability of 
the plasmids (Figures 15 and 16). Plasmid D, which included the MARs and HPRE 
elements, remained the most stable with the highest copies per cell at the last points 
before the plasmid completely lost or degraded. This indicated the positive enhancement 
of plasmid DNA stability in transfected cells upon the incorporation of MARs and HPRE 
elements together in the same vector. The effect can be mainly attributed to the HPRE 
element since plasmids carrying only MARs elements were not as stable as the HPRE-
containing plasmid, although MARs are known to facilitate plasmid DNA stability 
through their binding to nuclear matrix during mitosis (Cockerill and grnard, 1986; 
Mirkovitch et al., 1984; Hall et al., 1991; Hall and Spiker, 1994; Jenke et al., 2002). This 
means that HPRE had a more positive effect on plasmid stability than MARs in vitro. 
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Such effect may be explained by the fact that HPRE is located within the HBV 3′ end that 
contains a common polyadenylation site that prevents plasmid degradation by nucleases. 
Supporting this explanation is the reduction of the copy numbers of plasmid E that 
contained a BGH poly-A signal, as it was believed that the homopurine rich sequence in 
the BGH could make the DNA molecule more susceptible to exo/endo nucleases 
degradation and structural instability (Ribeiro et al., 2004). If we consider that HPRE is a 
cis-acting RNA element, then further testing for HPRE role on DNA level is strongly 
suggested.    
On the other hand, in HeLa cells a different picture has emerged. Although 
plasmid E has shown severe reduction at day 6 post-transfection, which may support the 
previous conclusion, it exhibited the highest copy number at the last point before the 
plasmid was completely lost or degraded. However, by considering the standard 
deviation, it was not significant when compared to plasmids C and D, therefore, it could 
not be considered as the most stable plasmid in this cell line (Figure 17). Cell type is one 
parameter for these results, as cellular proteins that may be necessary for regulatory 
element function may vary between cell types or may be absent, resulting in variation or 
inhibition of their regulatory function.  
Since plasmids can be diluted during mitosis (Pauletti et al., 1990), this would 
explain why average plasmid copy numbers were reduced after the first harvest point 
relative to the second harvest point in all transfected cells, as tumor cell lines have an 
especially high growth rate with fast doubling time, such as 21.8 hours for HeLa cells 
(Rao and Engelberg, 1966).  
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P53 expression level 
The effect of the regulatory elements was more pronounced on transgene 
expression than plasmid stability since they can act at the posttranscriptional level to 
enhance transgene expression in vitro. The highest level of gene expression was observed 
when both MARs and HPRE elements were present in the same plasmid (pD) in the three 
cell lines. This is consistent with the results of some previous studies on the effect of 
HPRE on gene expression in HEK293 cells (Xu et al., 2003; Guang and Mertz, 2005; 
Mähönen et al., 2007).  
The previous observation indicates that incorporation of HPRE with the other 
elements had a greater effect on p53 expression level than without HPRE. This was 
expected for the following reasons: (a) HPRE is RNA element that mediates RNA 
nuclear export to the cytoplasm through interaction with cellular factors (Donello et al., 
1998), (b) it facilitates and increases RNA accumulation, providing latent expression in 
the host (Huang and Liang, 1993; Huang and Yen, 1994, 1995) (c) it is also believed that 
HPRE posesses a polyadenylation site, as it is localized at the HBV 3′ end thus enabling 
RNA stability and 3′ end formation and protection from degradation (Sun et al., 2009) , 
and (d) HPRE may bind to specific cellular proteins to post-transcriptionally regulate 
gene expression, which can vary depending on the cell type and transgene (Huang et al., 
1996; Zang et al., 1998). The latter reason may result in cell or transgene-specific 
augmentation in the level of transgene expression (Klein et al., 2006), which could 
explain the differences in p53 expression level that were obtained from the same plasmid 
(plasmid D) in the different cell lines.  
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Despite the negative effect of BGH poly-A signal on plasmid DNA stability, it is 
known to stabilize the transgene mRNA level in the cell through a trade off between 
plasmid DNA stability and mRNA stability (Ribeiro et al., 2004). However, the results 
showed that BGH poly-A signal did not have a significant effect on p53 mRNA level 
when it was compared to the other plasmids in H1299 and HEK293 cells. One 
assumption could be the presence of a second poly-A signal in the 3′ end of the HPRE 
element that may dispense its function, which likely confirms the previous interpretation 
of HPRE effect on plasmid stability. Another possible reason is the presence of AU rich 
sequences in the BGH poly-A signal. As reported in some studies, this sequence may 
affect mRNA stability depending on the gene and cell type (Caput et al., 1986; Lagnado 
et al., 1994), which would explain the reduction in p53 expression level that was obtained 
from plasmid E in both cell lines. On the other hand, in HeLa cells, plasmid E showed the 
possibility of obtaining the same level of expression as plasmid D at day 12 post-
transfection, although it was more stable than plasmid D in terms of plasmid stability, but 
this stability did not reflect on the transgene expression level. Therefore, the possibility 
that the BGH poly-A signal may be targeted for degradation is considered.  
Interestingly, in H1299 cells and at day13 post-transfection, plasmid C that carries 
only the two MARs elements displayed a p53 expression level similar to plasmid D 
although it was not as stable as plasmid D in the previous DNA stability experiment. This 
confirmed the ability of MAR elements to posttranscriptionally stimulate transgene 
expression, by a mechanism such as bypass gene silencing (Allen et al., 2000; Levin et 
al., 2005), more than stabilizing DNA molecules. The same effect on gene expression 
was also reported in other studies when the transgene was flanked by MARs elements 
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(Kim et al., 2004; Zahn-Zabal et al., 2001; Girod et al., 2005). Additionally, another in 
vitro study by Cockerill and Grnard in 1986 supported this result, as it reported the 
presence of ATATAT boxes in MAR element that demonstrated on unwinding property 
for binding to nuclear matrix and thus augmentation of gene expression (Bode et al., 
1992). However, this effect may depend on the cell type, since it did not show the same 
results in the other cell lines. 
To ensure the occurrence of transfection event, all engineered plasmids were co-
transfected with β-galactosidase vector (encodes LacZ gene) and transfection efficiency 
was determined. The results indicate that HeLa cells contain more transfected pDNA than 
the others, which could be ascribed to many reasons: (a) different cellular uptake ability, 
(b) more stable plasmids in HeLa cells rather than the others, and (c) different regulatory 
element effects on plasmid stability. However, since the proportion of transfected 
plasmids DNA per cell within the same cell type is relatively constant at the first harvest 
point and also since plasmid D is the most stable among the constructs between the three 
cell types over time, determining transfection efficiency was not important at this stage.  
In conclusion, plasmid D, which contains all elements except BGH poly-A signal, 
demonstrated the most stability over the others. These elements together have shown not 
just their post-transcriptional regulation effect on the transgene expression, but they also 
positively influenced plasmid DNA resistance to nucleases. The positive effect on 
plasmid-mediated gene expression and stability was mainly obtained from the inclusion 
of HPRE element in combination with the other elements in the vector. Based on these 
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conclusions plasmid D was the most suitable choice for long-lived expression, which was 
needed in this study.   
Replication efficiency of oncolytic Ad5dlE1b55kDa in H1299 and 
HeLa cells 
Wild type tumor suppressor p53 protein is a well-known cellular defense against 
DNA damage and oncogenic activity specifically to viral challenge (Takaoka et al., 2003; 
Munoz-Fontela et al., 2005). Oncolytic Ad5dlE1b55kDa is able to preferentially replicate 
in p53-deficient cancer cells with mutant or null p53 status or sometimes in wild type p53 
for ambiguous reasons. In this chapter, we tried to evaluate the replication efficiency of 
Ad5dlE1b55kDa in different p53 cellular backgrounds and levels to find out the 
mechanism behind the sensitivity of its selectivity.  
Since normal cells are not an option for adenovirus oncolysis, H1299 (p53-null) 
and HeLa (wt-p53) cell lines were chosen as a different source of p53-cancer cells. The 
results indicated that H1299 cells were more supportive for Ad5wt and 
Ad5dlE1b55kDaB replication than HeLa cells (Figure 21). Actually, this was interesting 
since both H1299 and HeLa are considered to be p53 deficient cells. The wild type p53 
status of HeLa cells is functionally mutated due to the binding of HPV E6 to p53, causing 
blockage of its transactivation function. This blockage has been reported as a result of 
inhibition of p53 acetylation and phosphorylation by HPV E6 region (Thomas and 
Chiang, 2005; Ajay et al., 2012). However, the high replication rate in H1299 cells was 
expected because these cells do not contain p53 expression that can hinder their growth. 
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Unfortunately, this advantage of H1299 cells did not come as a benefit for AdGFP, as 
this virus still lacked the viral replicative genes (ΔE1) that are responsible for its 
production, which hindered its replication efficiency. Supporting this explanation, the 
reduction of its replication rate in HeLa cells as well.  
Although Ad5wt and Ad5dlE1b55kDa have a similar replication phenotype, the 
DNA level of Ad5wt was significantly higher when compared to Ad5dlE1b55kDa in the 
same H1299 cell line. This indicated that Ad5wt had more capability in replicating its 
genome and producing virions than Ad5dlE1b55kDa. This statement was supported to 
the strong CPE that was observed in Ad5wt-infected cells compared to Ad5dlE1b55kDa-
infected cells as shown in Figure 22. One consideration could be the effect of E1B55kDa 
deletion on the viral replication efficiency of Ad5dlE1b55kDa, which is the more likely 
reason. Another possibility could be the presence of an inhibitory effect that can be 
overcome by wild type adenovirus, but not mutant adenovirus. If we consider the latter 
reason, both viruses should replicate at the same level in HeLa cells, but this was not the 
case, which led us to ignore this possibility.  
Interestingly, when viruses replicated in H1299 cells better than in Hela cells, this 
meant that different cellular backgrounds, which could be indirectly related to p53, could 
affect the replication of oncolytic adenovirus differently.  
Effect of p53 levels on the replication of Ad5dlE1b55kDa in H1299 cells 
In addition to p53 backgrounds, we also evaluated the replication efficiency of 
Ad5dlE1b55kDa under various wild type p53 levels (the effect of p53 levels) in H1299 
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and HeLa cell lines. Since each virus differ in terms of the presence or absence of 
important viral genes such as E1A and E1B, different replication pattern between viruses 
and different replication starting points were obtained. This observed difference is mainly 
ascribed to the expression of functional wild type p53 protein that can directly interact 
with viral genes affecting viral production rate and efficiency.  
Ad5wt has the fastest replication and achieved the greatest rate among the others. 
It started earlier than the others and reached the highest viral DNA level among them at 
72 hours post-infection (Figures 23, 24 and 25). This higher efficiency was mainly due to 
the presence of E1B55kDa gene, whereas the delayed replication of the other mutant was 
mainly contributed to the absence of this gene that can counter p53 repression activity 
toward viral replication and spread. This means that Ad5wt had the ability to quickly 
inactivate and block p53 activity in favor of virus replication. As a result, p53 cannot 
induce apoptosis in response to viral infection thus facilitating the E1B transformation of 
the H1299 cell through the aid of the E1A protein for the favorite of virus production.  
This is consistent with previously reported binding of E1B55kDa gene to p53 
blocking its activity for efficient wild type adenovirus replication (Yew and Berk, 1992; 
Yew et al., 1994; Graham et al., 1974; Barker and Berk, 1987). Some of these studies 
have suggested that E1B55kDa has a transcriptional repressor domain that affects p53 
activation activity (Yew and Berk, 1992; Yew et al., 1994). Others studies have elicited 
the binding of E1B55kDa/E4-orf6 complex to p53, which antagonizes p53-mediated 
transactivation (Dobner et al., 1996; Nevels et al., 1997). 
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On the other hand, in the mutant viruses that lack E1B55kDa, p53 was not 
blocked, therefore, both viruses started to replicate in the late stage compared to Ad5wt. 
However, the replication efficiency of both mutant viruses was different. This variability 
can be mainly ascribed to the presence of E1A region in one leading to overcome the 
restriction and augment the replication of Ad5dlE1b55kDa to a level similar to Ad5wt but 
in lesser extent, which was shown in the case of the negative control whereas it was more 
restricted in the presence of p53 expression. The latter was not surprising since in the 
absence of E1B55kDa, p53 usually takes advantage by promoting cellular apoptosis to 
stop viral spread. In the case of AdGFP, the deletion of the entire E1 region (ΔE1) caused 
a severe defect in virus replication efficiency leaving the DNA level stagnant with no 
increase under the presence or absence of p53. These results confirm the fact that p53 
expression had a great effect in hindering viral replication of both mutant viruses at 
various extents but not in wild type adenovirus.  
 If we consider the hypothesis that different amounts of p53 can affect the viral 
replication efficiency to various degrees, different viral DNA level should be obtained 
under variable levels of p53 expression. In spite of this hypothesis, the different p53 
levels had an insignificant effect on the growth rate of all viruses as shown in Figures 23, 
24 and 25. Both Ad5wt and AdGFP were either replicated or did not replicate, 
respectively, in the presence or absence of p53, which is the negative control. The reason 
for these results in both cases was stated above, but the replication rate of each virus was 
the same under various p53 levels that expressed from different p53-expressing plasmids 
(A-E). On the other hand, although Ad5dlE1b55kDa replicated more efficiently in p53 
level obtained from plasmid B than the others at 48 hours post-infection, this significance 
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quickly disappeared at 72 hours post-infection and the viral replication rate reached the 
same level under the various expression levels. This supports the same results from 
Ad5wt and AdGFP and suggests that the effect of p53 is likely to be more qualitative 
(depend on function) than quantitative (amount) and that the functional status of p53 
could be the critical key behind its activity.   
Effect of p53 levels on the replication of Ad5dlE1b55kDa in HeLa cells 
It is known that HeLa cells containing the wild type p53 sequence are functionally 
inhibited due to the presence of the HPV E6 region that directly binds to p53, thereby 
facilitating its blockage and degradation. The replication phenotype of the three viruses in 
HeLa cells was different with a lowest replication efficiency of Ad5dlE1b55kDa. This 
observed difference is mainly relative to the presence of active p53 in either cases 
presence or absence of replicative viral genes. Both Ad5wt and AdGFP were replicated at 
high levels which was not surprising for Ad5wt since it possesses a special mechanism 
that blocks wild type p53 function to promote cell cycle progression and facilitates its 
replication (Figure 26). However, the replication of AdGFP to this extent was not 
expected since it lacks the region (ΔE1) that is responsible for the replication process.  
One logical reason that explains this phenomenon is the presence of the E1A 
region in Ad5dlE1b55kDa rather than AdGFP. The E1A gene in some studies was 
reported for its ability to overcome the blockage and degradation effect of HPV E6 on 
p53 in HeLa cells by stabilize p53 function through a phosphorylation process, as part of 
its function in the absence of E1B55kDa (Chiou and White, 1997; Chiou et al., 1994; 
Lowe and Ruley, 1993). In addition, it implements p53 dependent apoptosis in the 
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absence of the entire E1B region (Lowe and Ruley, 1993). These facts explain why 
Ad5dlE1b55kDa could not promote the replication under thvese conditions and viral 
DNA levels started to decrease two hours post-infection. Simply, what occurred is the 
action of E1A on blocking HPV E6 effect and restoring or stabilizing endogenous p53 
function has led to obtain functional active p53, which therefore was able to severely 
hinder the replication of Ad5dlE1b55kDa in the test plasmids as well as the negative 
control. Supporting this explanation, the better replication of viruses that lack the entire 
E1 region (AdGFP). Further support for this explanation was the accumulation of mutant 
p53 in the case of Ad5wt and AdGFP infection, whereas the cellular level of wild type 
p53 expression in Ad5dlE1b55kDa was maintained under the normal level. This reveals 
that the effect of HPV E6 was inhibited and p53 status returned to the normal level 
otherwise p53 expression level would have stayed the same across the viruses.  
It is not a surprise that variant levels of p53 expression had no significant effect 
on the viral replication rate, as was demonstrated previously in H1299 cells. This finding 
can be applied to both Ad5wt and AdGFP regardless the starting replication time (Figures 
26 and 27). However, if we consider the above stated explanation on Ad5dlE1b55kDa 
replication, this evaluation is not essential since the viral replication level reached zero in 
all cases (Figure 28). This agreement in the results on the p53 variant levels has led us to 
same conclusion in which the oncolytic Ad5dlE1b55kDDa replication efficiency may be 
based on the activity of p53 not the quantity, which needs an assessment.  
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Comparison of Ad5wt, AdGFP and Ad5dlE1b55kDa growth in 
H1299 and HeLa cells 
The conclusions that have been reported previously in this study have pushed us 
to make a relative comparison between the viruses’ replication phenotypes in both cell 
lines. Up until now, it was not clear whether oncolytic Ad5dlE1b55kDa mutant 
replication efficiency is based on the cell’s phenotype or p53 expression but it seems that 
both are correlated to each other. From the study’s results, it looks like every virus had a 
different replication rate in each cell line, especially Ad5dlE1b55kDa. The reason for this 
variable selectivity turned out to be the status of cellular p53 whether it is functional 
active or inactive due to a specific reason, even if it has a wild type sequence.  
Ad5wt showed its efficient replication capacity in either cell line because both are 
p53 deficient, and even the presence or absence of p53 is not important to implement 
replication in this case (Figure 21). When we compared the virus replication in HeLa 
cellular background and in PUC19 transfected HeLa, Ad5wt in HeLa background still 
showed deficiency in replication compared to PUC19 transfected HeLa although both are 
considered as negative controls. One possibility could be ascribed to the status of the cell 
cycle at the time of infection, as it was reported earlier that HeLa cells are more readily 
infected when they are in S phase and because of their rapid cycling, a high percentage of 
cells are infected (Goodrum and Ornelles, 1997).   
Supporting this explanation was the deficiency of AdGFP replication in both cell 
line backgrounds compared to PUC19 transfected matched cell lines (Figures 21 and 30). 
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Despite that, AdGFP was found to replicate more efficiently in HeLa cells than H1299 
cells. In line with this, the replication of Ad5dlE1b55kDa in defective p53 cells (H1299) 
to a higher extent in the absence of exogenous p53 expression, as shown in the negative 
control as well as in the rest of cases (A-E) at 72 hours post-infection, whereas it did not 
replicate in active wild type endogenous p53 (HeLa) as a result of E1A effect on p53 
effect (Figure 31). This comes in agreement with several reports that have also 
demonstrated the same observation on E1b deleted adenovirus restriction of replication in 
cancers with wild type p53, but better replication in H1299 cells (Bischoff et al., 1996; 
Harada and Berk, 1999). In addition, the same trend of the viral DNA replication were 
obtained after the infection of cellular backgrounds of H1299 and HeLa with the same 
virus regardless the deficiency of DNA levels which could be due to the previously stated 
reason of a cell cycle restriction condition (Figure 21).  
In conclusion, the replication efficiency of the oncolytic Ad5dlE1b55kDa mutant 
is more likely to be contributed to the functional status of cellular p53, either active or 
inactive, or to other cellular factors that are dependent on p53 more than the cellular 
phenotype or the quantity of p53 expression. This confirms the importance of the 
examination of functional status of mutant p53 in different cancers to obtain a clearer 
understanding of the relationship between oncolytic Ad5dlE1b55kDa and p53 status, 
which was already assessed and discussed in this study in the next chapter, thus a clear 
vision would then exist for further investigations in the field of oncolytic virotherapy.   
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The impact of p53 functional status on Ad5dlE1b55kDa growth  
Accumulation of genomic alteration in a given cell leads to deregulation of key 
signaling pathways that control the cell proliferation and fate. Tumor suppressor p53, 
which is the key cellular defense against unscheduled cell proliferation, is the most 
targeted gene in genetic alteration as well as in viral infection. Therefore, the mutant form 
of p53 provides a favorable environment for efficient viral replication. In this study, a 
genetic means was used to abolish p53’s DNA sequence binding ability through the 
introduction of point mutations in p53 that often affect its functional activity as tumor 
suppressor, resulting in uncontrolled cell proliferation and viral replication. However, not 
all mutations are successfully rescued the viral growth in the context of the oncolytic 
Ad5dlE1b55kDa mutant leading to a deferentially replication phenotype in different p53-
deficient cancers. Therefore, in this part of the study, we first assessed the functional 
activity of mutant p53 that rescued viral growth, and second we determined the impact of 
this activity on the sensitivity of oncolytic adenovirus replication. In other words, we 
investigated whether Ad5dlE1b55kDa growth is dependent on p53 function or not.  
General observation from the results in Figure 44 showed that Ad5wt replicated 
more efficiently with one log fold difference than Ad5dlE1b55kDa in all cases, wild type 
p53, mutant p53 and controls. This was expected and it reconfirms that the E1B55kDa 
region is an essential requirement in achieving efficient viral replication. This observation 
is consistent with the previously obtained results in chapter II and with other studies (Kim 
et al., 2002; Hann and Balmain, 2003). It was not surprising that the obtained DNA level 
of Ad5wt was the same across the following conditions: cells expressing wild type p53, 
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mutant p53P72R, mutant p53R175H and the controls. This is because adenovirus wild 
type is capable of controlling the cell towards its replication using its viral proteins.  
On the other hand, Ad5dlE1b55kDa was shown to have the highest DNA level in 
the expression of mutant p53R175H. This means that oncolytic Ad5dlE1b55kDa 
replicated more efficiently in this mutant than the other mutants and the wild type p53 as 
well. This demonstrates that mutant p53R175H rescued viral growth more efficiently 
than the others, although it did not reached the level of Ad5wt due to the absence of the 
E1B55kDa region.  
Actually, it was not surprising that the expression of wild type p53 restricted viral 
growth, as wild type p53-expressing cells usually undergo apoptosis in response to viral 
infection to prevent its spread as a result of p53 activity. Also, the reaction of mutant 
p53P72R and mutant p53N268D in restricting viral growth was not efficient. The 
mutations at these positions seem not to affect the protein functionality suggesting that 
p53P72R and p53N268D mutants were still retaining the wild type function although 
they are located distantly on the gene. This explanation aids the notion that mutations 
have a diverse effect on p53 functional activity (De Vries et al., 2002; Dehner et al., 
2005; Ang et al., 2006; Joerger et al., 2006) confirming the above suggestion.  
If we consider the above conclusion, mutant p53R175H should disrupt p53 
functional activity to a high extent, which means that this protein should be functionally 
inactive, in order to support the replication of Ad5dlE1b55kDa. However, this did not 
explain the reason for the relative low replication activity of the virus in the null cells 
(mock-transfected H1299). This suggests either of two possibilities: a) oncolytic 
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Ad5dlE1b55kDa replication does not correlate to p53 status, but rather to other factors in 
the cells. If we consider this possibility, we should have seen the same results across all 
of the conditions as we used the same cellular background, but this was not the case 
especially when wild type p53 restricted viral growth the most among the other 
conditions. Or b) mutant p53R175H possess an oncogenic activity or gain of new 
functions that support the replication of Ad5dlE1b55kDa, which is not provided by the 
other mutants. In order to confirm this possibility, we assessed and determined the 
functional status of p53R175H, which rescued the oncolytic viral growth, as well as the 
gain of function activity. 
Functional status of mutant p53R175H that rescued oncolytic 
Ad5dlE1b55kDa growth 
P53 acts as transcriptional activator of a large set of downstream target genes in 
its pathway that mediate its function including cell cycle arrest, DNA repair and 
apoptosis (Kern et al., 1991; Farmer et al., 1992; Zambetti et al., 1992). Therefore, we 
assessed the functional activity of mutant p53R175H along with p53 wild type, as a 
control, by looking at the expression of downstream target genes at the transcriptional 
level. The compared results revealed that the expression of wild type p53 and mutant 
p53R175H led to up and down regulation of many common genes that are known to 
mediate the function of p53. 
Most of the commonly expressed genes are activators and main regulators of 
downstream genes, which mediate the direct function of cell cycle control and division, 
or direct inducers of apoptosis and DNA repair. This indicates that these genes are critical 
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for the cell and are constantly expressed regardless of the functional status of the p53 
protein. These results are consistent with other studies that reported the same conclusion 
with different genes (Mu et al., 2009; Forte et al., 2013).  
However, the sixty-five differentially expressed genes were involved in different 
p53-related biological functions. Generally, most of the genes are more pronounced in 
apoptosis and cell cycle events. The differentially regulated genes that are required for 
p53-mediated cell death such as PIDD, CASP3 and BID were upregulated in the wild 
type p53 transcript whereas in the mutant transcript, these genes showed down regulation 
by 2 fold and greater. However, the apoptosis effectors and negative regulators including 
AXL and NFKB1 showed the opposite expression pattern. This means that upon p53 
expression in H1299 lung cancer, wild type p53 restored its function in the cell and 
started to induce apoptosis to stop the proliferation of cancer cells, which is also 
confirmed by the over expression of antiproliferative genes in the same cell. However, 
the mutant p53 did not have the ability to induce apoptosis upon expression, which is 
mainly ascribed to the presence of mutation at 175 hot spot that hinder the ability of p53 
to induce apoptosis. Further confirmation of this explanation is the up regulation of 
proliferative genes in the same cellular transcript including DNMT1 and SFN.  
Based on our findings, wild type p53 has restored its function and mutant p53 has 
lost its functional ability, this is also supported by the fact that the major genes such as 
cell cycle genes have arrested the cell cycle upon the expression of wild type p53. This 
was shown in the up regulation of cell cycle key regulators control and down regulation 
of negative regulators in the same transcript. However, the opposite results were obtained 
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in the mutant transcript, as the cell cycle was in the progression mode and the key 
regulators genes were downregulated and would not be able to control the cell whereas 
the negative regulators such as ATR went up in the same transcript. Consistent with this 
conclusion is the failure of the mutant p53 in implementing DNA repair event (Table 17).  
From the above results of differentially expressed genes, it seems that mutant 
p53R175H has completely lost its tumor suppressor function. However, if we consider 
the commonly expressed genes in both wild type and mutant p53 transcripts, some 
apoptosis related genes were still under control in both conditions and has the same 
expression pattern. This result has changed the obtained conclusion of complete loss of 
function suggesting that a partial loss of mutant p53R175H tumor suppressor function is 
highly likely to be as a result of defective apoptotic control and this loss might be 
sufficient for the oncolytic virus towards viral replication. This finding also indicates that 
the impact of mutations on p53 function may vary from a wild type-like activity to a 
partial function or complete loss of function. 
Correlation of p53 status with viral growth 
After the assessment of the functional status of mutant p53R175H, it was 
important to determine whether this partial loss of p53 function was the reason behind the 
activity of Ad5dlE1b55kDa replication or if this mutation resulted in the acquisition of a 
new phenotype that caused the successful rescue of the virus. So far, there is no study that 
investigated the Ad5dlE1b55kDa transcriptional reprogramming in mutant p53R175H as 
a means to identify deregulated targets and pathways. Both infected transcripts were 
normalized with the control sample (H1299 RNA) to identify whether the previous 
	   177	  
differentially regulated p53 target genes that were found in the mock-infected mutant p53 
transcript are the same potential targets for viral replication or it there are different genes 
that have become the target and correlated with Ad5dlE1b55kDa growth. 
Microarray gene expression results of the tested transcripts revealed a 107 
commonly expressed genes in both transcripts, which means that both transcripts share 
some similarities in the context of p53 biological functions. These genes are mostly the 
consistently expressed genes regardless of any stress. However, the forty-five 
differentially expressed genes revealed that some genes were upregulated in one 
transcript but downregulated in the other transcript and vice versa. These genes mediate 
direct functions in the p53 pathway including apoptosis, cell division, cell proliferation, 
DNA damage response, mitotic cell cycle and cell growth (Table 18 and Figure 48).  
From the obtained results, it seems that the differentially expressed genes are 
altered during viral infection as a direct effect of the virus. The alteration was more 
pronounced in the mutant p53 transcript than in the wild type p53 transcript in response 
to viral replication. This actually was expected since wild type p53 is functionally active 
and could therefore hinder the virus growth, whereas the mutant p53 has altered activity 
and cannot inhibit viral growth, resulting in successful replication.  
This was evident by two observations: first, the differentially expressed genes 
between the infected mutant p53 transcript and the infected wild type p53 transcript 
which revealed that mutant p53 did not have the ability to prevent the cell transformation 
process triggered by the virus. However, in the case of wild type p53, the virus failed in 
transforming the cell to the favorable viral growth environment. Of note, the completion 
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of cellular transformation can be reached by deregulating the expression of proliferative 
and cell cycle genes towards cell cycle progression. The positive regulators of these 
genes were upregulated in the case of mutant p53 whereas they were downregulated in 
the wild type p53 transcript such as K-ras and CDK20 genes. In parallel with this, the 
negative regulators were shown to have the opposite expression patterns, which confirms 
the defect of mutant p53 transcript in preventing and hindering the viral replication 
process resulting in viral growth.  
Second, the differentially expressed genes in the infected mutant p53 transcript 
did not show the same pattern of expression in the mock-infected mutant p53. Genes that 
are tightly correlated with viral replication were deregulated and showed different 
expression pattern such as Bax, MYC and Apaf1. This meant that mutant p53 transcript 
was still not the favorable transcript for Ad5dlE1b55kDa growth although it lost its 
defense ability towards viral challenge and stress. Therefore, once the virus entered the 
cell, it changed the expression patterns of these genes in favor of its replication. 
Supporting this explanation is the deregulation of some genes in the infected mutant p53 
transcript that are not found in the mock-infected mtp53 like ZEB2 and NOXA. These 
genes, which are targets for Ad5dlE1b55kDa, account for viral rescuing activity, which 
can be considered as gain of new function in this mutant.  
Finally, these results together suggested two findings. First, mutant p53R175H 
transcript is defective in blocking and preventing Ad5dlE1b55kDa growth. Therefore, it 
was a suitable target for the virus in order to replicate and generate virions even if p53 
still retained partial apoptotic function, which could be easily controlled by the viral 
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proteins. Second, the deficiency in the function of mutant p53R175H transcript indirectly 
benefits viral replication by allowing the virus to successfully reprogram the expression 
of some genes in the transcript that are potential targets for Ad5dlE1b55kDa, revealing a 
mechanism of Ad5dlE1b55kDa selectivity in the context of oncolysis. This indicates that 
rescuing viral growth is not equivalent to simply losing wild type p53 function, and the 
allowance of viral growth is an acquired or gained of new function by mutant p53R175H. 
This conclusion was found to be congruous with another finding, which showed that 
conformational mutations are more oncogenic than other mutations like DNA contact 
mutations (Gualberto, et al., 1998).  
The obtained findings led us to assume the viral rescuing mechanism at the basis 
of up regulation or down regulation of gene expression, under the mutant p53R175H 
properties, which begins with the entrance of Ad5dlE1b55kDa into a given cell. Briefly, 
once the virus reached the nucleus, it starts to govern the cell cycle, which represented in 
cell proliferation, cell division, cell growth and mitotic cell cycle. From the previously 
reported functions of viral proteins in the literature (described in introduction), it seems 
that the virus directed its proteins to deregulate the expression of many genes in the 
network to control the cell cycle, creating an optimal environment that supports its 
replication.  
Early E1A coupled with E1B19kDa work together in transforming the cell to S 
phase, the DNA synthesis phase, which is a required event for viral replication (Ruley, 
1983). Firstly, E1A interfered with cellular genes that are known to activate the 
proliferative and growth genes, which was demonstrated by the induction of EAF2, ZEB2 
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and K-ras genes. E1A also regulated the expression of cell cycle players by down 
regulating cyclin kinase inhibitors such as CDKN2A, up regulating cyclin dependent 
kinases like CDK20 and delaying the mitotic cell cycle process for long-lived S phase in 
favor of synthesizing more viral DNA. These results were in agreement with the known 
function of E1A viral protein in down regulating negative regulator of cell cycle control 
(Dyson and Harlow, 1992).  
The deregulation of the cell cycle by E1A activates the cellular mechanism to 
implement p53 dependent apoptosis, which is inhibited by E1B19kDa to prevent the 
premature death of host cells during productive infection (White et al., 1992). The latter 
is not just blocking p53-dependent apoptosis, extrinsic pathway, but also p53 independent 
apoptosis, intrinsic pathway (Sabbatini et al., 1997) in a proper way for efficient 
productive viral replication. This fact was demonstrated in our study as many apoptosis-
related genes showed down regulation in their expression as a result of E1B19kDa 
targeting to prevent the premature cell death, facilitating viral DNA synthesis and 
production. 
These genes are divided between the extrinsic (cell death receptors signaling) and 
intrinsic (mitochondrial signaling) related genes, in which the extrinsic genes started with 
the FAS death receptor and FASLG and continued down an apoptotic cascade passing 
key molecular components including BID and CASP8, critical activators of intrinsic 
genes pathway. Since FAS and FASLG were downregulated, all the downstream 
dependent genes showed down regulation in their expression including BID and CASP8.  
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CASP8 also cleaves and activates a downstream caspase cascade that implements 
apoptosis (Martin et al., 1998; Lin et al., 1999), which did not occur here as a result of its 
down regulation. Therefore, the downstream caspases did not show any activation as their 
expressions were down (shown in Table 18), and they eventually failed to initiate 
apoptosis. This suggests that E1B19kDa succeeded in blocking the cell from undergoing 
premature apoptosis, which is also an important activity for adenovirus to evade immune 
surveillance of the host. Supporting this conclusion is the downregulated expression of 
pro-apoptotic genes such as NOXA and Bax, a direct transcriptional target of p53 
(Miyashita and Reed, 1995).   
Also, E1A targeted different genes that are known to affect virus goal (growth) 
such as MYC, which function as a key cellular regulator of many genes, therefore it was 
not surprising when it serves as a major target for down regulation by viral proteins. This 
was previously reported as part of the virus strategy to create an optimal cellular 
environment for its replication (Ben-Israel et al., 2008). In addition, MDM2 was targeted 
for down regulation by the virus since it possesses an anti-viral response thus inhibiting 
its interaction with p53, which could be already inhibited due to a mutated form of p53. 
The two ways inhibition prevented p53 degradation by MDM2 leading to its 
accumulation in the cell. This was seen in the down regulation of MDM2 expression by 
greater than two fold, and p53 also went up by two fold and greater resulting in its 
stabilization. This result is consistent with the fact that MDM2 is a negative regulator of 
p53 and this stabilization is due to a failed interaction between both genes (Buschmann et 
al., 2000). Further evidence of viral targeting was demonstrated in another study when 
MDM2 expression was rapidly regulated during E1B deleted adenovirus infection 
	   182	  
resulting in enhanced viral gene expression (Yang et al., 2012). A brief illustration that 
shows the assumed viral rescuing mechanism is shown in Figure 53.  
 
 
 
 
 
 
 
Figure 53: An illustration of E1B55kDa-deleted adenovirus rescuing mechanism. 
Taken together, it seems that successful Ad5dlE1b55kDa replication entailed 
deregulation of cell cycle genes towards cell progression, which was achieved as a result 
of dysfunctional cell cycle control. It also entailed elimination or inhibition of premature 
cell death and bypassing of host antiviral mechanisms. This result does not mean that 
reported genes in this study are the only genes that are targeted by Ad5dlE1b55kDa, but 
since they are out of our study’s scope, another study on these genes is suggested for 
further understanding. However, logically those reported genes that were found in this 
study are the main targets for viral growth since they control apoptosis and the DNA 
synthesis phase, which are the main steps towards viral production. 
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CONCLUSION 
 In this project the efficacy of oncolytic Ad5dlE1b55kDa mutant in correlation 
with the status of p53 was studied by firstly evaluating Ad5dlE1b55kDa growth in 
different p53 backgrounds, levels and functional activity, and secondly by investigating 
the effect of mutant p53 on viral growth ability. Based on the presented data in this thesis, 
we can conclude the following: 
1- Post-transcriptional regulatory elements have a positive effect on transgene 
expression and plasmid DNA stability but at various degrees. Among the tested 
elements in this study, the inclusion of hepatitis posttranscriptional regulatory 
element (HPRE) in the expression vectors has positively influenced plasmid DNA 
stability as well as gene expression through exerting the following functions: 
RNA export and accumulation, increase mRNA stability and posttranscriptionally 
regulate gene expression. The effect on plasmid DNA stability needs to be further 
investigated.   
2- The replication efficiency of oncolytic Ad5dlE1b55kDa is correlated with cellular 
p53 activity, but not with the level and the quantity of wild type p53 expression.  
3- The differential replication ability of oncolytic Ad5dlE1b55kDa is dependent on 
the functional status of mutant p53. Mutant p53R175H is a supportive mutation as 
it supported viral growth by exerting two distinct activities: loss of function and 
gain of function. Loss of function by losing the transcriptional activity of target 
genes that mediate defense mechanism against viral challenge whereas gain of 
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function is by allowing the deregulation of transcription of genes that facilitates 
viral growth.  
4- The successful Ad5dlE1b55kDa replication entailed cell transformation to the 
progression mode, inhibition of premature cell death and bypass host antiviral 
mechanism through targeting and deregulating cell cycle genes, apoptosis related 
genes and antiviral genes.   
In summary, our study revealed that the replication ability of oncolytic 
Ad5dlE1b55kDa seems to be dependent on p53’s functional activity in terms of loss and 
gain of function activity. Therefore, it will be necessary to assay all mutations that 
support Ad5dlE1b55kDa growth for their functional activities to determine how these 
mutations are rescuing viral growth and whether these mutations share the same 
transcripts (mRNA profile) or not. This finding was based on an unbiased correlation 
between the p53 status and the replication ability of oncolytic Ad5dlE1b55kDa. 
Therefore, in the context of oncolytic virotherapy, examining p53 status will have a 
prognostic significance. Furthermore, knowledge about the functional status of p53 
would potentially help in determining the therapeutic outcome and would have a major 
impact on patients’ survival.  
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APPENDIX 
List of commonly expressed genes in the four tested samples (wtp53, mtp53, 
E1b/wtp53 and E1b/mtp53) after normalization with H1299 cellular RNA. 
 
 
List of commonly expressed genes in the mock-infected samples (wtp53 and mtp53) 
after normalization with H1299 cellular RNA. 
 
 
 
 
SEMA3F  CCNE2 PTEN VEGFA
BAI1 CyclinD3 EGFR IGF1R
CDC6 GADD45A ZEB1 GDF15
BTG2 GADD45B NANOG IGFBP6
CHEK1 p53BP1 SOX2  FADD
TSC2 XPC CD44  FOXO3
CDC25C Bcl-6 NOTCH  KAT2B
CDK9 p53AIP1 SIRT1  PRC1
CDK8 CASP6 LDHA  PRKCA
 RPRM GML ASCL4  XRCC5
ATF3 Tp53 XRCC5
SEMA3F  CCNE2 CDK1 Fas WIP-1/P21 ASCL1 TNFRSF10B  KAT2B
BAI1 CyclinD3 CDK2 ATM PTEN ASCL4 IGFBP6  PRC1
CDC6 GADD45A CDK4 Bax EGFR VEGFA GALE  PRKCA
BTG2 GADD45B CDK20 TP53BP2 ZEB1 IGF1R ATF3  RPRM
CHEK1 p53BP1  CCNB2 CASP8 NANOG IRS2  BIRC5  STAT1
TSC2 XPC CyclinD1 CASP6 SOX2 Tp53  FADD  TADA3
CDC25C CDKN1A cyclin B3 CASP9 CD44  Pin1  FASLG  XRCC5
CDK9 CDKN2A GADD45G cyc1 NOTCH GDF15  FOXO3  B2M
CDK8 E2F2 Bcl-6 CASP8 SIRT1 GTSE1  JUN TNFRSF6
MYC E2F1  PTTG1 GML LDHA TP53INP1 MDM4 p53AIP1
KAI TP73
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List of minimal change (NC) expressed genes in the mock-infected samples (wtp53 
and mtp53) after normalization with H1299 cellular RNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GD-AIF P48 RPS27L Vascular smooth muscle alpha-actin
PAI CHK1 PAG608 Collagen type XVIII alpha 1
Maspin P53R2 EF-1a Neurofilament subunit NF-L
TSP1 Noxa Zac-1 NB Thymosin beta
TP63 P53DINP1 E124/PIG8 LIM domain protein
P21 WAF1 KILLER/DR5 P2XM cAMP activated protein kinase B
Snoothelin CSR MCG10 Lysosomal Mannosidase alpha B
GOS2 PIG3 TauT TGF-Beta Superfamily protein
14-3-3s PIR121 SCOTIN Multiple exostoses type II protein
VLDL PUMA p85 purine rich element binding protein A
PTPA PA26 IL2 basic transcription factor 2 p44
c-HA-ras 1 CART CENPA Histone 2A-like protein
DM Kinase Fra-2 ESPL1 p14ARF
DRAL-FHL2  ESR1 H2AFX PTG2
ZNF127-Xp  PCBP4 ZNF107 Wip1
LISCH7  RB1 CCNB1 IL6
Tip-1  RELA FANCI cMet
NF-116 EAF2 MAD2L1 ABC3
MIHB MGP CENPK Quiescin/QSCN6
MIHC ITGB3 KIF15 Adipophilin
 IFNB1 RAD51 B99 DR4
IL4
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List of commonly expressed genes in the infected samples (E1b/wtp53 and 
E1b/mtp53) after normalization with H1299 cellular RNA. 
 
List of minimal change (NC) expressed genes in the infected samples (E1b/wtp53 
and E1b/mtp53) after normalization with H1299 cellular RNA. 
 
 
SEMA3F CDK2 PCNA SOX2 P53i3  STAT1
BAI1 CDK4 p53BP1 LIN28B IGFBP6  TADA3
KAI CDK6 XPC CD44 ATF3  TSC1
TP73 CDK9 AXL NOTCH  DNMT1  XRCC5
CDC6 CDK8 Bcl-6 KLF4  EGR1  B2M
BTG2  CCNB2 p53AIP1 SIRT1  FADD  HPRT1
CHEK1 cyclin A1 BCL-2 LDHA  FOXO3 IL2
CHEK2  CCNE2 CASP3 ASCL4  HDAC1  IFNB1
TSC2 CyclinD3 CASP6 VEGFA  HK2  PCBP4
BRCA2 CDC7 CASP9 IGF1R  JUN MSH2
BRCA1 cyclin E1 SIAH2 INSR  MCL1 NANOG
CDC25A CCNG2 IGFBP3 Tp53  MLH1 TNFRSF10B
CDC25C CyclinD1 GML  Pin1  MSH2  SESN2
CDKN1A CyclinB1 BID mmp2  NFKB1 CDK1
E2F2 cyclin B3 CASP2 GDF15  KAT2B GADD45G
E2F1 DDB2 WIP-1/P21 GTSE1  PRC1 ZEB1
E2F4 GADD45A PTEN RRM2B  PRKCA TP53INP1
E2F3 GADD45B EGFR PMAIP1  PTTG1  RPRM
GD-AIF B99 siah-3 P2XM IRS2 TGF-Beta Superfamily protein
PAI CyclinD2 CSR MCG10 PTG2 basic transcription factor 2 p44
Maspin Tip-1 PIG3 TauT Wip1 Multiple exostoses type II protein
TSP1 P48 PIR121 SCOTIN IL4 Vascular smooth muscle alpha-actin
TP63 CHK1 PUMA p85 IL6 Collagen type XVIII alpha 1
P21 WAF1 P53R2 RPS27L DR4 cMet Neurofilament subunit NF-L
Snoothelin Bak PAG608 PTPA BBC3 NB Thymosin beta
GOS2 SIAH-1 EF-1a p14ARF TNFRSF6 LIM domain protein
14-3-3s P53DINP1 Zac-1 IGF1 SFN cAMP activated protein kinase B
cdc2 KILLER/DR5 E124/PIG8 PA26 LISCH7 Lysosomal Mannosidase alpha B
MIHB MIHC Fra-2  ATR  RELA purine rich element binding protein A
 SIAH1  TNFRSF10D Adipophilin ABC3 VLDL Histone 2A-like protein
CART c-HA-ras 1 DM Kinase DRAL-FHL2 ZNF127-Xp Quiescin/QSCN6
NF-116  RB1
